
the Court of Appeal of the republic of singapore [2023] SGCA 5Civil Appeal No 41 of 2020BetweenIIa Technologies Pte Ltdâ€¦ Appellant AndElement Six Technologies Ltdâ€¦ RespondentIn the matter of HC/S 26/2016BetweenElement Six Technologies Ltdâ€¦ Plaintiff AndIIa Technologies Pte Ltdâ€¦ Defendantjudgment[Intellectual Property â€” Patents and Inventions â€” Claim Construction][Intellectual Property â€” Patents and Inventions â€” Invalidity â€” Insufficiency][Intellectual Property â€” Patents and Inventions â€” Patent specification][Intellectual Property â€” Patents and Inventions â€” Revocation]This judgment is subject to final editorial corrections approved by the court and/or redaction pursuant to the publisherâ€™s duty in compliance with the law, for publication in LawNet and/or the Singapore Law Reports.IIa Technologies Pte LtdvElement Six Technologies Ltd [2023] SGCA 5Court of Appeal â€” Civil Appeal No 41 of 2020  Sundaresh Menon CJ, Judith Prakash JA, Steven Chong JA2â€“4 August 2021, 20, 24â€“25 January 202217 February 2023â€ƒJudgment reserved.Sundaresh Menon CJ (delivering the judgment of the court):1â€ƒThe parties are competitors in the production of synthetic diamonds grown using chemical vapour deposition (â€œCVDâ€). At its simplest, under this process, a substrate (which is also known as a diamond seed) is placed in a reactor containing a mixture of gases, including methane (CH4) and hydrogen (H2). Upon exposure to high energy, the gaseous molecules break up into plasma containing carbon (or â€œCâ€) atoms. The C atoms are then deposited on the substrate, growing the synthetic diamond layer by layer.
                   1




Foot Note 1

Ã—



 â€ƒPrimer at para 3(b).



2â€ƒThe appellant, a company incorporated in Singapore, claims to be a major manufacturer of CVD diamonds and has a diamond-growing facility in Singapore.
                   2




Foot Note 2

Ã—



 â€ƒSee Appellantâ€™s Case (â€œACâ€) at para 2; Mr Meta Visha Jatinâ€™s AEIC at para 17 (III(B01) ROA 7).



 The respondent, a company incorporated in the United Kingdom, is part of the Element Six Group. The Element Six Group is a member of the De Beers Group, which is itself a subsidiary of the Anglo American PLC.
                   3




Foot Note 3

Ã—



 â€ƒMs Susan Jane Fletcher Wattsâ€™ AEIC at paras 4â€“5 (III(A1) ROA 7â€“8).



 The De Beers Group is an international diamond business and a diamond producer, while the Anglo American PLC is a global mining company. According to the respondent, the Element Six Group is a global leader in the design, development and production of â€œsynthetic diamond supermaterialsâ€.
                   4




Foot Note 4

Ã—



 â€ƒMs Susan Jane Fletcher Wattsâ€™ AEIC at para 5 (III(A1) ROA 8).



 The respondent claims that its CVD diamonds have potential technical applications in various industries, including optics, semiconductors and sensors.
                   5




Foot Note 5

Ã—



 â€ƒMs Susan Jane Fletcher Wattsâ€™ AEIC at para 7(b) (III(A1) ROA 9).



3â€ƒIn HC/S 26/2016 (â€œSuit 26â€), the respondent claimed that the appellant had infringed two of its patents registered in Singapore, Singapore Patent No 115872 (â€œSG 872â€) and Singapore Patent No 110508 (â€œSGÂ 508â€). To prove infringement, the respondent relied on three samples of diamonds, which were labelled Sample 2, Sample 3 and Sample 4 (collectively, the â€œSamplesâ€), allegedly purchased from the appellant or the appellantâ€™s related entities or distributors. It claimed that the Samples were made from CVD diamond material synthesised by the appellant and that the appellant must have used the method of growth taught in Claims 62 to 71 of SG 872.
                   6




Foot Note 6

Ã—



 â€ƒParticulars of Infringement (Amendment No 2) at para 4 (II(1) ROA 35â€“44). 



 In its defence, the appellant denied infringing the patents and, in any case, disputed their validity.
                   7




Foot Note 7

Ã—



 â€ƒDefence & Counterclaim (Amendment No 6) at paras 5â€“6 (II(1) ROA 26 and 69).



 The appellant also sought the revocation of both patents by way of a counterclaim.
                   8




Foot Note 8

Ã—



 â€ƒDefence & Counterclaim (Amendment No 6) at (3) and (7) (II(1) ROA 73).



 On 7 February 2020, the trial judge (the â€œJudgeâ€) declared that SG 508 was invalid and revoked it on the basis that it was neither novel nor inventive (Element Six Technologies Ltd v IIa Technologies Pte Ltd [2020]Â SGHCÂ 26 (â€œJudgmentâ€) at [291] and [478(d)]â€“[478(e)]). This was a complete defence to the respondentâ€™s claim for infringement in so far as SG 508 was concerned (Judgment at [416]). However, the Judge found that SG 872 was valid and declined to revoke it. She further found that the appellant had infringed specific claims in SG 872. In this appeal, although both parties proceeded on the basis that Claims 1ii), 1iii), 57, 58 and 62 of SG 872 were infringed,
                   9




Foot Note 9

Ã—



 â€ƒAC at para 3; Respondentâ€™s Case (â€œRCâ€) at para 5(e). 



 it is not entirely clear whether the Judge confined her finding of infringement to specific limbs of Claim 1 (Judgment at [9], [416], [443], [454], [456] and [478(a)]). But this difficulty need not detain us. Even taking Claims 1ii) and 1iii) as the point of departure for our analysis on invalidity, our conclusions affect the entirety of Claim 1 and the outcome of the appeal will not change even if the Judge had found the whole of Claim 1 to be infringed.  4â€ƒOn 6 March 2020, the appellant filed CA/CA 41/2020 (â€œCA 41â€) appealing against the Judgeâ€™s rejection of its defence that SG 872 is invalid and its counterclaim to revoke the entirety of SG 872. It also challenged the Judgeâ€™s finding that Claims 1ii), 1iii), 57, 58 and 62 in SG 872 had been infringed.
                   10




Foot Note 10

Ã—



 â€ƒSee Notice of Appeal in CA/CA 41/2020 dated 6 March 2020; AC at para 3.



 The respondent has not cross-appealed against the Judgeâ€™s findings in respect of SGÂ 508.5â€ƒThe Judge delivered her decision on costs (the â€œJudgeâ€™s Costs Decisionâ€) on 30 March 2020, holding that the respondent was entitled to the costs of Suit 26 on a standard basis as well as costs of $3,000 (all in) for the costs hearing which took place on 30 March 2020. On 25 June 2020, the appellant filed CA/CA 96/2020 (â€œCA 96â€) appealing against the entirety of the Judgeâ€™s Costs Decision.6â€ƒThis judgment deals only with CA 41.Background Procedural history and case management on appeal7â€ƒOn 17 August 2020, the appellant filed CA/SUM 87/2020 (â€œSUM 87â€), seeking leave to admit further evidence from Dr Werner Kaminsky (â€œDrÂ Kaminskyâ€, the appellantâ€™s expert) for the purpose of challenging the evidence of Dr Anthony Michael Glazer (â€œDr Glazerâ€, the respondentâ€™s expert) on his gap theory (â€œGap Theoryâ€) (see [36] below for relevance of the Gap Theory in this appeal). We dismissed SUM 87 on 16 September 2020.8â€ƒAs appears below, the technical background to SG 872 â€“ including the physical properties of diamonds, how SG 872 seeks to enhance the quality of CVD diamonds grown and the measurement or evaluation of the improvement brought about by SG 872 â€“ is highly complex. The following steps greatly assisted us in coming to grips with the difficult material: (a)â€ƒOn 19 April 2021, we directed the parties to prepare a â€œPrimerâ€ (with a 50-page limit) setting out their points of agreement and divergence on topics including the common general knowledge (such as different methods of growing diamonds and types of defects in diamonds), the state of the art (including other patents) and the inventive concept of SG 872.(b)â€ƒWe also convened a â€œTechnology Tutorialâ€ that was conducted on 2, 3 and 4 August 2021. Each party was allowed to nominate up to two presenters from among their expert witnesses to address these topics as well as provide an introduction to SG 872 and the Metripol system.
                   11




Foot Note 11

Ã—



 â€ƒCourtâ€™s letter dated 19 April 2021 at para 5, read with Appellantâ€™s letter dated 13 April 2021, p 4 s/n 4.



  The parties filed and exchanged Powerpoint slide decks prepared by their presenters seven days before the Technology Tutorial.In the section that follows, we outline the salient aspects of the background to SG 872 as presented in the Primer and Technical Tutorial, which will set the context for our analysis of its validity.9â€ƒFollowing the Technology Tutorial, CA 41 was heard over three half-day hearings on 20, 24 and 25 January 2022.10â€ƒSubsequently, on 14 September 2022, we wrote to the parties to clarify whether each product claim in SG 872 covers a class of products as opposed to an individual product. The significance of this point, as well as of the partiesâ€™ responses on 21 September 2022, will become clear when we analyse whether SG 872 should be revoked in its entirety.Technical background11â€ƒWe first set out the technical background to SG 872. As we later elaborate, SG 872 discloses a new single crystal CVD diamond material, at least 0.5mm in thickness, which possesses one or more properties stated in the patent. One such property is low â€œoptical birefringenceâ€ (henceforth referred to as â€œbirefringenceâ€). It is the respondentâ€™s case that without the new CVD growth process taught within SG 872, the single crystal CVD diamond material manufactured would not display the properties defined in the product claims of SG 872. It is said that these properties are indicative of a high-quality diamond.
                   12




Foot Note 12

Ã—



 â€ƒRC at para 12.



Synthetic diamonds and CVD12â€ƒDiamonds are a form of solid C (meaning carbon) in which each C atom is bonded to four neighbouring C atoms to form a tetrahedral structure. Many of these tetrahedral structures come together to form a diamond lattice. A â€œsingle crystalâ€ diamond, which is claimed in SG 872, is one in which the crystal lattice of the entire sample is continuous and unbroken. In contrast, a polycrystalline diamond consists of many single crystals.
                   13




Foot Note 13

Ã—



 â€ƒRC at para 13; Dr Mark Edward Newtonâ€™s 1st Report (â€œNewton-1â€) at p 34 (I RSCB 133); Primer at para 80; Transcript, 3 August 2021, p 20:26-27 (Dr Newton). 



13â€ƒDiamonds may form naturally within the Earthâ€™s crust or be manufactured in a laboratory.
                   14




Foot Note 14

Ã—



 â€ƒPrimer at paras 2â€“3. 



 CVD is one of the main ways of manufacturing diamonds, the other of which involves applying high-pressure-high-temperature (â€œHPHTâ€) on a C source mixed with a catalyst.
                   15




Foot Note 15

Ã—



 â€ƒPrimer at para 3(a).



Impurities, defects and strain in diamonds14â€ƒIn reality, no diamond (natural or man-made) is an array of equally spaced atoms which are purely C. Diamonds will contain impurities and defects. We make this point to provide context to what the respondent/patentee sought to achieve through the new growth processes taught in SG 872. As will become clear, the type and extent of defects in a diamond bear on its physical properties, such as its strength,
                   16




Foot Note 16

Ã—



 â€ƒSee, eg, Primer at para 52.



 and hence its potential industrial use(s) and application(s). The respondent sought to produce CVD single crystal diamonds with certain qualities which were required for specific industrial applications. Allegedly, such diamonds could only be produced using the processes claimed in SG 872. What follows elaborates on the nature of defects or impurities arising in diamonds and the relationship between these imperfections and a diamondâ€™s physical properties. 15â€ƒImpurities refer to non-C atoms bonded into the diamondâ€™s lattice structure. Common impurities include nitrogen (N2) and boron. The concentration of nitrogen and boron is expressed in parts per million (â€œppmâ€) or parts per billion (â€œppbâ€). 
                   17




Foot Note 17

Ã—



 â€ƒPrimer at para 4.



 Based on its purity, a diamond can be categorised into two main types: Type I and Type II. These can be further sub-divided into Types Ia, Ib, IIa and IIb. Type I diamonds contain relatively large amounts of nitrogen â€“ up to 0.3% (5ppm to ~ 3000ppm). Most of the nitrogen atoms in Type Ia diamonds are found in clusters, but this is not the case in Type Ib diamonds.
                   18




Foot Note 18

Ã—



 â€ƒPrimer at para 7.



 Type II diamonds contain nitrogen below 5ppm. The only impurity in Type IIa diamonds is nitrogen, whereas impurities in Type IIb diamonds consist of nitrogen and boron.
                   19




Foot Note 19

Ã—



 â€ƒPrimer at para 8.



16â€ƒWhen impurities (meaning non-C atoms) enter the diamondâ€™s structure, a point defect is created in the lattice structure.
                   20




Foot Note 20

Ã—



 â€ƒPrimer at para 18. 



 Extended defects, on the other hand, are structural defects caused by disruptions to the diamond lattice that extend across the crystal.
                   21




Foot Note 21

Ã—



 â€ƒPrimer at para 19.



 One example of an extended defect is a stacking fault, which occurs where the relative positioning of two adjacent layers (or planes) of crystal structure does not conform with the rest of the crystal: Figure 1: Diagram depicting stacking faultsAnother type of extended defect is a dislocation. Dislocations occur where there are atoms out of position in the crystal structure that, among other things, form an extra line of atoms within the structure (that is, an edge dislocation):
                   22




Foot Note 22

Ã—



 â€ƒPrimer at para 19.



Figure 2: Diagram depicting dislocations17â€ƒExtended defects can be visualised using X-ray topography images where stacking faults appear as dark planes (Figure 3) and dislocations appear as dark lines (Figure 4). Thicker and relatively darker lines show bundles of dislocations: 
                   23




Foot Note 23

Ã—



 â€ƒIV ACB 164.



Figure 3: 2-D X-ray topography of IIa HPHT diamond showing stacking faults (black areas) (from H Sumiya et al, â€œCrystalline perfection of high purity synthetic diamond crystalâ€ (1997) 178 Journal of Crystal Growth 485 at 490)Figure 4: X-ray topography of CVD diamond showing dislocations as black lines (from I Friel et al, â€œControl of surface and bulk crystalline quality in single crystal diamond grown by chemical vapour depositionâ€ (2009) 18 Diamond & Related Materials 808 at 812)18â€ƒDislocations cause strain, or distortion to the position of atoms, in the diamond structure.
                   24




Foot Note 24

Ã—



 â€ƒSee Transcript, 2 August 2021, p 12:6â€“7.



 The strain extends across the full length of the dislocation, which typically runs all the way across the diamond.
                   25




Foot Note 25

Ã—



 â€ƒPrimer at paras 22 and 40.



 Strain weakens the chemical bonds, which then can be broken with lower energy. This reduces the strength of the diamond to withstand external pressure.
                   26




Foot Note 26

Ã—



 â€ƒPrimer at para 22.



 According to Dr Christoph Erwin Nebel (â€œDr Nebelâ€), the appellantâ€™s principal expert,
                   27




Foot Note 27

Ã—



 â€ƒAC at para 11.



 if there is strain, electrons between the atoms are no longer homogenously distributed, resulting in an electric field that may interact with light and increase birefringence in the diamond (a property we explore in some detail at [20]â€“[27] below).
                   28




Foot Note 28

Ã—



 â€ƒTranscript, 2 August 2021, p 12:3â€“11.



 19â€ƒDislocation density refers to the number of dislocations per square cm or mm of surface. Dislocations extend across the diamond like a line (hence, â€œline defectsâ€) and terminate only on the surface:
                   29




Foot Note 29

Ã—



 â€ƒPrimer at para 29.



Figure 5: Dislocations originate from the substrate surface and propagate into the diamond. They can multiply during growth and become decorated with nitrogen.Dislocation termination points reveal themselves as etch pits. An optical evaluation of the number of etch pits across the surface area of the diamond will reveal its dislocation density:Figure 6: Etch pits on diamond with dislocation density of 3300/mm2Figure 7: Cross-section of an etch pitBirefringence20â€ƒBirefringence is a physical property of diamonds relevant to the key claims in SG 872. We shall therefore explore this concept in some detail.21â€ƒ Birefringence, stated generally, is related to how light interacts with a certain object. Light is made of waves of electric and magnetic fields. These waves oscillate in all directions perpendicular to the direction of the transmission of light. The distance travelled when an electromagnetic wave goes through one full oscillation cycle is called wavelength, which is denoted by Î». The wavelength of light determines its colour.
                   30




Foot Note 30

Ã—



 â€ƒPrimer at para 33.



Figure 8: Diagram of a light wave in terms of its electro-magnetic field22â€ƒWhile normal light consists of electric fields oscillating in all directions in the plane perpendicular to the direction of propagation, a polariser filter may be used to only allow light containing electric fields oscillating in a single direction to pass through. â€œPolarised lightâ€ therefore has only one direction of oscillation.
                   31




Foot Note 31

Ã—



 â€ƒPrimer at para 35.



23â€ƒThe atomic arrangement in a material affects the speed at which light travels through it. The speed of light in an optical material is determined by the materialâ€™s refractive index. The denser the material, the higher its refractive index and the slower that light travels through it.
                   32




Foot Note 32

Ã—



 â€ƒPrimer at para 36.



24â€ƒWhere the internal structure of the crystalline material is perfect, in that it has no impurities or defects, the crystalline material is highly symmetrical. Such material is referred to as isotropic. In isotropic materials, the refractive index is the same in all directions. This means that light passes through an isotropic crystal at a single velocity.25â€ƒBut for anisotropic materials, the refractive index may vary in different directions. Although a diamond may theoretically be isotropic due to its highly symmetrical uniform lattice of C atoms, in reality, diamonds are anisotropic due to strain caused by dislocations.
                   33




Foot Note 33

Ã—



 â€ƒPrimer at para 37.



 When polarised light is passed through a diamond with strain, the light splits into two relevant components which travel at different velocities. One component travels faster along the path in the material with the smallest refractive index (nâ€) and the other travels slower along the path in the material with the largest refractive index (nâ€™). The difference between the smallest and largest available refractive index is called birefringence (Î”n = |nâ€™ â€“ nâ€™â€™|).
                   34




Foot Note 34

Ã—



 â€ƒPrimer at para 38.



 In other words, strain in diamonds results in birefringence.
                   35




Foot Note 35

Ã—



 â€ƒPrimer at para 40; Transcript, 3 August 2021, p 29 (Dr Newton).



26â€ƒThe gap between the faster and slower components of light when they emerge out of the material is defined as the optical retardation (also referred to as â€œretardationâ€ or â€œpath differenceâ€). Light of any wavelength which passes through a sample of an anisotropic material having birefringence Î”n, where the sample has a thickness of â€œLâ€, will display retardation of LÂ·Î”n. Dr Nebel depicted birefringence and retardation as follows:
                   36




Foot Note 36

Ã—



 â€ƒDr Christoph Erwin Nebelâ€™s technical tutorial (â€œDr Nebelâ€™s technical tutorialâ€), slide 15.



Figure 9: Diagram showing how the variation in the refractive index causes birefringence27â€ƒFor light of a particular wavelength (or Î»), retardation can also be represented as phase shift â€œÎ´â€:
                   37




Foot Note 37

Ã—



 â€ƒPrimer at para 39.



 Dr Nebel represented the components of the above equation, using the following diagrams of light components that have split up when passing through an object:
                   38




Foot Note 38

Ã—



 â€ƒDr Nebelâ€™s technical tutorial, slide 17.



Figure 10: Diagrammatic representation of retardation as a â€œphase shiftâ€Salient features of SG 87228â€ƒThis appeal concerns SG 872, which was filed on 20 November 2003. In essence, the patent covers a new optical quality synthetic single crystal CVD diamond material and the method for its production.
                   39




Foot Note 39

Ã—



 â€ƒStatement of Claim (Amendment No 2) at para 2 (II(1) ROA 27).



 The patent contains both product and process claims. A product claim is one which â€œasserts exclusive rights over a new thing, such as new machines, items or articles of manufacture and composition of matterâ€. Although the patentee may describe only one use of his invention, he has the right to stop others from using it for other purposes (Susanna H S Leong, Intellectual Property Law of Singapore (Academy Publishing, 2013) (â€œSusanna Leongâ€) at para 18.002). We will henceforth refer to a diamond falling within any of the product claims in SG 872 as an â€œSG 872 Diamondâ€. On the other hand, â€œa process claim covers a new activity such as a process or method of manufacturing and logically, in a method or process claim, it is the process used and not the end result which must be new to justify patentability.â€ (Susanna Leong at para 18.003). 29â€ƒThe pivotal product claim, which all subsequent claims refer back to, is Claim 1:1. â€ƒA CVD single crystal diamond material which shows at least one of the following characteristics, when measured at room temperature (nominally 20oC):i)â€ƒa high optical homogeneity, with the transmitted wavefront differing from the expected geometrical wavefront during transmission through diamond of a specified thickness of at least 0.5 mm, processed to an appropriate flatness and measured over a specified area of at least 1.3 mm x 1.3 mm, by less than 2 fringes, where 1 fringe corresponds to a difference in optical path length equal to Â½ of the measurement wavelength of 633 nm; ii) â€ƒa low optical birefringence, indicative of low strain, such that in a sample of a specified thickness of at least 0.5 mm and measured in a manner described herein over a specified area of at least 1.3 mm x 1.3 mm, the modulus of the sine of the phase shift, |sin Î´|, for at least 98% of the analysed area of the sample remains in first order (Î´ does not exceed Ï€/2) and the |sin Î´| does not exceed 0.9;iii)â€ƒa low optical birefringence, indicative of low strain, such that in a sample of a specified thickness of at least 0.5 mm and measured in a manner described herein over a specified area of at least 1.3 mm x 1.3 mm, for 100% of the area analysed, the sample remains in first order (Î´ does not exceed Ï€/2), and the maximum value of Î”n[average], the average value of the difference between the refractive index for light polarised parallel to the slow and fast axes averaged over the sample thickness, does not exceed 1.5 x 10-4;iv)â€ƒan effective refractive index in a sample of specified thickness of at least 0.5 mm, measured in a manner described herein over a specified area of at least 1.3 mm x 1.3 mm, which has a value of 2.3964 to within an accuracy of +/-0.002; v) â€ƒcombination of optical properties such that when the diamond material is prepared as a diamond plate in the form of an etalon of a specified thickness of at least 0.5 mm and measured using a laser beam with a wavelength near 1.55 Î¼m and a nominal diameter of 1.2 mm over a specified area of at least 1.3 mm x 1.3 mm, it exhibits a free spectral range (FSR) which, when measured at different positions over the plate, varies by less than 5 x 10-3 cm-1;vi)â€ƒa combination of optical properties such that when the diamond material is prepared as a diamond plate in the form of a Fabry-Perot solid etalon of a specified thickness of at least 0.5 mm, and measured using a laser beam with a wavelength near 1.55 Î¼m and a nominal diameter of 1.2 mm over a specified area of at least 1.3 mm x 1.3 mm, and which has no coatings applied to the optically prepared surfaces, it exhibits when measured at different positions over the plate a contrast ratio exceeding 1.5; vii)â€ƒa combination of optical properties such that when the diamond material is prepared as a diamond plate in the form of an etalon of a specified thickness of at least 0.5 mm, and measured using a laser beam with a wavelength near 1.55 Î¼m and a diameter of 1.2 mm over a specified area of at least 1.3 mm x 1.3 mm, it exhibits an insertion loss not exceeding 3 dB;viii)â€ƒa variation in refractive index over a volume of interest, said volume comprising a layer of a specified thickness of at least 0.5 mm, measured in a manner described herein over a specified area of at least 1.3 mm x 1.3 mm, which is less than 0.002.30â€ƒSingle crystal CVD diamond material falling within Claim 1 has low strain and exhibits at least one of the optical properties defined in the eight limbs of Claim 1.
                   40




Foot Note 40

Ã—



 â€ƒPrimer at para 140.



 Two of these limbs, limbs ii) and iii), assume significance in this dispute. Following the terminology used by the parties and the Judge, we will refer to these two limbs as â€œClaim 1ii)â€ and â€œClaim 1iii)â€ respectively. As the respondent pleads that Claims 1ii) and 1iii) were infringed (see Judgment at [417]),
                   41




Foot Note 41

Ã—



 â€ƒParticulars of Infringement (Amendment No 2) dated 26 October 2018 at para 1 (II(1) ROA 31â€“32).



 we elaborate on these. Claims 1ii) and 1iii) assert a monopoly over single crystal CVD diamond material with low birefringence. Low birefringence is quantified in Claim 1ii) as a sample (a) remaining in the first order (Î´ does not exceed ); and (b) with the modulus of the sine of the phase shift (that is, |sin Î´|) not exceeding 0.9. Low birefringence is quantified in Claim 1iii) as a sample (a) remaining in the first order (Î´ does not exceed ); and (b) with the maximum value of Î”n[average] (that is, the average birefringence across the thickness of the sample) not exceeding 1.5 x 10-4.31â€ƒWe highlight four key points pertaining to Claims 1ii) and 1iii) which the parties do not dispute. First, the term â€œfirst orderâ€ for the purposes of SGÂ 872 (and Claims 1ii) and 1iii) in particular) has been defined in a specific way. The partiesâ€™ experts, when explaining certain technical concepts (see above at [27] and below at [191]),
                   42




Foot Note 42

Ã—



 â€ƒSee also Primer at para 47.



 referred to each â€œorderâ€ as a multiple of 2Ï€, with â€œfirst orderâ€ covering a range of values where Î´ does not exceed 2Ï€ (or again, expressed as an equation, Î´ â‰¤ 2Ï€). However, SG 872 defines â€œfirst orderâ€ in a much more limited sense, namely, where Î´ does not exceed  (or again, expressed as an equation, Î´ â‰¤ ) (the â€œSG 872 First Orderâ€).
                   43




Foot Note 43

Ã—



 â€ƒPrimer at paras 155â€“156; see Bundle of Materials dated 28 June 2021 (â€œBOMâ€) at p 363.



32â€ƒSecond, it is undisputed that SG 872 directs the person skilled in the art (â€œPSAâ€) to use a Deltascan (which has been renamed as the Metripol since 2001)
                   44




Foot Note 44

Ã—



 â€ƒPrimer at para 146; Dr Nebelâ€™s technical tutorial, slide 66.



 or a â€œsimilar instrument with similar resolutionâ€ to determine the value of |sinÂ Î´| and Î”n[average].
                   45




Foot Note 45

Ã—



 â€ƒBOM at pp 302 and 308. Primer at para 146.



 The Metripol is an optical microscope-based imaging system,
                   46




Foot Note 46

Ã—



 â€ƒPrimer at para 146.



 which was developed by Dr Glazer (the respondentâ€™s expert), Dr Kaminsky (the appellantâ€™s expert), and Dr Morten Geday (â€œDr Gedayâ€) (the appellantâ€™s witness) in or around 1995. The Metripol has a polariser that rotates in fixed multiples of different angles (for example, by 30o, 60o, 90o) (â€œRotation Anglesâ€). At each angle, polarised light passes through the specimen and is captured by a camera. The Metripol calculates the intensities of light received by the camera at different Rotation Angles, and thereafter computes |sin Î´|, which is a function of Î´.33â€ƒIt will be recalled that Î´ is the optical retardation of light of a particular wavelength that passes through a material, and is related to the birefringence of the material by the formula set out at [27] above.
                   47




Foot Note 47

Ã—



 â€ƒPrimer at para 150.



 As appears from the three graphs below (in particular, the green arrows in graphs (b) and (c)), |sin Î´| is the amplitude of a sinusoidal curve (meaning half the distance from the highest point of the curve to its lowest point). This sinusoidal curve is derived by plotting the intensity of polarised light that passes through the diamond specimen on the y-axis, against the polariserâ€™s Rotation Angle on the x-axis.
                   48




Foot Note 48

Ã—



 â€ƒPrimer at para 151.



 Depending on whether and the extent to which the intensity of light varies when the polariser is angled differently, |sin Î´| will assume a different value:
                   49




Foot Note 49

Ã—



 â€ƒDr Nebelâ€™s technical tutorial, slide 68; see also Primer at para 151.



 Figure 11: Graphs depicting the variation of intensities of light against the polariserâ€™s Rotation Angle34â€ƒThird, after computing |sin Î´|, the Metripol produces colour-coded images of the material, where the different colours represent different |sin Î´| values at any place within the image (the â€œMetripol |sin Î´| Mapâ€).
                   50




Foot Note 50

Ã—



 â€ƒPrimer at para 147.



 The Metripol is capable of refining the |sin Î´| value at each pixel position in the Metripol |sin Î´| Map.
                   51




Foot Note 51

Ã—



 â€ƒPrimer at para 157.



 An illustration of the Metripol |sin Î´| Map can be found in the following diagram, taken from the respondentâ€™s Technology Tutorial slides:Figure 12: Illustration of a colour-coded image produced by the Metripol (that is, the Metripol |sin Î´| Map)The same Metripol |sin Î´| Map can also be represented in greyscale. The patent specification of SG 872 states that the spatial variation of |sin Î´| can be appreciated from these images.
                   52




Foot Note 52

Ã—



 â€ƒSee BOM at p 330.



 The patent specification also states that for each sample, sets of |sin Î´| images are to be recorded for analysis.
                   53




Foot Note 53

Ã—



 â€ƒBOM at p 331.



35â€ƒFourth, it is agreed between the parties that the Metripol data on its own does not tell the PSA whether the Î´ value of a diamond falls within the SG 872 First Order (the â€œMetripol Uncertainty Problemâ€).
                   54




Foot Note 54

Ã—



 â€ƒPrimer at paras 154â€“155.



 The Metripol does not calculate Î´. As mentioned, it generates the value of |sinÂ Î´|.
                   55




Foot Note 55

Ã—



 â€ƒPrimer at para 152.



 However, each |sin Î´| value corresponds to many Î´ values, and only one of these Î´ values lies within the SG 872 First Order.
                   56




Foot Note 56

Ã—



 â€ƒPrimer at para 153 and Figure 44.



 From the |sin Î´| value alone, the PSA cannot derive a corresponding Î´ value and will not know whether the Î´ value of a diamond is within or outside the SG 872 First Order. This point can be illustrated in Figure 13 below, where Î´1 is the value that lies within the SGÂ 872 First Order:
                   57




Foot Note 57

Ã—



 â€ƒPrimer at para 152.



Figure 13: Graph showing that |sin ğ›¿| of 0.9 may indicate multiple possible values of ğ›¿ If the Metripol shows that the |sin Î´| value of the diamond is 0.9, the corresponding Î´ value can be 1.12, 2.02, 4.26, 5.16, or any other higher value not reflected in Figure 13 above.
                   58




Foot Note 58

Ã—



 â€ƒPrimer at para 153 and Figure 44.



 Î´ will only be within the SG 872 First Order if it has a value of 1.12, as that is the only value that does not exceed  (see above at [31]). The rest of the values lie outside the SG 872 First Order. From this range of possible Î´ values, the PSA relying solely on the Metripol reading cannot determine the Î´ value of the diamond, and accordingly, cannot ascertain whether Î´ is within the SG 872 First Order.36â€ƒIn this appeal, as they did in the proceedings below, the parties diverge on the issue of whether the PSA knew of solutions to overcome the Metripol Uncertainty Problem at the relevant time. The thrust of the appellantâ€™s contention is that the PSA, faced with the Metripol Uncertainty Problem and with no knowledge of any workable solution at the relevant time, would not be able to determine whether the Î´ value of the diamond was within the SG 872 First Order and hence within the scope of the asserted monopoly. For this reason, the appellant contends that SG 872 is insufficient.
                   59




Foot Note 59

Ã—



 â€ƒAC at paras 151â€“211; Defendantâ€™s Closing Submissions in Second Tranche of Trial (â€œDCS2â€) at paras 307 and 311â€“347 (III(G5) ROA 149â€“151 and 152â€“169).



 In turn, the respondentâ€™s case is that the PSA would have no difficulty ascertaining that the Î´ value of the diamond was within the SG 872 First Order by using various methods, such as the Gap Theory proposed by Dr Glazer.
                   60




Foot Note 60

Ã—



 â€ƒRC at paras 175â€“194; Plaintiffâ€™s Closing Submissions in Second Tranche of Trial (â€œPCS2â€) at paras 898â€“906 (III(G3) ROA 130â€“134).



 We will deal with this issue in our analysis later.37â€ƒWe now turn to Claim 62, the main process claim in SG 872 to which all other process claims in SG 872 refer. Claim 62 specifies a method of producing low-strain single crystal CVD diamond material that exhibits optical properties defined in the product claims in SG 872. Claim 62 states as follows:62â€ƒA method of producing a CVD diamond material suitable for optical applications and according to any one of the preceding claims, which method includes the steps of: -â€ƒproviding a substrate substantially free of crystal defects,-â€ƒproviding a source gas,-â€ƒdissociating the source gas to produce a synthesis atmosphere which contains 300 ppb to 5 ppm nitrogen, calculated as molecular nitrogen, and allowing homoepitaxial diamond growth on the surface which is substantially free of crystal defectswherein the surface damage of the substrate is minimised by including a plasma etch on the surface on which homoepitaxial diamond growth is to occur, whereby a density of defects at the surface of the substrate is such that surface etch features related to the defects is below 5 x 103/mm2, wherein the level of nitrogen is controlled with an error of less than 300 ppb (as a molecular fraction of the total gas volume) or 10% of the target value in the case phase, whichever is the larger, and wherein the level of nitrogen is selected to be sufficient to prevent or reduce strain generating defects whilst being low enough to prevent or reduce deleterious absorptions and crystal quality degradation, thereby producing a CVD single crystal diamond material meeting the requirements of one or more of claims 1 to 61.38â€ƒCertain terms relating to the growth process, which are referred to subsequently, call for further explanation. The â€œsource gasâ€ in the CVD chamber comprises several gases, including a â€œCâ€ source which is typically methane (CH4) and a source of atomic hydrogen which is typically hydrogen (H2). The parties agree that other gases, such as an inert gas (like argon) and a dopant gas (like nitrogen, boron or phosphorous), a source of impurities which is used to affect the electrical or optical properties of a diamond, are also used depending on the desired characteristics of the CVD diamond.
                   61




Foot Note 61

Ã—



 â€ƒNewton-1 at para 236 (IIIA(24) ROA 171); Dr Newtonâ€™s 2nd Report (â€œNewton-2â€) at para 155 (IIIA(56) ROA 74); Dr Nebelâ€™s 2nd Report (â€œNebel-2â€) at para 117 (IIIB(62) ROA 63); Primer at para 96. 



 Each input gas is controlled by a mass flow controller (â€œMFCâ€). The flow of gases across MFCs is measured as cubic centimetres of gas flowing through the MFC per minute (expressed as standard cubic centimetres per minute or â€œsccmâ€). The concentration of each gas is represented as a percentage, ppm or ppb.
                   62




Foot Note 62

Ã—



 â€ƒPrimer at para 97.



 As for the â€œplasma etchâ€ performed on the substrate prior to the commencement of the CVD process, this involves â€œexposing the substrate to a plasma formed by hydrogen (H2) and/or oxygen (O2) at high temperature in a CVD chamber.â€
                   63




Foot Note 63

Ã—



 â€ƒPrimer at para 92.



 The specification of SG 872 states that such in situ plasma etching minimises the surface damage of the substrate.
                   64




Foot Note 64

Ã—



 â€ƒBOM at p 317.



 We note, however, that the respondent disputes
                   65




Foot Note 65

Ã—



 â€ƒRC at para 150. 



 whether the use of a plasma etch to achieve this effect is common general knowledge to a PSA (we will explain the concepts of common general knowledge and the PSA at [63]â€“[75] below).39â€ƒThe respondent claims that the production of low-strain single crystal CVD diamond material disclosed in Claims 1 to 61 and 72 to 78 was not possible prior to the discovery of the process in Claim 62.
                   66




Foot Note 66

Ã—



 â€ƒTranscript, 4 August 2021, p 38:11â€“20.



 The respondent argues that the growth process in Claim 62, specifically, the addition of 300ppb to 5ppm nitrogen to the synthesis atmosphere (the â€œClaim 62 Nitrogen Rangeâ€), is novel because it runs contrary to previous thinking that adding nitrogen to the synthesis atmosphere would have a deleterious effect on the quality of the diamond produced; nitrogen was regarded as an impurity.
                   67




Foot Note 67

Ã—



 â€ƒRC at para 18.



 As the Judge noted, the common general knowledge at the material time was that the addition of nitrogen would increase birefringence. The Claim 62 Nitrogen Range is therefore the inventive concept asserted in Claim 62 (see Judgment at [253]). We agree. According to the specification of SG 872, the Claim 62 Nitrogen Range is not too high because it accomplishes the aim of â€œprevent[ing] or reduc[ing] local strain generating defects whilst being low enough to prevent or reduce deleterious absorptions and crystal quality degradation.â€
                   68




Foot Note 68

Ã—



 â€ƒBOM at p 310.



 Nor is the range too low, because, according to SG 872, â€œmaterial grown under conditions with essentially no nitrogen, or less than 300ppb nitrogen has a comparatively higher level of local strain generating defectsâ€.
                   69




Foot Note 69

Ã—



 â€ƒBOM at p 312.



 Dr Philippe Bergonzo (â€œDr Bergonzoâ€), one of the respondentâ€™s experts, depicted the benefits of operating within the Claim 62 Nitrogen Range as follows (see the curve in black):
                   70




Foot Note 70

Ã—



 â€ƒDr Philippe Bergonzoâ€™s technical tutorial slides, slide 41.



 40â€ƒAs against this, the appellant regards the purported benefits of using the Claim 62 Nitrogen Range as â€œillusoryâ€ and â€œfalseâ€.
                   71




Foot Note 71

Ã—



 â€ƒAC at paras 131â€“132.



 It questions why, in the 17 or so years since SG 872, not a single paper has been published discussing or evidencing this discovery. However, as we shall explain, even assuming that the purported benefits of the Claim 62 Nitrogen Range are scientifically true, there are other issues undermining the validity of the patent. Decision below41â€ƒAgainst the appellantâ€™s arguments to the contrary, the Judge held that Claims 1 and 62 of SG 872 were valid. For brevity, we will only summarise the Judgeâ€™s reasons for rejecting the appellantâ€™s contentions on insufficiency, and only in so far as they are relevant to the determination of this appeal.42â€ƒThe Judge observed that the appellant had relied on sÂ 25(5) of the Patents Act (Cap 221, 2005 Rev Ed) (â€œPatents Act (2005 Rev Ed)â€), 
                   72




Foot Note 72

Ã—



 â€ƒThe version as at 30 April 2014.



 which provided that claims shall be â€œclear and conciseâ€ in s 25(5)(b). Citing this courtâ€™s decision in First Currency Choice Pte Ltd v Main-Line Corporate Holdings Ltd and another appeal [2008] 1 SLR(R) 335 (â€œFirst Currency Choiceâ€) at [72], the Judge held that the requirement of clarity was not a ground for revocation under the Patents Act (2005 Rev Ed). She emphasised that what was important was whether the invention has been disclosed sufficiently for a PSA to perform it (Judgment at [191]â€“[192]), and proceeded to consider the appellantâ€™s contentions on why Claim 1 was insufficient. One of these contentions was that Claim 1 of SG 872 was insufficient because the Metripol could not identify whether Î´ was within the SG 872 First Order (Judgment at [193]â€“[196]). She eventually rejected that contention because she accepted Dr Glazerâ€™s evidence that the PSA would know how to determine whether Î´ was within the SG 872 First Order using the Gap Theory (Judgment at [200]â€“[206]).43â€ƒThe Judge also found that Claim 62 had sufficiently disclosed the claimed invention. The appellant argued that the PSA would not know how to calibrate the other growth conditions to the chosen nitrogen concentration to grow an SG 872 Diamond.
                   73




Foot Note 73

Ã—



 â€ƒDCS2 at para 428 (III(G6) ROA 10).



 The Judge rejected this submission given Dr Bergonzoâ€™s evidence that the missing details would be known to a PSA with a working knowledge of the research and development of CVD diamond synthesis (Judgment at [285]).44â€ƒAnother of the appellantâ€™s submissions was that the insufficiency of Claim 62 was demonstrated by how the single crystal CVD diamond material grown in Examples 1 and 14 of SG 872 as well as Examples 4 and 6 of SG 508 had different qualities, even though these examples disclosed a growth process where the synthesis atmosphere had 300ppb to 5ppm nitrogen. The Judge rejected this submission, noting that the respondent had explained that the difference in other parameters of the growth process (such as gas flow and methane concentration in the synthesis atmosphere) between SG 508 and SGÂ 872 resulted in a diamond with different qualities being grown. She also observed that these other parameters did not, in any event, constitute the inventive concept of SG 872 (Judgment at [286]â€“[287]).45â€ƒGiven her finding that Claims 1 and 62 of SG 872 were valid, the Judge did not revoke SG 872 and proceeded to find that both Claims 1 and 62 had been infringed (Judgment at [416]). In particular, she found that the Samples infringed Claim 1 on the basis that they fulfilled limbs ii) and iii) of Claim 1 (Judgment at [431]â€“[443]). The Judge therefore made the following orders, amongst others (Judgment at [478(a)]â€“[478(c)]):(a)â€ƒa declaration that SG 872 is valid and has been infringed;(b)â€ƒan injunction to restrain the defendant, whether by themselves, their directors, officers, servants, agents from (a) making, disposing of, offering to dispose of, using, importing and/or keeping products which infringe SG 872, and/or (b) using or offering for use in Singapore processes which infringe SG 872; and(c)â€ƒan order for the delivery up and/or destruction, to be verified upon oath, of all products or articles which infringe SG 872.The partiesâ€™ casesAppellantâ€™s case46â€ƒThe appellantâ€™s attack on the Judgeâ€™s decision cuts across many areas of patent law, such as novelty, inventive step, and sufficiency. Much reliance has also been placed on concepts recognised in English law which have not been recognised locally, such as â€œBiogen insufficiencyâ€. For the purposes of the present appeal, we only need to focus on two parts of the appellantâ€™s case, both of which concern the non-fulfilment of the sufficiency requirement and are determinative of this appeal.47â€ƒThe first relates to the insufficiency of Claim 62 on the basis that the patent specification fails to teach the â€œnovelâ€ growth process clearly and completely enough for it to be performed by a PSA. In particular, the appellant faults Claim 62 for not disclosing â€œwhat ranges of temperature, gas flow rate or methane concentration will give diamond material within claim 1iii) or any other product claims for that matter.â€
                   74




Foot Note 74

Ã—



 â€ƒAppellantâ€™s Reply (â€œARâ€) at paras 44 and 52.



 We shall refer to these variables, and any other variables in the patented CVD growth process (other than the concentration of nitrogen), as the â€œOther Growth Conditionsâ€. The appellant argues that it is not enough to point to the examples in SG 872 because these â€œdo not support a claim of the breadth of claim 62.â€
                   75




Foot Note 75

Ã—



 â€ƒAR at paras 46 and 50.



 As a result, the PSA is â€œleft with a long and extensive research project to find out what ranges of these other process parameters are required to obtain claim 1iii) or 1ii) diamond materialâ€ and that, therefore, SG 872, is insufficient.
                   76




Foot Note 76

Ã—



 â€ƒAR at para 52; Appellantâ€™s Counselâ€™s Note (â€œACNâ€) at para 11(e).



 48â€ƒThe appellant contends that the respondentâ€™s own arguments under novelty establish insufficiency. Relevantly, the respondent argues that Examples 4 and 6 of SG 508, which teach the use of 2.5ppm and 3.8ppm of nitrogen in the synthesis gas mixture respectively, do not anticipate SG 872 because there are â€œa lot of differencesâ€ in terms of gas flow, temperature and methane concentration between those examples and Claim 62.
                   77




Foot Note 77

Ã—



 â€ƒRC at paras 95â€“97.



 The respondent asserts on this basis that Examples 4 and 6 in SG 508 do not anticipate Claim 62 because following those examples will not inevitably lead to the production of an SG 872 Diamond.
                   78




Foot Note 78

Ã—



 â€ƒRC at para 98.



 But if this is correct, the appellant points out that it must mean â€œthere are other ranges of essential parameters for the process in SGÂ 872 to â€˜workâ€™â€ and that their omission from Claim 62 or the specification of SGÂ 872 means that the invention is insufficiently disclosed.
                   79




Foot Note 79

Ã—



 â€ƒAR at para 46.



49â€ƒBefore proceeding further, we note the respondentâ€™s submission that  pursuant to O 57 r 9A(5B) of the Rules of Court (2014 Rev Ed), the appellant cannot impugn the clarity and completeness of SG 872 as this ground of insufficiency is not particularised in the Appellantâ€™s Case (the â€œO 57 Objectionâ€).
                   80




Foot Note 80

Ã—



 â€ƒRespondentâ€™s skeletal arguments (â€œRSAâ€) at para 38.



 Notwithstanding the respondentâ€™s contentions, we are inclined to consider the appellantâ€™s arguments on this issue (see Oxley Consortium Pte Ltd v Geetex Enterprises Singapore (Ptd) Ltd and another matter [2021]Â 2 SLR 782 at [45]; Global Yellow Pages Ltd v Promedia Directories Pte Ltd and another matter [2017] 2 SLR 185 at [22]). Although the Appellantâ€™s Case focused on another type of insufficiency that we will turn to next, it foreshadowed the possibility of other insufficiency arguments arising â€œdepending on how the Respondent trie[d] to avoid invalidity.â€
                   81




Foot Note 81

Ã—



 â€ƒAC at para 148.



 And in its Reply, the appellant developed its submissions on this point in direct response to the Respondentâ€™s Case. The respondent also did not press the O 57 Objection in oral submissions and instead dealt substantively with the appellantâ€™s arguments in question.
                   82




Foot Note 82

Ã—



 â€ƒSee, eg, Transcript, 24 January 2022, p 50:9â€“19.



 There is therefore no procedural impropriety afoot and/or prejudice to the respondent that precludes the appellant from relying on this ground of insufficiency. 50â€ƒThe second part of the appellantâ€™s case which we will focus on concerns the insufficiency of Claim 1 arising from ambiguity or uncertainty. The appellant argues that the Judge erred in failing to consider this type of insufficiency, which arises where the PSA does not know whether he is inside or outside the claim.
                   83




Foot Note 83

Ã—



 â€ƒAC at para 150.



 On the facts, it argues that the Claim 1 and SG 872 are insufficient because the PSA cannot tell whether the Î´ value of a particular single crystal CVD diamond was within the SG 872 First Order and hence within the scope of the asserted monopoly.Respondentâ€™s case51â€ƒThe respondent supports the Judgeâ€™s findings that SG 872 is not anticipated, obvious or insufficiently disclosed.52â€ƒIts case is that SG 872 claims a new single crystal CVD diamond material with exceptionally low strain and a new method of producing said diamond material.
                   84




Foot Note 84

Ã—



 â€ƒRSA at paras 1â€“4.



 By way of a letter dated 21 September 2022, which was sent in response to our query (see above at [10]), the respondent accepts that each product claim in SG 872 covers a class of products. The distinction between a single product and a class of products is relevant to the issue of insufficiency. If the claim is to a single product, then it is sufficient if it enables the making of that one product. If, on the other hand, the claim is to a class of products, that class of products is sufficiently enabled only if the skilled man can work the invention in respect of all members of the class (Regeneron Pharmaceuticals Inc v Kymab Ltd and another [2016] EWHC 87 (Pat) at [209]). We return to these principles at [108]â€“[112] and [184] below. 53â€ƒIn response to the appellantâ€™s submission that the patent is insufficient because it fails to teach the Claim 62 growth process clearly and completely enough, the respondent argues that the correct test is whether the patentâ€™s specification as a whole discloses the invention sufficiently.
                   85




Foot Note 85

Ã—



 â€ƒRespondentâ€™s Counselâ€™s Note (â€œRCNâ€) at para 51(b).



 It argues that the specification of SG 872 (in particular Example 1 read with Example 9) gives full disclosure of the Other Growth Conditions, including temperature, pressure and gas flow rates. It stresses that the burden is on the appellant to show that the invention is unworkable by the PSA who is â€œtrying to give practical meaning to the patent specification.â€
                   86




Foot Note 86

Ã—



 â€ƒRCN at para 51(d).



54â€ƒNext, as to the appellantâ€™s submission that the Judge erred in failing to consider a further type of insufficiency brought about by ambiguity or uncertainty, the respondent submits that the Judge rejected the appellantâ€™s argument on insufficiency arising from â€œambiguityâ€, on the basis that in First Currency Choice we held that lack of clarity under s 25(5)(b) of the Patents Act (2005 Rev Ed) is not a ground for revocation.
                   87




Foot Note 87

Ã—



 â€ƒRC at para 173.



 It further submits that the appellant has not explained how the Judge erred in following First Currency Choice, or why the court should depart from the position at law that lack of clarity is not a basis for revocation.
                   88




Foot Note 88

Ã—



 â€ƒRC at para 174.



 On the facts, the respondent submits that the PSA can determine that Î´ is within the SG 872 First Order by using four different methods.
                   89




Foot Note 89

Ã—



 â€ƒRC at para 175.



Issues to be determined 55â€ƒIn light of the foregoing, the issues we shall address in this decision are as follows: (a)â€ƒWhether the product claims in SG 872 cover a single product or a range of products?(b)â€ƒWhether any or all of the claims in SG 872 are invalid due to insufficiency?(c)â€ƒWhether SG 872 should be revoked in its entirety?Foundational principlesPatents in general56â€ƒTo set the context for the analysis that follows, we first touch on some foundational principles that guide us, beginning with the objectives of the patent regime and how these are advanced. Where relevant, we also explain principles of patent law which are engaged in the reasoning of this judgment, or which provide context to our analysis.57â€ƒThe patent regime has two main aims. First, it seeks to encourage innovation by granting the patentee a monopoly over the patented invention for a limited period (meaning the right to exclude others from using that invention). In this regard, each patent demarcates the monopoly which the patentee asserts. Apart from incentivising innovation with the promise of a monopoly right, the patent regime also seeks to disseminate knowledge. This second objective, the dissemination of knowledge, is as important as the first and is achieved by requiring the patentee to teach, in the patent specification, how to work or make the asserted invention. This is so that the public, following the expiry of the limited-term monopoly, may freely use or build on the invention in light of the teachings in the patent (see Ng-Loy Wee Loon, Law of Intellectual Property of Singapore (Sweet & Maxwell, Revised 3rd Ed, 2022) (â€œNg-Loyâ€) at paras 29.1.2â€“29.1.3 and Colin Birss et al, Terrell on the Law of Patents (Sweet & Maxwell, 19th Ed, 2022) (â€œTerrellâ€) at para 1-01). 58â€ƒTo ensure that patents effectively incentivise innovation in furtherance of the first aim, the patent regime only grants monopolies over deserving inventions. An invention must be novel, contain an inventive step and be capable of industrial application, before it will be patentable (ssÂ 13â€“16 of the Patents Act (2005 Rev Ed)). If any one of these requirements is not met, the patent may be revoked (sÂ 80(1)(a) of the Patents Act (2005 Rev Ed)). We briefly introduce the concepts of novelty and inventive step as the parties have made submissions on them (although, as foreshadowed at [46] above, we will not analyse the partiesâ€™ submissions on these requirements in this judgment). 59â€ƒNovelty requires the invention to be new, in that it does not form part of the state of the art (s 14(1) of the Patents Act (2005 Rev Ed)). If directions forming part of the state of the art (meaning a piece of prior art) lead inevitably to something that would infringe the patent, the invention lacks novelty and the patent can be revoked (MÃ¼hlbauer AG v Manufacturing Integration Technology Ltd [2010] 2 SLR 724 (â€œMÃ¼hlbauerâ€) at [17]). The state of the art comprises all matter (whether a product, a process, information about either, or anything else) which has at any time before the priority date of that invention been made available to the public (whether in Singapore or elsewhere) by written or oral description, by use or in any other way (s 14(2) of the Patents Act (2005 Rev Ed)). By default, the â€œpriority dateâ€ of an invention is the filing date of the patent application (s 17(1) of the Patents Act (2005 Rev Ed)). Under certain conditions, a patentee can depart from this default position by claiming that the priority date of the invention takes reference from the date of filing of an earlier patent application or applications (see s 17(2) of the Patents Act (2005 Rev Ed)), which has the effect of limiting the state of the art to what it was at that earlier date. On the other hand, a later priority date may widen the pool of material which may anticipate the invention. 60â€ƒAn invention shall be taken to involve an inventive step if it is not obvious to a PSA, having regard to any matter which forms part of the state of the art as at the priority date of the invention (s 15 of the Patents Act (2005 Rev Ed)). When considering the issue of obviousness, it is assumed that the invention is novel and differs in some identifiable respect from the prior art. The key question then is whether these differences constitute steps that would have been obvious (Ng-Loy at para 30.2.48; MÃ¼hlbauer at [20] citing Windsurfing International Inc v Tabur Marine (Great Britain) Ltd [1985] RPC 59 (â€œWindsurfingâ€)). This is a question of degree. 61â€ƒSeparately, the second aim of the patent regime, namely knowledge dissemination, is advanced by the â€œsufficiencyâ€ or â€œenabling disclosureâ€ requirement, which provides that the patent specification must disclose the invention in a clear and complete manner for it to be performed by a PSA. This requirement is statutorily embodied in ss 25(4) and 80(1)(c) of the Patents Act (2005 Rev Ed), with the latter providing for the revocation of the patent if the patent specification is insufficient.62â€ƒUnderlying the novelty, obviousness and sufficiency inquiries is the need for the court to first construe the patent claims before undertaking the substantive analyses (Ng-Loy at paras 30.2.34 and 30.2.52; Terrell at para 13-15). Claim construction identifies the invention that is said to be novel, non-obvious and sufficiently disclosed, and in respect of which the monopoly is claimed. It is therefore a pivotal exercise that frames the substantive analyses which follow thereafter.63â€ƒAnother point of commonality is that the court, when undertaking the novelty, obviousness and sufficiency inquiries, as well as in construing the claims, dons the mantle of the PSA, that is, someone in the field of technology relevant to the invention in question and who possesses, amongst other characteristics, common general knowledge in the art (MÃ¼hlbauer at [18] (novelty); ASM Technology Singapore Pte Ltd v Towa Corp [2018] 1 SLR 211 at [78] (obviousness); First Currency Choice at [60]â€“[61] (sufficiency); Lee Tat Cheng v Maka GPS Technologies Pte Ltd [2018] 1 SLR 856 (â€œLee Tat Cheng (CA)â€) at [41] (claim construction)). Common general knowledge is information which, at the relevant date, is common knowledge in the art to which the alleged invention relates, so as to be known to duly qualified persons engaged in that art (British Thomson-Houston Co Ltd v Stonebridge Electrical Co Ltd (1916)Â 33 RPC 166 at 171; Terrell at para 8-61).64â€ƒWhilst the PSA and his common general knowledge are important concepts which feature in multiple areas of patent law, they assume relevance in different ways. When determining whether the patented invention is novel or contains an inventive step, the PSA employs his common general knowledge to interpret prior art, amongst other purposes (see MÃ¼hlbauer AG at [20], citing Windsurfing; Synthon BV v SmithKline Beecham plc [2005] UKHL 59 at [32]; Terrell at paras 8-62, 11-55, 12-10 and 12-19). Interpreting the prior art is crucial to determining what information is conveyed to the PSA at the priority date of the patent in suit or the date on which the piece of prior art (such as a book or journal) was published and whether that information renders the invention obvious and/or anticipates the invention (see Terrell at paras 11-55â€“11-60 and 12-10). However, this is not the case where claim construction and sufficiency are concerned. In these contexts, the PSA mainly directs his common general knowledge towards interpreting the patent claims and working the invention disclosed therein (see Lee Tat Cheng v Maka GPS Technologies Pte Ltd [2018] 3 SLR 1334 (â€œLee Tat Cheng (HC)â€) at [54]; Genelabs Diagnostics Pte Ltd v Institut Pasteur and another [2000] 3 SLR(R) 530 (â€œGenelabs (CA)â€) at [61]â€“[63]).65â€ƒFurther, the precise assumptions applicable to the PSA are not identical in all areas of patent law. For instance, in matters of claim construction and sufficiency, the PSA is assumed to have the patent specification in his hands whereas when considering the issue of obviousness, the PSA is deemed only to be considering the prior art without the patenteeâ€™s invention in front of him (Terrell at para 8-19).66â€ƒThe central issues concerned in our decision relate to claim construction and insufficiency. To reiterate, the former identifies the invention that is the subject of the claims, whilst the latter entails a consideration of whether the patent specification sufficiently enables a PSA to perform that invention. It is in this context that we now turn to examine the characteristics of the PSA relevant to our reasoning in the present judgment, and the common general knowledge he (or, the notional team comprising the PSA) would possess.The person skilled in the art67â€ƒThe PSA, apart from possessing common general knowledge in the art, also has a practical interest in the subject matter of the patent and is likely to act on the directions given in it with the desire to make the directions in the patent work. He is a reasonably intelligent but unimaginative workman or technician who has the skill to make routine workshop developments, but not to exercise inventive ingenuity or think laterally (Ng Kok Cheng v Chua Say Tiong [2001] 2 SLR(R) 326 (â€œNg Kok Chengâ€) at [21]; First Currency Choice at [28]; Ng-Loy at para 30.1.12).68â€ƒThe PSA may be an individual person or a notional team of people. The need for a notional team may arise where it is clear that the patent specification engages more than one set of skills which in the real world would be possessed by more than one person. This may be the case where the art is one that concerns a highly developed technology. In such circumstances, the specification can be said to be addressed to a team, with each member contributing his or her individual skill which would in turn be employed in combination in interpreting and carrying into effect the instructions in the patent (Terrell at paras 8-35â€“8-36; The General Tire & Rubber Company v The Firestone Tyre and Rubber Company Limited and others [1972] RPC 457 (â€œGeneral Tireâ€) at 483; Schlumberger Holdings Ltd v Electromagnetic Geoservices AS [2010] EWCA Civ 819 at [33]; Halliburton Energy Services, Inc v Smith International (North Sea) Ltd [2006] RPC 2 at 46; see also Institut Pasteur and another v Genelabs Diagnostics Pte Ltd and another [2000] SGHC 53 (â€œGenelabs (HC)â€) at [194]). For the avoidance of doubt, the formation of such a notional team does not mean that the common general knowledge of the PSA is only that which is common to persons with these different backgrounds (Inhale Therapeutic Systems Inc v Quadrant Healthcare Plc [2001] All ER (D) 211 (Jun) at [39]â€“[42]; First Currency Choice at [31]).69â€ƒAs noted at [65] above, when considering the issues of claim construction and sufficiency, the PSA is assumed to have the patent specification in his hands and have the same attributes for both inquiries (see Terrell at para 8-19). The PSA, for the purposes of the insufficiency inquiry, is â€œtrying to carry out the invention and achieve successâ€ (Zipher Ltd v Markem Systems Ltd and another [2008] EWHC 1379 (Pat) (â€œZipherâ€) at [366]). It is through the eyes of the PSA that the patent will fall to be interpreted, and the PSA must know how to perform the invention upon reading the specification in light of his common general knowledge.70â€ƒMoving now to the PSA in the present case, the Judge found that the PSA, for the purpose of claim construction, would be a notional team of persons working in the field of growing CVD diamonds, with expertise in diamonds (including natural, HPHT and CVD diamonds) and the sciences (including applied physics, optical engineering and material sciences) (Judgment at [14]):In the present case the defendantâ€™s PSA is a composite person having a Masterâ€™s degree in mechanical or chemical engineering and having a doctorate in applied physics, electrical engineering, optical engineering or a closely related field, aided by an engineer/technician with skills in mechanical polishing, laser cutting and correlated measurements. The plaintiff disputes this, and contends that the PSA is a team of people collectively having a Bachelor of Science in physics, chemistry or material sciences, and knowledge of diamond properties in all its forms at the material time (natural, high-pressure high-temperature (â€˜HPHTâ€™) and CVD diamonds) as well as working knowledge of CVD diamond synthesis and commercial production. This disagreement has no practical significance, as no finding in the case turns upon this fine distinction. The present case would require consideration of a team of persons working in the field of growing CVD diamonds. In my judgment, the relevant PSA in such a field would include a team of individuals with expertise in diamonds and science generally, with access to individuals possessing doctorate qualifications.[emphasis added]71â€ƒThe parties have not challenged the Judgeâ€™s finding in that passage of the composition and qualifications of the notional team of persons. Further, as already mentioned at [69] above, the PSA for the purposes of claim construction and sufficiency will be the same. However, before us, the appellant seeks to impute the PSA with the specific purpose of growing single crystal CVD diamond material for use in the most demanding optical applications â€“ â€œetalons and anvilsâ€.
                   90




Foot Note 90

Ã—



 â€ƒAppellantâ€™s Skeletal Arguments (â€œASAâ€) at para 21; AR at para 12; Transcript, 20 January 2022, p 15:24â€“26.



 The respondent rejects this imputation.
                   91




Foot Note 91

Ã—



 â€ƒRC at paras 44, 68, 148 and 165.



 Although this dispute between the parties mainly arises in the course of their submissions on novelty and obviousness, a proper identification of the PSAâ€™s practical interest is also important in the context of claim construction and sufficiency.72â€ƒAs earlier stated, the PSA is trying to carry out the invention (see [69] above) and has a practical interest in the â€œsubject matter of the patentâ€ (see [67] above). What the subject matter of the patent is should be determined by reference to the patent specification. Having regard to the specification of SG 872, we are satisfied that the PSAâ€™s interest would not be limited to producing etalons and anvils. The patent specification describes the invention in SG 872 in more general terms â€“ a single crystal CVD diamond material which possesses certain desirable characteristics, and which can be used in connection with a wide range of optical applications which â€œinclude but are not limited toâ€ optical windows, laser windows, optical reflectors, optical refractors and lenses, diffractive optical elements, etalons, ornamental use and anvils [emphasis added].
                   92




Foot Note 92

Ã—



 â€ƒBOM at p 322. 



 Accordingly, the PSAâ€™s practical interest lies in using the growth process taught in SG 872 to grow low-strain diamonds for a range of optical applications.The common general knowledge73â€ƒAs already noted, the PSA is imputed with common general knowledge in the art. He draws upon such knowledge to understand a patent and in his attempts to carry it into effect. As mentioned at [63] above, common general knowledge is information which, at the relevant date, is common knowledge in the art to which the alleged invention relates, so as to be known to duly qualified persons engaged in that art. The relevant art to which the alleged invention is to be gathered from the patent specification itself (First Currency Choice at [30]).74â€ƒCommon general knowledge is ordinarily established, where not agreed, by expert evidence which is usually supported by reference to textbooks or other reference works which the PSA would be expected to have access to and acquire his information from. The publication at or before the relevant date of such documents may be prima facie evidence tending to show that the statements contained in them were part of the common general knowledge, but that is far from complete proof as those statements may well have been discredited, forgotten or ignored (Terrell at paras 8-75â€“8-77). It is also not sufficient just to point out that it was said in a scientific paper that has been well circulated. A particular disclosure does not become common general knowledge merely because it is widely read, and still less because it is widely circulated. To prove that a particular disclosure in scientific paper has become common general knowledge, it must be shown that it is generally known and generally regarded as a good basis for further action by the bulk of those who are engaged in the particular art to which the disclosure relates (General Tire at 480â€“481).75â€ƒIn the present case, as identified by the Judge, the art relates to the growth of CVD diamonds (Judgment at [14]). In our view, this includes methods of measuring the physical properties of the CVD diamonds grown. Based on the Primer,
                   93




Foot Note 93

Ã—



 â€ƒSee Primer at p 1 et seq.



 the parties are agreed that the information set out at [11]â€“[27], [32]â€“[35] and [38] above constituted common general knowledge in the art of growing CVD diamonds at the relevant time. There are further points of agreement on what was part of the common general knowledge and they will be mentioned, where relevant, when we apply the principles of sufficiency to the facts of this case. But before going into the issue of sufficiency, it is pertinent for us to first consider how the claims, in particular the product claims, ought to be construed. It is to this issue that we now turn.Patent construction: do the product claims in SG 872 cover a single product or a class of products? 76â€ƒThe question here is whether the product claims in SG 872 cover a single product or a class of products. As we shall see, this affects what, in law, must be enabled by the specification of SG 872 (see [108]â€“[112] below), and whether the claims in SG 872 are in fact insufficient (see, eg, [184]â€“[185] below).77â€ƒWhether the patent claims a single product or a range of products is a question of construction of the claim(s) in the patent (Regeneron Pharmaceuticals Inc v Kymab Ltd [2021] 1 All ER 475 (â€œRegeneron (SC)â€) at [3]. Before setting out the principles on claim construction in detail, we touch on the relevance of the priority date(s) of the product claims in SGÂ 872 to their interpretation. 78â€ƒIn Lee Tat Cheng (CA) at [53] and [55], we held that the relevant date for claim construction is the date of the patent application (meaning its filing date) (see also Lee Tat Cheng (HC) at [49]). However, it does not appear that the patentee there claimed that its invention took priority from an earlier filing. If the patentee there had claimed priority, a conundrum noted by the authors of Terrell would have arisen. That conundrum arises from the fact that the English cases are divided over whether the relevant date for patent construction is the priority date or filing date of the patent application, or the publication date of the patent (see Terrell at paras 9-08â€“9-014). At present, the respondent does claim priority from GB Patent Application No 0227261.5 (â€œGB 261â€), which was filed on 21 November 2002. The parties agree that Claim 1ii) takes priority from 21 November 2002 but disagree on whether Claims 1iii) and 62 enjoy the same priority.
                   94




Foot Note 94

Ã—



 â€ƒAC at paras 26 (Claim 1iii)) and 31 (Claim 62).



 This specific complication did not present in Lee Tat Cheng (CA). However, nothing in this case turns on which of the three dates should be adopted in law and the parties do not submit otherwise. We therefore prefer to leave this issue for an appropriate case and proceed on the basis that the relevant date for patent construction is the filing date of SGÂ 872 (that is, 20 November 2003). Consequently, any common general knowledge which may be relevant to patent construction must be shown to exist by this date. In addition, whether the asserted priority date is granted only assumes significance in this case in relation to the issues of novelty and obviousness. However, as stated at [46], we need not reach or address the latter issues in this judgment. 79â€ƒTurning to the substantive principles on claim construction, in Lee Tat Cheng (CA), we reaffirmed the correctness of construing a patentâ€™s claims purposively (at [41] and [55]). This entails, among other things, viewing the claims through the lens of the PSA (at [41]):(a) In ascertaining the true construction of a patent specification, the claims themselves are the principal determinant. What is not claimed is deemed to be disclaimed. (b) The description and other parts of the patent specification form the context for, and may assist in, the construction of the claims. (c) The claims are to be construed purposively, and not literally. This would give the patentee the full extent, but no more than the full extent, of the monopoly which a person skilled in the art, reading the claims in context, would think the patentee was intending to claim. In this regard, the starting point is to ask the threshold question: What would the notional skilled person have understood the patentee to mean by the use of the language of the claims? The Improver questions (see [30] above), which were derived from Catnic ([26] supra), have also been used as guidance in construing patent claims. (d) As a general rule, the notional skilled person should be taken to be a workman or technician who is aware of everything encompassed in the state of the art and who has the skill to make routine workshop developments, but not to exercise inventive ingenuity or think laterally. (e) Purposive construction does not entitle the court to disregard clear and unambiguous words in a patent claim, and the court is not entitled to rewrite or amend the claim under the guise of construction. In construing a claim purposively, the language that the patentee has adopted is more often than not of utmost importance. It is not permissible to put a gloss on or expand a claim by relying on a statement in the patent specification. (f) If an allegedly infringing article falls within the words of one of the claims of a patent properly construed, the patent would have been infringed. To constitute infringement, the article concerned must usurp each and every one of the essential elements of the claim in question.80â€ƒThe patent â€œspecificationâ€, referred to in the passage above, comprises the description of the invention, drawings (if any) and the claims (Halsburyâ€™s Laws of Singapore vol 13(3) (LexisNexis, 2020 reissue) (â€œHalsburyâ€™s Singapore IPâ€) at para 160.321). Examples illustrating how to carry out the invention also form part of the patentâ€™s specification (see rr 19(3) and 19(5)(e) of the Patents Rules (1996 Rev Ed)). However, the claims serve a different purpose from the rest of the patentâ€™s specification, as explained by Floyd LJ in Adaptive Spectrum & Signal Alignment Inc v British Telecommunications PLC [2014] EWCA Civ 1462 at [45]: ... The specification describes and illustrates the invention, the claims set out the limits of the monopoly which the patentee claims. As with the interpretation of any document, it is conceivable that a certain, limited, meaning may be implicit in the language of a claim, if that is the meaning that it would convey to a skilled person, even if that meaning is not spelled out expressly in the language. However it is not appropriate to read limitations into the claim solely on the ground that examples in the body of the specification have this or that feature. The reason is that the patentee may have deliberately chosen to claim more broadly than the specific examples, as he is fully entitled to do.[emphasis in original]81â€ƒThe parties initially appear to have approached this appeal on the basis that each product claim is a claim to a single product â€“ a new CVD diamond material. For instance, the Appellantâ€™s Case states that â€œClaim 1 is a product claim, so the eight alternates in Claim 1 disclose the same physical thing â€“ a particular CVD diamond material, characterised in eight different waysâ€.
                   95




Foot Note 95

Ã—



 â€ƒAC at para 19.



 The Respondentâ€™s Case states that â€œSG 872 claims a new diamond materialâ€ [emphasis in original omitted; emphasis added in italics].
                   96




Foot Note 96

Ã—



 â€ƒRC at para 11.



 Both parties took similar positions in their written closing submissions in the second tranche of the trial.
                   97




Foot Note 97

Ã—



 â€ƒPCS2 at para 871 (III(G3) ROA 122â€“123); DCS2 at para 56 (III(G6) ROA 36).



 82â€ƒWe wrote to the parties on 14 September 2022 seeking clarification on this issue. The appellant confirmed its view that SG 872 teaches the PSA a new method to â€œgrow one product, i.e. a CVD single crystal diamond material having one or more of the specified parameters.â€ It argued that the â€œdifferent ranges and combination of properties in each product claims [were] therefore variations of the same product grown from the one process described in SG 872â€ [emphasis added].
                   98




Foot Note 98

Ã—



 â€ƒRespondentâ€™s letter dated 21 September 2022 at para 5.



 In contrast, the respondent took the view that each product claim could be said to cover a class of products. In particular, the respondent noted that â€œgiven that the product claims of SG 872 claim, inter alia, a range of values (or depend on a claim which does), these would cover a class of products meeting the values within that range as opposed to an individual product.â€
                   99




Foot Note 99

Ã—



 â€ƒAppellantâ€™s letter dated 21 September 2022 at para 2(b).



83â€ƒWe agree with the respondent. Properly construed, each claim asserts a monopoly over a class of single crystal CVD diamond materials. 84â€ƒWe turn first to Claim 1, which, as noted above, is the claim that all the other product claims refer back to. In our judgment, Claim 1 can be infringed by various types of single crystal CVD diamond materials, each with a different combination of the physical properties defined in the limbs of Claim 1. That the diamond materials falling within Claim 1 may possess different combinations of physical properties is clear from the words in the chapeau of Claim 1: â€œA CVD single crystal diamond material which shows at least one of the following characteristicsâ€ [emphasis added]. Our reading of the plain language of Claim 1 is fortified by the description of the invention in the specification of SG 872. The relevant portion of the description reads as follows:
                   100




Foot Note 100

Ã—



 â€ƒBOM at p 309.



 The diamond material of the invention can be tailored to specific applications, and although it may not be endowed with all of the above properties in all cases, in many applications it is the ability of the diamond material to show a substantial set or particular combination of the above properties which makes its use particularly beneficial. For example, for use as an etalon, the material may require optical homogeneity, low absorption, high thermal conductivity and the ability to be processed flat and parallel, but laser damage thresholds and mechanical strength may be less important.[emphasis added in bold italics]The â€œabove propertiesâ€ referred to in the passage include optical homogeneity, effective refractive index, birefringence, optical absorption, optical scatter, laser damage threshold, thermal conductivity, parallelism, flatness and mechanical design strength.
                   101




Foot Note 101

Ã—



 â€ƒBOM at pp 301â€“308.



 Thus, the description indicates that the invention covers a range of single crystal CVD diamonds possessing different combinations of physical properties.85â€ƒFurther, as noted in Lee Tat Cheng (CA) at [41(c)], the language of the claim must be construed through the eyes of a PSA. In this regard, we found the evidence of Dr Mark Edward Newton (â€œDr Newtonâ€), the respondentâ€™s expert witness, to be instructive. As the respondent alluded to in its letter of 21 September 2022,
                   102




Foot Note 102

Ã—



 â€ƒRespondentâ€™s letter dated 21 September 2022 at para 2(a).



 Dr Newton testified that the various limbs in Claim 1 cover optical properties which â€œmay be related but remain differentâ€ [emphasis added in bold italics]. 
                   103




Foot Note 103

Ã—



 â€ƒNewton-2 at paras 79, 83 (I RSCB 173).



 He added that â€œ[m]any are not directly derivable one from anotherâ€.
                   104




Foot Note 104

Ã—



 â€ƒNewton-2 at para 76 (1 RSCB 171).



 It is not clear if these observations also apply to Claims 1ii) and 1iii), which both relate to birefringence. Dr Newtonâ€™s evidence nevertheless reinforces our understanding that diamonds which fulfil different combinations of limbs in Claim 1 are in fact different diamonds. Our conclusion would be different if the measurements in each limb of Claim 1 were different ways of quantifying the same property.86â€ƒAlthough Dr Nebelâ€™s first report dated 13 May 2019 (â€œDr Nebelâ€™s 1st Reportâ€) stated that a diamond satisfying one limb of Claim 1 will also satisfy all remaining limbs, and that the properties mentioned in Claim 1 are â€œmerely ... different measurement techniques for a common aspect of the diamondâ€ [emphasis added in bold italics], we reject this.
                   105




Foot Note 105

Ã—



 â€ƒDr Nebelâ€™s 1st Report (â€œNebel-1â€) at para 69 (III(B13) ROA 90).



 For one, he offered no credible evidence in his Reply Report dated 26 June 2019 or oral testimony to support this assertion. In his reply report, Dr Nebel asserted that measurements like â€œdislocation density, Raman peak width, X-ray rocking curve width and birefringenceâ€ measure â€œstrain in diamond ... and any change in strain in a diamond reflects a proportional change in these measurement parameters.â€
                   106




Foot Note 106

Ã—



 â€ƒIII(B62) ROA 93 (para 223); see also III(D5) ROA 119:3â€“6.



 But Dr Nebel did not explain nor has the appellant otherwise shown that the optical properties or measurements described in each limb of Claim 1, including optical homogeneity, free spectral range, contrast ratio, insertion loss and variation in refractive index, merely measure a common property or will necessarily be present if one limb of Claim 1 is fulfilled. Crucially, Dr Nebelâ€™s evidence does not square with the specification of SG 872. The â€œSummary of the Inventionâ€ states clearly that the CVD single crystal diamond material invented â€œmay not be endowed with all of the above properties in all casesâ€, but should show â€œat least one, preferably at least two, more preferably at least three, and even more preferably at least fourâ€ characteristics which are listed. The listed characteristics in the Summary of the Invention correspond to properties defined under the limbs in Claim 1, and include optical homogeneity (see Claim 1i)), birefringence (see Claims 1ii) and 1iii)), effective refractive index (see Claim 1iv)), free spectral range (â€œFSRâ€) (see Claim 1v)) and contrast ratio (see Claim 1vi)).
                   107




Foot Note 107

Ã—



 â€ƒSee BOM at pp 301â€“308, 363â€“365.



 Moreover, in its submissions below, the appellant did not appear to dispute the correctness of the portion of Dr Newtonâ€™s evidence that we have accepted at [85] above.
                   108




Foot Note 108

Ã—



 â€ƒSee Defendantâ€™s skeletal oral reply at para 26 (III(G6) ROA 227), read with PCS2 at para 288 (III(G2) ROA 129â€“131).



 87â€ƒTurning now to the subsequent product claims, these likewise cover a range of diamonds. These claims may be placed into three categories based on their phraseology, all of which incorporate Claim 1. The first category of claims incorporates all preceding claims, including Claim 1. An example is Claim 6, which states: â€œA CVD single crystal diamond material according to any one of the preceding claims, which has a value of effective refractive index of 2.3964 to within an accuracy of +/-0.001â€ [emphasis added]. 
                   109




Foot Note 109

Ã—



 â€ƒBOM at p 309.



 The second category of claims expressly incorporates a preceding claim, the latter of which incorporates Claim 1. An example is Claim 7, which states: â€œA CVD single crystal diamond material according to claim 6, which has a value of effective refractive index of 2.39695 to within an accuracy of +/-0.0005.â€ By referring back to Claim 6, Claim 7 likewise incorporates Claim 1. The third category consists only of Claim 72. It reads: â€œA CVD single crystal diamond material produced by a method according to any one of claims 62 to 71.â€ Claims 62 to 71 disclose a process that purportedly enables a PSA to produce a CVD diamond in one or more of Claims 1 to 61. By referencing all of these process claims, Claim 72 includes the range of diamonds defined under Claim 1.88â€ƒOnce a subsequent product claim incorporates Claim 1, it asserts a monopoly over a range of products. This is because any diamond within the class of products in Claim 1, which also fulfils the additional parameter expressed in the subsequent claim, will fall within that subsequent claim. It is irrelevant that the additional parameter in the subsequent claim is a specific or single value of a particular physical property (for instance, Claim 6, in so far as the additional parameter, â€œeffective refractive index of 2.3964 within an accuracy of +/-0.001â€, expresses a single value of an effective refractive index) or a binary condition that is or is not satisfied (for instance, Claim 50, which has an additional requirement that the CVD diamond be formed into a polished gemstone). For reference, these claims state as follows: 6. A CVD single crystal diamond material according to any one of the preceding claims, which has a value of effective refractive index of 2.3964 to within an accuracy of +/-0.001.50. A CVD single crystal diamond material according to claim 49, which is formed into a polished gemstone.In these instances, the PSA would be satisfied that the patentee contemplated multiple diamonds in the Claim 1 range fulfilling the additional parameter in Claims 6 and 50. This is because the claim incorporates the entire range of diamonds in Claim 1 and there is nothing in the language of Claims 6 and 50, or for that matter in any other similar claim, to justify limiting the monopoly to a single product. We approach this on the basis that the respondent should be afforded the full extent of the monopoly that is supported by the language it has adopted.89â€ƒIt is even more the case that where the additional parameter in the subsequent claim is itself expressed as a range of values, the claim covers a range of products. One example of this is Claim 4, which states: â€œA CVD single crystal diamond material according to any one of the preceding claims, wherein the modulus of the sine of the phase shift, |sin Î´|, for at least 98% of the analysed area remains in first order and does not exceed 0.4â€ [emphasis added in bold italics]. The phrase â€œdoes not exceed 0.4â€ indicates that Claim 4 monopolises a class of CVD single crystal diamond materials which have different |sin Î´| values falling within the range of less than or equal to 0.4 (and which fulfil any preceding claim). By way of example, a CVD single crystal diamond material for which |sin Î´| is equal to 0.2 as well as a CVD single crystal diamond material for which |sin Î´| is equal to 0.3 could fall within the scope of Claim 4, subject to the diamond material also satisfying a preceding claim.90â€ƒWe find support for our construction of the product claims in the courtâ€™s analysis in Anan Kasei Co. Ltd and another company v Neo Chemicals and Oxides Ltd (formerly Molycorp Chemicals and Oxides (Europe) Ltd) and another company [2019] EWCA Civ 1646 (â€œAnanâ€). The patent contained a product claim for ceric oxide, which stated as follows: â€œA ceric oxide consisting essentially of a ceric oxide, and wherein said ceric oxide has a specific surface area of not smaller than 30.0 m2/g when subjected to calcination at 900ËšC for 5 hours.â€ (at [8]). One issue which arose was whether a claim limited by reference to a desirable physical characteristic, namely high specific surface area, and specifying that it remained the same after being subjected to a high temperature, insufficiently described the invention and was invalid. In analysing this issue, Floyd LJ (with whom Lewison and Peter Jackson LJJ agreed) noted that the claim covered a class of products (at [53]): The claim in the present case is to a class of products identified by their composition (consisting essentially of ceric oxide), their physical characteristics (their [specific surface area or] SSA), and their performance in the calcining test. That it is a class of products is plain from the fact that the claim can be satisfied by a range of degrees of purity, and SSA, and from the fact that performance in the calcining test may vary from pass to distinction.[emphasis added]91â€ƒRegeneron (SC) is also illuminating. The patent in the suit contained a product claim which read as follows:A transgenic mouse that produces hybrid antibodies containing human variable regions and mouse constant regions, wherein said mouse comprises anÂ in situÂ replacement of mouse VDJ regions with human VDJ regions at a murine chromosomal immunoglobulin heavy chain locus and anÂ in situÂ replacement of mouse VJ regions with human VJ regions at a murine chromosomal immunoglobulin light chain locus.Lord Briggs summarised the claim in these terms (at [15]):This is of course a product claim, seeking a monopoly for the 'making' (at first sight a strange but serviceable word to use of an animal) of a genetically engineered mouse having the characteristics described in the claim. The characteristics related both to what such a mouse does (namely produce the hybrid antibodies described) and to what is contained in its genome, namely the Reverse Chimeric Locus, achieved by a process of 'in situÂ replacement' of the murine variable regions in both the light and heavy chain gene loci with the corresponding but of course different human variable regions. The claim seeks protection for the making and exploitation of any type of mouse having those characteristics. Since the description of what the mouse does is more loosely worded than the description of what lies within its genome, it is the latter description which mainly controls the breadth of the claim.[emphasis added in italics and bold italics]92â€ƒRelevantly, the appeal in Regeneron (SC) proceeded on the basis that the claim covered a range of transgenic mice, which differed based on the amount of human antibody genes implanted into the genome of the mouse (see [7], [16]â€“[17] and [81]). However, it bears highlighting that this issue of claim construction was resolved by the courts below and was not an issue in the appeal before the UK Supreme Court (â€œUKSCâ€).93â€ƒIn the present case, by defining parameters using ranges of values or incorporating claims which do so, each product claim in substance claims or asserts a monopoly over a range of single crystal CVD diamonds, each with a different combination of physical properties.94â€ƒBefore leaving this issue, we note that while Dr Newtonâ€™s evidence assisted us in construing the product claims, the expert evidence is not entirely clear as to whether each product claim covers a class of products or not. Be that as it may, claim construction is ultimately a task for the court. In particular, while expert evidence is useful in explaining the technical terms and technical features of the invention, the nature of the invention for which a patent is granted must be ascertained by the judge and not an expert (Brooks v Steele and Currie (1896) 13 RPC 46 at 73 and Dyson Appliances Ltd v Hoover Ltd [2002] RPC 22 at [13], cited in Terrell at paras 9-182 and 9-184). For the reasons given above, we hold that each of the product claims in SG 872 covers a range of products.InsufficiencyThe law of insufficiency95â€ƒThe sufficiency or enabling disclosure requirement finds statutory expression in ss 25(4) and 80(1)(c) of the Patents Act (2005 Rev Ed). Section 25(4) of the Patents Act (2005 Rev Ed), in the context of prescribing the requirements of a patent application, states that: The specification of an application shall disclose the invention in a manner which is clear and complete for the invention to be performed by a person skilled in the art.96â€ƒNon-compliance with s 25(4) of the Patents Act (2005 Rev Ed) is a ground for revoking the patent, as provided for in s 80(1)(c) of the Patents Act (2005 Rev Ed):Subject to the provisions of this Act, the Registrar may, on the application of any person, by order revoke a patent for an invention on (but only on) any of the following grounds:â€¦(c) the specification of the patent does not disclose the invention clearly and completely for it to be performed by a person skilled in the art;97â€ƒIt is this requirement that compels the inventor to tell the world how his invention works so that, after the expiry of the patent when his invention falls into the public domain, a PSA will have sufficient information to work the invention and build on it (see Ng-Loy at paras 29.1.3 and 30.3.1).98â€ƒEnglish case law may be instructive when interpreting the scope of the sufficiency requirement under our Patents Act (2005 Rev Ed). Section 25(4) of the Patents Act (2005 Rev Ed) is in materially similar terms as s 14(3) of the UK Patents Act 1977 (c 37) (â€œUK Patents Act 1977â€), which reads:The specification of an application shall disclose the invention in a manner which is clear enough and complete enough for the invention to be performed by a person skilled in the art.[emphasis added in italics]99â€ƒSection 80(1)(c) of the Patents Act (2005 Rev Ed) is also materially similar to s 72(1)(c) of the UK Patents Act 1977, which states:Subject to the following provisions of this Act, the court or the comptroller may by order revoke a patent for an invention on (but only on) any of the following grounds, that is to sayâ€”â€¦(c) the specification of the patent does not disclose the invention clearly enough and completely enough for it to be performed by a person skilled in the art;[emphasis added in italics and bold italics]100â€ƒAlthough the word â€œenoughâ€ is omitted in ss 25(4) and 80(1)(c) of the Patents Act (2005 Rev Ed) (and, for that matter, the same provisions in the Patents Act 1994 (2020 Rev Ed)), the sufficiency requirement in Singapore is not stricter. Our courts have held that a patent specification suffices if it is â€œclear enoughâ€ and â€œcomplete enoughâ€; absolute clarity and completeness are not uncompromisingly required. This is because under ss 25(4) and 80(1)(c) of the Patents Act (2005 Rev Ed), as long as the specification is sufficiently clear â€œfor [the invention] to be performed by a person skilled in the artâ€, it does not matter that the specification does not state every single step required for performance. After all, the PSA does not have to be told what is self-evident or what is part of his common general knowledge (First Currency Choice at [73]; Ng Kok Cheng at [47] and [49]). In this regard, the local position is in line with the ssÂ 14(3) and 72(1)(c) of the UK Patents Act 1977.101â€ƒThat said, not every aspect of English law on insufficiency is applicable in our context. The UK Patents Act 1977 was passed to give effect to the Convention on the Grant of European Patents, 5 October 1973, 1065Â UNTSÂ 199 (â€œEuropean Patent Conventionâ€). Section 130(7) of the UK Patents Act 1977 provides that certain provisions, including ss 14(3) and 72(1)(c) of the UK Patents Act 1977, were â€œso framed as to have, as nearly as practicable, the same effects in the United Kingdom as the corresponding provisions of the European Patent Conventionâ€. The English courts have thus approached the law in these respects with the objective of striving for consistency between European and English patent law (Regeneron (SC) at [30]; Generics (UK) Ltd and others v H Lundbeck A/S [2009] 2 All ER 955 (â€œGenerics v Lundbeck (HL)â€) at [86] per Lord Neuberger; Merrell Dow Pharmaceuticals Inc and another v H N Norton & Co Ltd and another; Merrell Dow Pharmaceuticals Inc and another v Penn Pharmaceuticals Ltd and another (1997) 33 BMLR 201 at 205). In interpreting and developing the jurisprudence under ssÂ 14(3) and 72(1)(c) of the UK Patents Act 1977, the English courts have therefore introduced certain concepts into English law from European patent law to give effect to this harmonising objective. Such concepts, however, are not necessarily applicable to ss 80(1)(c) and 25(4) of the Patents Act (2005 Rev Ed), and their applicability falls to be determined with reference to the text and legislative objective of ss 80(1)(c) and 25(4) as well as the Patents Act (2005 Rev Ed) as a whole. 102â€ƒWe begin by noting the policy that undergirds the sufficiency requirement. Both English and local case law have recognised that the sufficiency requirement lies at the heart of what is sometimes called the â€œpatent bargainâ€. As already alluded to above at [57], the inventor/patentee is rewarded with a limited-term monopoly over the claimed invention, in exchange for enabling a PSA to work the claimed invention and dedicating it to public use after the monopoly has expired (Rohm and Haas Electronic Materials CMP Holdings, Inc (formerly known as Rodel Holdings, Inc) v NexPlanar Corp and another [2018] 5 SLR 180 (â€œRohmâ€) at [161]; Warner-Lambert Company LLC v Generics (UK) Ltd t/a Mylan and another [2019] 3 All ER 95 at [17]). The patent bargain breaks down if the patent does not sufficiently teach a PSA how to perform the invention, in which case it makes little sense to reward the inventor/patentee with a monopoly. It is for this reason that the failure to satisfy the sufficiency requirement is a ground for patent revocation. 103â€ƒWe now turn to set out general principles applicable to the legal requirement of sufficiency in Singapore. References to English jurisprudence will be made where appropriate.104â€ƒIt is well-settled under Singapore law that the burden of proving insufficiency rests on the party challenging the validity of a registered patent (Ng Kok Cheng at [48]).105â€ƒThe assessment of whether the legal requirement of sufficiency is met proceeds in two steps. The first step involves identifying the invention and deciding what it claims to enable the PSA to do. The second steps asks whether the specification enables him to do it (Kirin-Amgen Inc and others v Hoechst Marion Roussel Ltd and others; Hoechst Marion Roussel Ltd and others v Kirin-Amgen and others [2005] RPC 169 (â€œKirin-Amgenâ€) at [103] per Lord Hoffmann, cited with approval in First Currency Choice at [61]). Indeed, the court can only ascertain whether the disclosure has been sufficient after ascertaining what needs to be disclosed (meaning the invention).106â€ƒBoth steps of the inquiry require the court to don the mantle of a PSA possessing common general knowledge of the art. The first step involves the construction of the patent claims from the perspective of the PSA. Claim construction principles as set above at [79]â€“[80] are applied (see Towa Corp v ASM Technology Singapore Pte Ltd and another [2017] 3 SLR 771 at [66] and Main-Line Corporate Holdings Ltd v United Overseas Bank Ltd and another (First Currency Choice Pte Ltd, third party) [2007] 1 SLR(R) 1021 at [72]). At the second step, the PSA uses his common general knowledge to supplement the information contained in the specification in order to perform the invention (see Genelabs (CA) at [61]â€“[63]). The sufficiency inquiry at the second stage is undertaken with reference to the date of filing of the patent application (Biogen Inc v Medeva PLC [1997] RPC 1 (â€œBiogenâ€) at 54 per Lord Hoffmann, followed in Kirin-Amgen Inc v Transkaryotic Therapies Inc [2003] RPC 3 at 70). This is sensible, since s 25(4) of the Patents Act (2005 Rev Ed) imposes the requirement of sufficiency at the time the patent application is made (see also Genelabs (HC) at [202]; Susanna Leong at para 16.266). As an aside, since we are regarding the relevant date for construing the patent claims (see at [78] above) and assessing insufficiency as the date of filing of SG 872, and we do not intend to discuss the issues of novelty and obviousness, we need not rule on the respondentâ€™s claim for priority from GB 261. 107â€ƒWhere the invention is a process, enablement at the second step requires that process to be carried out by the PSA; where the invention is a product, enablement requires the PSA to be able to make that product (Generics v Lundbeck (HL) at [20]; Roughton, Johnson & Cook, The Modern Law of Patents (LexisNexis, 5th Ed, 2022) (â€œThe Modern Law of Patentsâ€) at para 4.37).108â€ƒRegardless of the nature of the invention, the patent specification must enable the invention to be performed by the PSA over the full breadth of the monopoly claimed, as we explain further below. Lord Hoffmann, who delivered the leading decision in the House of Lords in Biogen, observed that this is a long-established principle in English law (at 48) (see also Idenix Pharmaceuticals, Inc v Gilead Sciences, Inc and others [2014] EWHC 3916 (Pat) (â€œIdenix (HC)â€) at [468]; Regeneron (SC) at [3] and [80]). Later in Kirin-Amgen at [102], Lord Hoffmann expressly applied this principle to sÂ 72(1)(c) of the UK Patents Act 1977, which embodies the concept of sufficiency in the context of patent revocation:â€¦ The law on this point is contained in s. 72(1)(c) of the [UK Patents Act 1977]. A patent may be revoked if the specification does not disclose the invention 'clearly enough and completely enough for it to be performed by a person skilled in the artâ€™. That means that the disclosure must enable the invention to be performed to the full extent of the monopoly claimed: see Biogen Inc v Medeva plc [1997] RPC 1, 48.This court in First Currency Choice at [61] cited Kirin-Amgen at [102] with approval when setting out the applicable principles in relation to sÂ 80(1)(c) of the Patents Act (2005 Rev Ed).109â€ƒTo illustrate what it means for a specification to enable the invention to be performed to the full extent of the monopoly claimed, Lord Hoffmann gave the following illustrations in Biogen at 48:â€¦ If the invention discloses a principle capable of general application, the claims may be in correspondingly general terms. The patentee need not show that he has proved its application in every individual instance. On the other hand, if the claims include a number of discrete methods or products, the patentee must enable the invention to be performed in respect of each of them.[emphasis added in italics]Subsequently, in H Lundbeck A/S v Generics (UK) Ltd and others [2008] RPC 437 at [34], Lord Hoffmann re-iterated that where a claim is to a class of products, the class of products is enabled only if the PSA can work the invention in respect of all members of the class. The specification can show that this is empirically demonstrated or disclose a principle which can reasonably be expected to apply across the class.110â€ƒHowever, the patent need not set out every detail necessary for the performance of the invention across its entire scope. As mentioned at [100] above, the patentee can leave the PSA to employ his skill and common general knowledge to work out what needs to be done. But the PSA must not be expected or required to exercise inventive ingenuity or exert undue effort in order to perform the invention across its entire breadth.111â€ƒThe requirement of enablement across the full breadth of the claim can be understood with reference to the patent bargain. The inventor/patentee should only be entitled to the full extent of the monopoly claimed if he has fulfilled his end of the bargain by disclosing the full scope of the invention clearly and completely enough.  Only if this is done can the second aim of the patent regime, knowledge dissemination, be achieved by way of allowing the public to benefit from the invention after it falls into the public domain. A patent system which allows the inventor/patentee to monopolise more than that which he has sufficiently enabled may unduly stifle research, contrary to its primary aim of encouraging innovation (see Regeneron (SC) at [23]; Lionel Bently et al, Intellectual Property Law (Oxford University Press, 6th Ed, 2022) at pp 607â€“608). Hence, even where a patent specification is clear and complete enough to teach a PSA how to perform part of the claimed invention, that does not justify a monopoly over the entire breadth of the invention and the patent may be revoked pursuant to s 80(1)(c) of the Patents Act (2005 Rev Ed).112â€ƒBefore leaving this point, we note in passing that the majority of the UKSC in Regeneron (SC) held that it is enough if the patent enables the PSA to make â€œsubstantially all the types or embodiments of products within the scope of the claimâ€ (at [56(iv)]) [emphasis added]. This threshold appears to be satisfied where there remain a â€œtiny or inconsequential number of embodiments which are not enabledâ€ such that the scope of non-enablement is de minimis (at [36] and [56(v)]). The standard of substantiality was endorsed by the majority because it was the position in EU law (at [31]â€“[32] and [36]), and s 130(7) of the UK Patents Act 1977 requires interpretative consistency between European and UK patent law. We are not bound by a similar obligation. Without the benefit of submissions, we shall defer consideration of this aspect of Regeneron (SC) to an appropriate case. In any event, as we shall see, the threshold of substantiality does not have a material bearing on this case.113â€ƒNext, although insufficiency is a single ground of objection to the validity of a patent contained in s 80(1)(c) of the Patents Act (2005 Rev Ed), there are distinct ways in which a patent may be insufficient (see Zipher at [362]; Anan at [22]). As will become clear, the appellantâ€™s case engages different aspects of the rule on patent sufficiency, two of which are determinative of this appeal. We now turn to consider the different ways a patent may be insufficient under English and/or Singapore law.114â€ƒThe first way in which a patent may be insufficient is where the patent specification is not clear and complete enough to enable the PSA to perform the invention across the whole breadth of the claim(s) without an undue burden (see Terrell at para 13-31). This objection, termed â€œclassical insufficiencyâ€, is well-established in English and local jurisprudence (see First Currency Choice at [60]â€“[62]). In evaluating the merits of this allegation, the court has to assess the steps which would be necessary for the PSA to take under the patentâ€™s specification to carry out the invention (see Zipher at [363]).115â€ƒUnder English law, a patent specification which enables a PSA to perform the full breadth of the claim without undue effort (meaning that it is not classically insufficient), may nonetheless suffer from another type of insufficiency, known as â€œBiogen insufficiencyâ€. This form of insufficiency arises where the scope of the claim exceeds the technical contribution to the art made by the invention (see Terrell at para 13-09), whereas classical insufficiency is concerned with the mismatch between the scope of the claim and the method of performance taught in the patent specification. The â€œtechnical contribution to the artâ€ does not refer to the technicalities of performing the claimed invention, but, more generally, to how the invention has in a practical sense added to or advanced the state of the art (that said, we note that the precise concept of â€œtechnical contribution to the artâ€ has been articulated in various ways (see Generics v Lundbeck (HL) at [95] per Lord Neuberger, at [45] per Lord Mance and at [30] per Lord Walker)).116â€ƒConsider, for example, a claim to â€œa heavier than air flying machineâ€ in a patent which only discloses how to make an airplane. Assume for the moment that an airplane is a new and non-obvious invention, and the patent specification is clear and complete enough for a PSA to make an airplane. The airplane is a machine that is (a) capable of flight and (b) heavier than air, and by teaching the PSA how to make an airplane, the patent specification has enabled performance of every integer (or â€œelementâ€, see Rohm at [103] and [179]) of the claim. In other words, the patent specification has sufficiently enabled the full breadth of the claim and can avoid a classical insufficiency attack. Yet, because the language of the claim has defined the invention in such general terms, the monopoly asserted by the claim is capable of extending to all other forms of heavier than air flying machines that are not airplanes and which may be manufactured by a wholly different process. The breadth of the claim thus exceeds what the patentee has contributed to the state of the art, in this example, how to make an airplane. This gives rise to Biogen insufficiency (see Anan at [52], citing Biogen at 52).117â€ƒAt present, Singapore patent law has not recognised the concept of Biogen insufficiency under s 80(1)(c) of the Patents Act (2005 Rev Ed), and it is unclear whether it should. We observe that Biogen insufficiency was first recognised by Lord Hoffmann in Biogen at 54, in the light of the jurisprudence under the European Patent Convention:In my view, however, there is an important difference between the 1949 and 1977 Acts which make decisions on the earlier Acts an unsafe guide. Section 72(1)(c) of the [UK Patents Act 1977] is not only intended to ensure that the public can work the invention after expiration of the monopoly. It is also intended to give the court in revocation proceedings a jurisdiction which mirrors that of the Patent Office under section 14(3) o[f] the E.P.O. under article 83 of the EPC, namely, to hold a patent invalid on the substantive ground that, as the E.P.O. said in Exxon/Fuel Oils (T 409/91) [1994] O.J. E.P.O. 653, paragraph 3.3., the extent of the monopoly claimed exceeds the technical contribution to the art made by the invention as described in the specification. In the 1949 Act, this function was performed by another ground for revocation, namely that the claim was not â€˜fairly based on the matter disclosed in the specificationâ€™ (section 32(1)(i)). The requirement of sufficiency was therefore regarded as serving a narrower purpose. But the disappearance of â€˜lack of fair basisâ€™ as an express ground for revocation does not in my view mean that general principle which it expressed has been abandoned. The jurisprudence of the E.P.O. shows that it is still in full vigour and embodied in articles 83 and 84 of the EPC, of which the equivalents in the [UK Patents Act 1977] are section 14(3) and (5) and section 72(1)(c).[emphasis added]As the present appeal can be resolved without considering the applicability of Biogen insufficiency in Singapore, we leave this question open for determination in a future case.118â€ƒApart from classical insufficiency and â€œBiogen insufficiencyâ€, there is a third way in which insufficiency may arise under English law, that is, where the PSA does not know how to determine whether a particular product or process is within or outside the scope of the claim, even after employing the common general knowledge and applying the normal process of claim construction (see Generics [UK] Ltd (t/a Mylan) v Yeda Research and Development Co Ltd and another [2012] EWHC 1848 (Pat) (â€œGenerics v Yeda (HC)â€), approved in Generics [UK] Ltd (t/a Mylan) v Yeda Research and Development Co Ltd and another [2013] EWCA Civ 925 (â€œGenerics v Yeda (CA)â€) at [78]; Unwired Planet International Ltd & Ors v Google Commerce Ltd (2016) [2016] EWHC 576 (Pat) (â€œUnwiredâ€) at [163]). English courts previously labelled this type of insufficiency as â€œambiguityâ€ (see for example, Zipher at [374] and Unwired at [149]). However, Floyd LJ and Lewinson LJ in Anan (at [24]â€“[25] and [101]) considered this is a misnomer, because â€œambiguityâ€ usually refers to a situation where words in a claim are capable of more than one meaning, but this in itself does not render the claim invalid if the normal process of claim construction through the eyes of the PSA can resolve this issue. In place of the term â€œambiguityâ€, Floyd LJ and Lewinson LJ held that the term â€œuncertaintyâ€ more accurately described this third type of insufficiency.119â€ƒUncertainty is a distinct objection from classical insufficiency. The latter is concerned with whether the patent specification sufficiently teaches the PSA how to obtain the product or work the process that is the subject of the claim, while the former is concerned with whether the PSA, after following the teachings in the patent specification, can tell whether the product obtained, or process worked, falls within the scope the claim. This distinction is illustrated by the facts of Kirin-Amgen, the first House of Lords decision to recognise uncertainty as a species of insufficiency. There, claim 19 of the patent was to a recombinant erythropoietin (â€œrEPOâ€) made by a specified process with, amongst other characteristics, a higher molecular weight than urinary erythropoietin (â€œuEPOâ€) (at [14]):Claim 19 is forâ€”'A recombinant polypeptide having part or all of the primary structural conformation of human or monkey erythropoietin as set forth in Table VI or Table V or any allelic variant or derivative thereof possessing the biological property of causing bone marrow cells to increase production of reticulocytes and red blood cells to increase haemoglobin synthesis or iron uptake and characterised by being the product of eucaryotic expression of an exogenous DNA sequence and which has a higher molecular weight by SDS-PAGE from erythropoietin isolated from urinary sources.'120â€ƒThe difficulty with claim 19 lay in identifying the uEPO to test against the rEPO. Different uEPOs had different molecular weights and depending on the uEPO selected as the benchmark, a particular rEPO could either be within or outside the scope of the claim. As the specification did not disclose exactly which uEPO to use, it was impossible to determine whether a particular rEPO fell within claim 19 and the PSA was left guessing which uEPO the patentee had in mind. And, because different uEPOs had different molecular weights, the PSA would not know in advance whether any given uEPO would bring a particular rEPO within the claim. On this basis, the House of Lords, per Lord Hoffmann, invalidated claim 19 for insufficiency pursuant to sÂ 72(1)(c) of the UK Patents Act 1977 (at [121]â€“[125], [129] and [131]). In arriving at this conclusion, Lord Hoffmann pointed out that the choice of uEPO has â€œnothing to do with making the invention workâ€ (meaning that it has nothing to do with classical insufficiency) but relates to the criterion against which one tests whether a particular rEPO falls within the claims (at [129]).121â€ƒIn a sense, the objection of uncertainty in Kirin-Amgen arose from the application of a test prescribed by the patent. The prescribed test for ascertaining whether the claim boundary had been crossed was whether the molecular weight of a particular rEPO was higher than the molecular weight of uEPO. The uncertainty resided in how that prescribed test was to be applied, because the PSA did not know which uEPO to use as the benchmark. However, uncertainty in which test should be used to determine whether a particular product or process meets the characteristics specified in the claim can also sustain an objection of uncertainty in the context of insufficiency. This can be seen in Glaxo Group Ltd and other companies v Vectura Ltd [2018] EWHC 3414 (Pat) (â€œGlaxo Groupâ€). The validity of five patents was in issue in that case, but for the sake of illustration, we focus only on claim 1 of one of these patents, European Patent (UK) No. 1 337 240 (â€œPatent 240â€). Claim 1 of Patent 240 claimed a method of making composite active particles. The method involved the milling of particles of active material in the presence of particles of an additive material, such that the â€œparticles of additive material become fused to the surface of the particles of active materialâ€ (at [86]). The patent contained very little guidance as to how the PSA was to determine whether the specified process had produced composite active particles with additive particles fused to the surface of the active particles (at [177]). The patent proprietorâ€™s expert gave evidence that the PSA could carry out electron dispersive X-ray spectroscopy (â€œEDXâ€) to cross-check if this was the case, but Arnold J rejected this for two reasons. First, he found that a patent is insufficient if the technique for determining whether a particular product or process falls within the scope of the claims is not mentioned in the patent specification and is not part of the PSAâ€™s common general knowledge. On the facts, EDX could not save the patent from insufficiency because the relevant test was not mentioned in the patent specification and was not part of the PSAâ€™s common general knowledge even though it existed at the priority date (at [180]). Second, EDX had limitations which made it unsuitable for determining whether the product or process in question had the characteristic called for by the claim. The patent proprietor had also failed to validate the use of EDX for this purpose (at [181]). Arnold J therefore found that Patent 240 was invalid for insufficiency on the basis that it did not enable the PSA to determine whether a process or product fell within the claim (at [176] and [181]).122â€ƒWhilst uncertainty as a type of insufficiency is well-established in English patent law, it has not been expressly recognised under Singapore patent law. The possibility of uncertainty giving rise to insufficiency was only contemplated in passing in First Currency Choice at [72], where we said:[W]here there is insufficient disclosure of the invention in the specification as a result of an ambiguous or meaningless claim, the invention itself may not be properly enabled, and revocation under sÂ 80(1)(c) of the [Patents] Act may still be possible.This proposition rested on two authorities: Simon Thorley et al, Terrell on the Law of Patents (Sweet & Maxwell, 16th Ed, 2006) (â€œTerrell 16thâ€) at para 7-106 and Kirin-Amgen at [124]â€“[129], both of which recognise uncertainty (which is referred to as â€œambiguityâ€ in Terrell 16th at para 7-106) as an objection against the sufficiency of a patent.123â€ƒOn the facts, the appellantâ€™s case relating to the Metripol Uncertainty Problem is in essence an objection of uncertainty. The Judge considered and rejected the appellantâ€™s factual contention that the PSA in this case would not know how to tell when the Î´ value of the single crystal CVD diamond remains in the SG 872 First Order (Judgment at [200]â€“[206]), but did not comment on whether Singapore patent law does or should recognise uncertainty as a distinct type of patent insufficiency. On appeal, the appellant urges us to hold, as a matter of Singapore patent law, that a claim is insufficient if it is uncertain such that the PSA will not know whether he is inside or outside the claim.
                   110




Foot Note 110

Ã—



 â€ƒAC at para 150.



124â€ƒIn our judgment, where a PSA does not know how to determine if a particular product or process is within the scope of the claim even after employing his common general knowledge and the normal claim construction process, the sufficiency requirement in ss 25(4) and 80(1)(c) of the Patents Act (2005 Rev Ed) is not satisfied. We refer to this as uncertainty. Insufficiency remains a single ground of revocation embodied in s 80(1)(c) of the Patents Act (2005 Rev Ed), but it may arise in at least two distinct ways: classical insufficiency and uncertainty. We arrive at this view for three reasons.125â€ƒFirst, as a matter of logic, a PSA can only be said to know how to perform the invention, if he knows what steps he needs to take to arrive within the claimed invention and knows how to determine if he has in fact obtained a product or worked a process within the scope of the claimed invention. It is meaningless for the PSA to know the former, meaning what steps he must take, if he does not also know the latter, meaning whether he has successfully taken those steps and made the invention. As Birss J said in Unwired at [159], the problem in Kirin-Amgen was that there was â€œa failure to disclose the invention clearly enough for it to be performed at all because the [PSA] could never know if they were within it or notâ€ [emphasis added in bold italics].126â€ƒSecond, the sufficiency requirement seeks to ensure that others would be able to work the invention and benefit from it when it falls into the public domain following the expiry of the patent. But what benefit is there to the public if even the PSA does not know whether he is working the invention? In such circumstances, the inventor/patentee has not fulfilled his end of the patent bargain and ought to be denied a limited-term monopoly over the claimed invention.127â€ƒThird, a patentee filing a patent application is in essence asking the State to grant it a property right. This much is recognised in s 41(1) of the Patents Act (2005 Rev Ed):41.â€”(1) Any patent or application for a patent is personal property (without being a thing in action), and any patent or any such application and rights in or under it may be transferred, created or granted in accordance with this section.[emphasis added in bold italics]It therefore behoves the patentee to properly define when that property right has been infringed so that others would know how not to trespass. As Lewison LJ in Anan said at [99]:A patent is personal property, without being a chose in action. We know that because section 30 (1) of the Patents Act 1977 tells us so. The essence of a right of property is that it distinguishes between what is mine and what is not mine. So there needs to be a boundary. If someone crosses the boundary, he invades my property right. The function of the claims is to delineate that boundary. As Lord Russell put it in Electrical & Musical Industries v Lissen Ltd (1939) 56 RPC 23, 39:â€˜The function of the claims is to define clearly and with precision the monopoly claimed, so that others may know the exact boundary of the area within which they will be trespassers.â€™â€ƒ[emphasis added]128â€ƒSimilar sentiments were echoed by the High Court in Rohm at [102]:â€¦ A patent is a property right. It is for the patentee to clearly set out and define the subject-matter over which the property right is claimed (see s 25(5) of the Patents Act). The words and expressions used are the patenteeâ€™s alone. It is by reference to the specifications that members of the public determine the boundaries of the claimed property right. â€¦A patentee has not properly defined the extent of his property right if a PSA does not know how to ascertain when a particular product or process constitutes the subject matter over which the property right is claimed. Much uncertainty would be engendered if the law were to grant or recognise the asserted monopoly in such circumstances.129â€ƒWe turn to consider the respondentâ€™s submission that the Judge, on the basis that lack of clarity under s 25(5)(b) of the Patents Act (2005 Rev Ed) was not a ground for revocation, rejected the appellantâ€™s argument on insufficiency arising from â€œambiguityâ€.
                   111




Foot Note 111

Ã—



 â€ƒRC at para 173; RSA at para 50.



 The respondent further suggests that the acceptance of the appellantâ€™s argument on insufficiency by uncertainty requires a departure from the position at law that the failure to comply with the clarity requirement is not a basis for revocation.
                   112




Foot Note 112

Ã—



 â€ƒRC at para 174.



130â€ƒWe disagree with the respondentâ€™s interpretation of the Judgeâ€™s reasoning. The Judge was aware that the appellantâ€™s arguments on the Metripol Uncertainty Problem went towards the issue of sufficiency instead of clarity (see Judgment at [192]â€“[197]), and she did not dismiss the appellantâ€™s arguments on the basis that lack of clarity is not a ground for revocation.131â€ƒMore importantly, the respondentâ€™s submissions raise the need to clarify the distinction between insufficiency arising from uncertainty for the purposes of ss 25(4) and 80(1)(c) of the Patents Act (2005 Rev Ed), and lack of clarity for the purpose of sÂ 25(5)(b) of the Patents Act (2005 Rev Ed). This distinction is important, because the former is a ground for revoking a patent once granted while the latter is not (see Ng Kok Cheng at [74] and First Currency Choice at [72]). The test for clarity is whether the PSA can understand the words used in the claims. In this regard, there is no need to remove all conceivable doubt as to the meaning of the claims, but the claims must be as clear as the subject matter reasonably permits (see The Modern Law of Patents at para 4.133, citing Chevron Research Companyâ€™s Extension [1975] FSR 1 at 13 and LG Philips LCD v Tatung (UK) [2007] RPC 21 at [20]). A lack of clarity in the claimâ€™s language, however, does not per se amount to uncertainty in the context of insufficiency (see The Modern Law of Patents at paras 4.58 and 4.132). To result in uncertainty giving rise to insufficiency pursuant to ss 25(4) and 80(1)(c) of the Patents Act (2005 Rev Ed), the lack of clarity in claim language must leave the PSA unclear as to how to determine whether a particular product or process is within the scope of the claim even after drawing upon his common general knowledge or applying the typical claim construction process (see First Currency Choice at [72]; Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429 at [72]; Anan at [24]â€“[25] and [101]). As we have explained above, lack of clarity under s 25(5)(b) of the Patents Act (2005 Rev Ed) is not the issue we are concerned with when dealing with the issue of uncertainty.132â€ƒIn the light of the foregoing discussion, we turn to consider the substantive arguments on sufficiency in the context of this case. But before doing so, we should add that while the preceding discussion (including that at [56]â€“[75]) referred to the 2005 Revised Edition of the Patents Act, on which the partiesâ€™ claims and counter-claims are based, these views apply equally to the 2020 Revised Edition of the Patents Act 1994 because the differences between the relevant provisions in these editions are not material to the points made.Whether any or all of the claims in SG 872 are invalid due to classical insufficiencyWhether Claim 62 is classically insufficient133â€ƒThe appellant submits that Claim 62 presents the PSA with â€œa classic undue burdenâ€ as he is faced with a research project to find out what Other Growth Conditions are necessary to obtain a specific type of SG 872 Diamond.
                   113




Foot Note 113

Ã—



 â€ƒASA at para 28 n 40, para 39; AR at para 44.



  To evaluate the appellantâ€™s submission, it is necessary to understand when a PSA is saddled with an â€œundue burdenâ€ to work the invention. (1)â€ƒWhat is an â€œundue burdenâ€134â€ƒTo re-capitulate, the patent specification need not set out every detail necessary for performance, including what is self-evident or part of common general knowledge, and can leave the PSA to use his skill to perform the invention (First Currency Choice at [62]; Ng-Loy at para 30.3.4). However, the PSA must be able to perform the invention â€œwithout prolonged research, enquiry and experimentâ€ (Halliburton Energy Services Inc v Smith International (North Sea) Ltd and others [2006] EWCA Civ 1715 at [13]; see also Susanna Leong at para 16.273). An oft-cited passage from the judgment of Aldous J in Mentor Corporation and another v Hollister Incorporated [1991] FSR 557 at 562 explains the point as follows (see Terrell at para 13-18):The section requires the skilled man to be able to perform the invention, but does not lay down the limits as to the time and energy that the skilled man must spend seeking to perform the invention before it is insufficient. Clearly there must be a limit. The subsection, by using the words, clearly enough and completely enough, contemplates that patent specifications need not set out every detail necessary for performance, but can leave the skilled man to use his skill to perform the invention. In so doing he must seek success. He should not be required to carry out any prolonged research, enquiry or experiment. He may need to carry out the ordinary methods of trial and error, which involve no inventive step and generally are necessary in applying the particular discovery to produce a practical result. In each case, it is a question of fact, depending on the nature of the invention, as to whether the steps needed to perform the invention are ordinary steps of trial and error which a skilled man would realise would be necessary and normal to produce a practical result.[emphasis added in bold italics]135â€ƒAs we noted in First Currency Choice at [60], â€œ[i]t would not be desirable, and, indeed, probably quite impossible, to lay down any hard-and-fast ruleâ€ as to the required degree of clarity and completeness to satisfy the requirement for sufficiency of disclosure. The amount of teaching required in the specification may vary from invention to invention (Mentor Corporation and another v Hollister Inc [1993] RPC 7 at 11, cited in Susanna Leong at para 16.281). 136â€ƒFurther, the examples in the patent specification may be taken into account when determining whether there is sufficiency. This is self-evident from the Patents Act (2005 Rev Ed) and Patents Rules. Section 80(1)(c) of the Patents Act (2005 Rev Ed) provides that the â€œspecificationâ€ of the patent must â€œdisclose the invention clearly and completelyâ€. And s 25(3)(b) of the Patents Act (2005 Rev Ed), read with rr 19(3) and 19(5)(e) of the Patents Rules, shows that the specification must contain a description of the invention, which may itself include examples where appropriate. It was also recognised in Eli Lilly and Co v Human Genome Sciences Inc [2008] EWHC 1903 (Pat) at [239] that sufficiency must be assessed â€œon the basis of the specification as a whole including the description and the claimsâ€ [emphasis added] (see also Pacific Biosciences of California, Incâ€™s Applications BL O/500/18 at [43], cited in CIPA Guide to the Patents Act (Paul Cole & Richard Davis eds) (Sweet & Maxwell, 9th Ed, 2022) at para 14.28). (2)â€ƒDoes Claim 62 impose an undue burden on the PSA trying to work it?137â€ƒIn light of the foregoing principles, the question before us is whether Claim 62 enables a PSA to perform the entire breadth of the claim without an undue burden. In summary, we consider that Claim 62 does impose an undue burden on the PSA because: (a)â€ƒThe Other Growth Conditions do affect the quality of the CVD diamond produced.(b)â€ƒThe specification of SG 872 (including the examples therein) merely provides a starting point for an onerous research programme: (i)â€ƒThe patent specification does not teach the PSA how to determine where within a range of values he should operate, in respect of each of the Other Growth Conditions, so as to produce an SG 872 Diamond with a particular property or combination of properties. (ii)â€ƒCalibrating the value of each Other Growth Condition is complex because these conditions and the appropriate nitrogen concentration in the source gas are interrelated.(iii)â€ƒThe CVD growth process and the resulting diamond are sensitive to changes in the Other Growth Conditions. (iv)â€ƒ The authorities show that providing discrete examples of sets of values of the Other Growth Conditions, and the corresponding quality of the diamond produced, does not provide enabling disclosure across the entire breadth of the product claims, each of which asserts a monopoly over a range of products.(c)â€ƒExperimental data, while not adduced in this case, is not necessary to ground a classical insufficiency challenge.(d)â€ƒThe respondent has not proved that the manner of calibrating the Other Growth Conditions in order to produce a CVD diamond of a particular quality forms part of the common general knowledge which need not be taught by SG 872.We elaborate on these points.(A)â€ƒOther Growth Conditions affect the quality of the CVD diamond produced138â€ƒClaim 62 states that the process taught therein enables the production of â€œa CVD single crystal diamond material meeting the requirements of one or more of claims 1 to 61â€ [emphasis added in bold italics].
                   114




Foot Note 114

Ã—



 â€ƒBOM at p 374.



 To provide sufficient enablement across its entire breadth, Claim 62, read with the specification of SG 872, must teach the PSA to produce every diamond falling within each of the product claims in SG 872 (which themselves cover a range of diamonds), or any combination of the product claims.139â€ƒAccording to the appellant, the gap in SG 872 is that it fails to specify the Other Growth Conditions that should be applied in order to produce a diamond meeting the requirements of a particular product claim or a combination of product claims. The implicit premise of the appellantâ€™s argument is that the Other Growth Conditions do affect the quality of the CVD diamond produced, and this in turn affects whether the single crystal CVD diamond falls into one or more of the product claims in SG 872.140â€ƒWe deal first with this implicit premise. In our judgment, the fact that the Other Growth Conditions do affect the quality of the CVD diamond produced is evidenced by both partiesâ€™ experts. 141â€ƒThe respondentâ€™s expert, Dr Newton, accepted that â€œunder high gas flow conditions the gas flow could have an effect on the chemistry of the [growth] processâ€ [emphasis added].
                   115




Foot Note 115

Ã—



 â€ƒNewton-2 at para 151 (II ACB 204).



 As noted at [47] above, â€œgas flowâ€ is one of the Other Growth Conditions. Dr Newtonâ€™s oral testimony, when asked about whether a PSA following SG 508 and SG 872 will end up with the same diamond, is particularly illuminating. He said that while the nitrogen ranges taught in the two patents overlap â€œit is not sufficient just to look at one of the parameters. You must look at the methane, the hydrogen, the flow rates, the temperature, the pressure. Itâ€™s a sensitive process. You start changing one of those and you go into a different regime of growthâ€
                   116




Foot Note 116

Ã—



 â€ƒTranscript, 7 August 2019, pp 100:18â€“101:3 (III(D13) ROA 105â€“106); RCN at para 49(b)(iii).



 [emphasis added]. Dr Bergonzo, another of the respondentâ€™s experts, also testified that higher gas flows could reduce the effectiveness of in-situ etches in removing subsurface damage and thus reducing strain in the grown layers.
                   117




Foot Note 117

Ã—



 â€ƒDr Bergonzoâ€™s 2nd Report (â€œBergonzo-2â€) at para 227 (I RSCB 202)



 On the appellantâ€™s side, Dr Nebel similarly recognised that â€œ[t]he gas flow around the substrate as well as the plasma exposure affect the growth of diamond significantly.â€
                   118




Foot Note 118

Ã—



 â€ƒNebel-1 at para 141 (III ACB 43); RSA at para 36(b).



142â€ƒAside from the expert evidence, it is the respondentâ€™s own submission that following the growth process in SG 508 will not inevitably lead to a diamond fulfilling the parameters of Claim 1iii) because of, among other things, differences between the Other Growth Conditions in SG 508 and SG 872.
                   119




Foot Note 119

Ã—



 â€ƒRC at paras 86â€“88.; see also Plaintiffâ€™s outline of oral reply in second tranche of trial at para 88 (III(G6) ROA 199); PCS2 at para 1331 (III(G3) ROA 239).



 In other words the respondent accepts that the Other Growth Conditions do influence the quality of the diamond produced. For context, SG 508 teaches the conversion of a coloured single crystal CVD diamond to another colour under heat treatment (referred to as annealing).
                   120




Foot Note 120

Ã—



 â€ƒRCN at para 47; BOM at p 213.



 As part of its case that Examples 4 and 6 of SG 508 anticipate Claim 62, the appellant submits that the growth processes taught in SG 508 and Claim 62 overlap. A table produced by Dr Nebel,
                   121




Foot Note 121

Ã—



 â€ƒNebel-1 at para 668 (III(B14) ROA 22â€“23).



 and adapted by the appellant, helpfully summarises the overlap (emphases by appellant omitted):
                   122




Foot Note 122

Ã—



 â€ƒAC at para 60.



 Essential integer of Claim 62 of SG 872Disclosure in SG508 and [its priority document, GB 0220772.8 or â€œGB 772â€]A substrate [with a] density of defects at the surface ... below 5 x 103/mm2... Page 14 of SG508â€œThe preferred low density of defects is such that the density of surface etch features related to defects, as described above, are below 5 x 103/mm2, and more preferably below 102/mm2â€
                   123




Foot Note 123

Ã—



 â€ƒBOM at pp 223 (SG 508), 374 (Claim 62).



The substrate undergoes a plasma etch on the surface... page 15 of SG508:â€œOne specific method of minimising the surface damage of the substrate, is to include an in situ plasma etch on the surface on which the homoepitaxial diamond growth is to occur.â€
                   124




Foot Note 124

Ã—



 â€ƒBOM at pp 224 (SG 508), 374 (Claim 62).



A provision of a source gas and dissociating the source gas to produce a synthesis atmosphere which contains 300 ppb to 5 ppm calculated as molecular nitrogenpage 7 of SG508: â€œIn order to achieve reproducible results and tailor the final product the N in the process needs to be controlled. Typical concentrations in the gas phase are 0.5 ppm â€“ 500 ppm, more preferably 1 ppm â€“ 100 ppm, and more preferably 2 ppm to 30 ppm.â€
                   125




Foot Note 125

Ã—



 â€ƒBOM at pp 216 (SG 508), 374 (Claim 62); see also AC at para 60.



Page 34 of SG 508:â€œthe gas mixture included 2.5 ppm of nitrogenâ€
                   126




Foot Note 126

Ã—



 â€ƒBOM at pp 243 (Example 4), 245 (Example 6).



Page 36 of SG 508:â€œthe gas mixture included 3.8 ppm of nitrogenâ€In an attempt to distinguish the growth process in SG 508 from that in SG 872, the respondent, as stated at the start of this paragraph, argued that while the nitrogen concentrations used in Examples 4 and 6 of SG 508 (and the nitrogen range in SG 508, generally) fall within or overlap with the Claim 62 Nitrogen Range, there are â€œa lot of differences in terms of gas flow, temperature and methane concentrationâ€ and that therefore, following Examples 4 and 6 will not inevitably lead to an SG 872 diamond. This clearly shows the materiality of the Other Growth Conditions. 143â€ƒWe therefore accept that the Other Growth Conditions do affect the strain in the diamond that is eventually grown and that it is necessary for the PSA to determine the precise values of the Other Growth Conditions to use in order to grow a CVD diamond of a particular quality.(B)â€ƒSpecification of SG 872 merely provides a starting point for an onerous research programme144â€ƒWe now turn to consider the guidance the patent specification gives in respect of the Other Growth Conditions, to determine whether the PSA is faced with an undue burden of ascertaining the precise values to use.145â€ƒWe begin with some general observations on the process claims and relevant portions of the patent specification. None of the process claims provides directions on the precise values the PSA should use for the Other Growth Conditions, so as to produce diamonds with particular characteristics satisfying one or more of the product claims. As we shall see, this conclusion remains unchanged even after the process claims are read in the context of the entirety of SG 872, in particular the examples.146â€ƒThe description in the patent specification indicates ranges of values for some of the Other Growth Conditions:(a)â€ƒHigh gas pressure: 50â€“500 x 102 pascals (â€œPaâ€), and preferably 100â€“450 x 102 Pa.
                   127




Foot Note 127

Ã—



 â€ƒBOM at p 319.



(b)â€ƒHigh plasma power density, resulting from high microwave power (typically 3â€“60kW, for substrate diameters of 25â€“300mm).
                   128




Foot Note 128

Ã—



 â€ƒBOM at p 319.



Regarding temperature, the specification of SG 872 provides no guidance on the appropriate atmospheric temperature or substrate temperature to use during the growth process. It merely notes that a process called â€œannealingâ€, in which elevated temperature is used in a controlled manner to bring about a beneficial modification to any property of diamond, may be combined with the â€œdiamond of the inventionâ€ to enhance specific properties. Annealing takes place between 1200oC and 2800oC.
                   129




Foot Note 129

Ã—



 â€ƒBOM at pp 319â€“320.



 However, this temperature range in relation to annealing say nothing about the temperature conditions that should be applied in the process claims of SG 872.147â€ƒAdditionally, the patent specification identifies one main set of specific values for the Other Growth Conditions in Example 1 (the â€œExample 1 Other Growth Conditionsâ€). The same values are used in the other 14 examples in SG 872, subject to modifications to the gas pressure in Examples 9 and 14 and the concentration of methane in Example 14.148â€ƒIn Example 1, 1ppm nitrogen was used together with these Other Growth Conditions:
                   130




Foot Note 130

Ã—



 â€ƒBOM at p 339.



1)â€ƒThe 2.45 GHz reactor was pre-fitted with point of use purifiers, reducing unintentional contaminant species in the incoming gas stream to below 80 ppb.2)â€ƒAn in situ oxygen plasma etch was performed using 15/75/600 sccm (standard cubic centimetre per second) of O2/Ar/H2 at 263 x 102 Pa and a substrate temperature of 730oC. 3)â€ƒThis moved without interruption into a hydrogen etch with the removal of the O2 from the gas flow. 4)â€ƒThis moved into the growth process by the addition of the carbon source (in this case CH4) and dopant gases. In this instance was CH4 flowing at 36 sccm and 1 ppm N2 was present in the process gas, provided from a calibrated source of 100 ppm N2 in H2 to simplify control. The substrate temperature at this stage was 800oC.[emphasis added in bold italics]To summarise, the Example 1 Other Growth Conditions teach the use of: (a) a 2.45 GHz reactor; (b) gas flow of 15/75/600 sccm for O2/Ar/H2, and 36 sccm for CH4; (d) pressure of 263 x 102 Pa; and (e) substrate temperature of 730oC during in situ etching, and 800oC during growth. The parties also agree that Example 1 teaches the use of 5% of CH4 in the source gas.
                   131




Foot Note 131

Ã—



 â€ƒNebel-1 at para 1262 (III(B14) ROA 159); PCS2 at para 1329 (III(G3) ROA 238).



 SG 872 does not expressly state which claim(s) the resulting diamond satisfies, although it appears to fulfil at least Claim 1v). This is because the diamond grown â€œhad a FSR of 1.6678Â±2x10-4cm-1â€ and Claim 1v) covers diamonds with a FSR which varies by less than 5 x 10-3 cm-1.
                   132




Foot Note 132

Ã—



 â€ƒBOM at pp 340, 364.



 149â€ƒExample 9 introduced a variation to the gas pressure. It shows that using 5ppm of nitrogen with â€“ (a) the Example 1 Other Growth Conditions or (b) the Example 1 Other Growth Conditions, save that the gas pressure is 210 x 102 Pa â€“ yields an SG 872 diamond. While not expressly stated, it appears that the diamonds grown under Example 9 satisfy Claims 16i) and 17 of SG 872. The optical scatter of the diamonds falls within the ranges defined in these claims.
                   133




Foot Note 133

Ã—



 â€ƒBOM at pp 353, 367.



150â€ƒExample 14 shows that using the Example 1 Other Growth Conditions with modifications to either gas pressure or methane â€“ (a) 5ppm of nitrogen with 330 x 102 Pa gas pressure or (b) 2.5ppm nitrogen with 3.5% CH4 â€“ yields an SG 872 Diamond. The diamond grown under (a) is referred to as â€œE14.1â€, while the diamond grown under (b) is â€œE14.4â€. While not expressly stated, it appears that the optical absorption of E14.1 and E14.4 falls within the range defined in Claim 19.
                   134




Foot Note 134

Ã—



 â€ƒBOM at pp 360, 367.



151â€ƒWith this context in mind, we now arrive at the heart of the issue â€“ whether the need to determine the Other Growth Conditions places an undue burden on the PSA to work the entire breadth of Claim 62. Having reviewed the evidence, we answer this question in the affirmative for the following reasons. (I)â€ƒGuidance in patent specification (including examples) is limited152â€ƒFirst, the guidance on the Other Growth Conditions provided in SG 872 â€“ both the ranges of values provided in the specification (see [146] above) and Examples 1, 9 and 14 â€“ is inadequate.153â€ƒWith regard to the ranges of values, these only concern two variables: â€œgas pressureâ€ and â€œplasma power densityâ€. There is no such guidance on other variables such as gas flow, temperature and the concentration of the remaining gases in the source gas. And even, for the ranges provided, there is no teaching on how to determine where within the range the PSA should operate so as to produce a CVD diamond with a particular characteristic or combination of characteristics. 154â€ƒThe respondent argues that Example 1, read with Example 9, gives â€œfull disclosure of the reactor conditions such as temperature, pressure and gas flow ratesâ€.
                   135




Foot Note 135

Ã—



 â€ƒRCN at para 51(c).



 We disagree. The Example 1 Other Growth Conditions, even when read with Example 9, only disclose the Other Growth Conditions to be used with 1ppm and 5ppm of nitrogen to produce three variants of an SG 872 diamond. These three variants are differentiated by the growth conditions used to produce them: (a) Example 1 Other Growth Conditions with 1ppm nitrogen (Example 1); (b) Example 1 Other Growth Conditions with 5ppm nitrogen (Example 9); and (c) Example 1 Other Growth Conditions, save for a gas pressure of 210 x 102 Pa, with 5ppm nitrogen (Example 9). These examples in no way enable the PSA to know what values of the Other Growth Conditions to use to produce diamonds falling within all of the 68 product claims in SG 872 either individually, or in any combination of the product claims. This deficiency remains even when Example 14 is taken into account. This example merely introduces two other variations to the Example 1 Other Growth Conditions â€“ a gas pressure of 330 x 102 Pa with 5ppm nitrogen, and 3.5% CH4 with 2.5ppm nitrogen.
                   136




Foot Note 136

Ã—



 â€ƒBOM at p 360.



 (II)â€ƒCalibrating the Other Growth Conditions is a complex process155â€ƒSecond, and crucially, the determination of the specific values of the Other Growth Conditions to use in order to produce a diamond of a particular quality is a complex process. The Other Growth Conditions and the nitrogen concentration in the source gas are interrelated. The specification of SG 872 reveals that several of the Other Growth Conditions affect the appropriate concentration of nitrogen to be used. SG 872 pertinently states that the concentration of nitrogen to be used in the growth process is â€œa sensitive function of the growth conditions, including temperature and pressureâ€ [emphasis added].
                   137




Foot Note 137

Ã—



 â€ƒBOM at p 314.



 The specification adds that the limits to the concentration of nitrogen to be used â€œare process dependent, such that they may vary according to the process conditions used, including the actual gaseous source of N, and also the specific material properties required, and are best illustrated by way of exampleâ€ [emphasis added in bold italics].
                   138




Foot Note 138

Ã—



 â€ƒBOM at p 314.



 Yet, there is no exposition on the nature of the relationships between the Other Growth Conditions and the appropriate nitrogen concentration, or how these relationships should be taken into account when determining the values of the Other Growth Conditions. The specification also recognises that the relationships between nitrogen concentration and the Other Growth Conditions are â€œbest illustrated by way of exampleâ€, but, in our judgment, fails to deliver on that promise (for reasons given at [154] above). Instead, the PSA is left to undertake extensive research to uncover the relationships between the variables in the growth process depending on the physical properties sought in the diamond grown. (III)â€ƒGrowth process is sensitive to changes in the Other Growth Conditions156â€ƒThird, to compound matters, the entire growth process and the resultant diamond material are sensitive to changes in any of the Other Growth Conditions. It is not as though the PSA can vary the Other Growth Conditions without any material consequences to the quality of the diamond produced. This point is elucidated in Dr Newtonâ€™s oral testimony. He stated that the growth process is â€œsensitiveâ€ in the sense that a change to one variable will result in a â€œdifferent regime of growthâ€ altogether (see above at [141]). Dr Newtonâ€™s evidence coheres with the specification of SG 872, which states that the appropriate concentration of nitrogen is a â€œsensitive function of the growth conditionsâ€ [emphasis added].
                   139




Foot Note 139

Ã—



 â€ƒBOM at p 314.



 157â€ƒThe upshot of all of this is that the PSA is unduly burdened with the need to experiment with innumerable combinations of Other Growth Conditions across the entire nitrogen range in Claim 62, so as to determine which combination will result in a diamond meeting the desired product claim(s). This is an onerous research programme because there are many values for each variable to experiment with, all while balancing the (undefined) relationships between the Other Growth Conditions and appropriate nitrogen concentration. Without any adequate teaching of a principle of general application or unifying characteristic that can guide the PSA to determine the appropriate value of each of the Other Growth Conditions, the PSA must resort to a prolonged trial and error experiment, fraught with uncertainty and unpredictability, using arbitrarily selected values for each variable in the growth process.  (IV)â€ƒAuthorities highlight the insufficiency of providing a starting point for an onerous research programme158â€ƒBased on the foregoing, Examples 1, 9 and 14, as well as the ranges of values for gas pressure and plasma power density in the description, at best provide a starting point for an onerous research programme. 159â€ƒThe case law holds that an undue burden is imposed if this is all that the patentâ€™s specification affords.160â€ƒIn Bayer Schering Pharma/Reach-through claim [2009] OJ EPO 516 (â€œBayerâ€), the patent in suit was for the use of compounds, which are capable of â€œstimulating the soluble guanylate cyclase independently of the heme group in the enzyme, to manufacture medicaments for the treatment of cardiovascular disordersâ€. The patent was held to be insufficient under Art 83 of the European Patent Convention because â€œcompoundsâ€ was not defined by any chemical structure, but solely by the functional ability to â€œstimulate guanylate cyclaseâ€. Article 83, similarly to sÂ 25(4) of the Patents Act (2005 Rev Ed), requires the invention to be stated â€œin a manner sufficiently clear and complete for it to be carried out by a person skilled in the art.â€ The Technical Board of Appeal (â€œBoardâ€) held that trial and error on â€œevery conceivable chemical compoundâ€ for the claimed capability was an undue burden. It also noted that â€œthe simple structural identification of one suitable compound class of general formulaâ€ would not help the PSA. By analogy, the provision by Example 1 in SG 872 of a baseline for a research project cannot cure Claim 62 of insufficiency. We therefore agree with the appellant that the examples in SG 872 â€œcannot support a claim of the breadth of claim 62â€.
                   140




Foot Note 140

Ã—



 â€ƒAR at para 46; see also Transcript, 20 January 2022, p 61:10.



 It is useful to reproduce the relevant portion of the Boardâ€™s reasoning in full (at [5.2]): .. not all conceivable compounds possess the capability of stimulating the soluble guanylate cyclase independently of the heme group in the enzyme as required by the claim, and it is up to the skilled person to pick from this indefinite and innumerable host of alternatives the suitable ones. In order to pick from that host the skilled person cannot draw on his common knowledge to identify from the host of possible alternatives those suitable chemical compounds which, along with the compounds of general formula (I) exemplified in the application in suit, are also covered by the functional definition in the claim, because the application in suit (p.1, ll.5 and 6) discloses that the invention is based on a â€˜new mechanism of actionâ€™. In selecting the chemical compounds possessing the necessary capability, all he has to rely on is the information provided in the application in suit. In the absence of any selection rule in the application in suit, not even in the form of a structure activity relationship on the basis of which he could identify from the outset suitable compound classes, the skilled person must resort to trial-and-error experimentation on arbitrarily selected chemical compounds using the screening method cited in the application in suit to identify within the host of possible alternative compounds those which stimulate the soluble guanylate cyclase independently of the heme group in the enzyme. Nor does he have any information at his disposal in the application in suit leading necessarily and directly towards success through the evaluation of initial failures. Nor would the simple structural identification of one suitable compound class of general formula (I) in the application in suit be of any help to the skilled person. To find all the suitable alternatives, he would therefore have to test every conceivable chemical compound for the claimed capability; this represents for the skilled person an invitation to perform a research programme and thus an undue burden.[emphasis added]161â€ƒAldous LJâ€™s obiter dictum in American Home Products Corporation v Novartis Pharmaceuticals UK Ltd [2001] RPC 8 equally emphasises the inadequacy of supplying a starting point for a research programme (cited in Terrell at para 13-25). The patent in suit there was for the â€œ[u]se of rapamycin for the preparation of a medicament for inhibiting organ or tissue transplant rejection in a mammal in need thereofâ€ (at [5]). A competitor produced a derivative, which gave rise to the issue of whether the derivative fell within the scope of the claim. The English Court of Appeal held that the claim did not extend to derivatives but considered the position of insufficiency under sÂ 72(1)(c) of the UK Patents Act 1977 in the event it did. Aldous LJ opined that the patent would be insufficient because, as the judge had found below, the number of possible derivatives was â€œvastâ€ and many would not exhibit the required immunosuppressant activity. As a result, â€œwhether any particular molecule derived from rapamycin would work at all was impossible to predict with certaintyâ€ (at [42]â€“[43]): 42.â€ƒThe judge held that the number of possible derivatives was vast and whether any particular molecule derived from rapamycin would work at all was impossible to predict with certainty. Many derivatives would not exhibit immunosuppressant activity. Those which involved small changes to the side chain would be the most likely to work. Thus the skilled person could make up a list of possibles, with those believed to be the most likely at the top of the list. Even so, finding appropriate derivatives, if they existed, would involve a systematic and iterative process. Further, when a derivative which had appropriate activity had been identified, it would be impossible to be certain that it did not exhibit unpredictable defects. To discover whether it did would require further tests which would take a long time.43.â€ƒThe very uncertainty and unpredictability found by the judge meant that the skilled person was being required to carry out research. The duty upon the patentee is to provide a description which enables the skilled person to perform the invention, in this case across the breadth of the claim; not to supply a starting point for a research programme. If the claim includes derivatives of rapamycin, an enabling description of such derivatives is needed so that the products of the claim can be ascertained.[emphasis added in italics and bold italics]162â€ƒSo too is the case of Amorphous silica/INEOS T 1743/06 (â€œAmorphous Silicaâ€) on point. The patent there was found to be insufficient as the process claim for producing amorphous silicas according to the product claims involved variables which the PSA was not taught to calibrate. Similar to the present case, the product claims for â€œamorphous silicaâ€ were characterised by a series of physical properties. For reference, the process claim stated as follows:18. Process for the production of amorphous silicas according to claims 1 to 17 comprising:âˆ’ adding a 17.0 to 21.5% solution of 2.1 to 2.5 Molar Ratio silicate solution to water,âˆ’ then further adding a 17.0 to 21.5% solution of 2.1 to 2.5 Molar Ratio silicate solution together with a 15 to 20% sulfuric acid solution, over a period of over 40 minutes at such flow rates that the pH is maintained in the range from 8.0 to 9.0,âˆ’ then aging the resultant slurry for a period of 0 to 30 minutes at a temperature of 90 to 100Â°C,âˆ’ doing a second addition of a 15 to 20% sulfuric acid solution to bring the pH down to pH 3 to 5,âˆ’ aging the resulting slurry for a period of 0 to 20 minutes at pH 5 at a temperature of between 90 and 100Â°C,âˆ’ adjusting the pH to pH 3.5 to 5, andâˆ’ eventually filtering, washing and drying the final slurry.163â€ƒThe patent contained two examples of specific amorphous silicas possessing characteristics that fell within the ranges of values defined under the product claim (at [1.2]). In respect of the process claim, the Board noted as follows: 1.3 Concerning the preparation of the amorphous silicas disclosed in the patent in suit, there is the information at paragraphs [0022] and [0021] that amorphous silicas presenting good cleaning characteristics without damaging teeth and which are particularly good at preventing stain formation can be obtained through a process â€˜comprising:âˆ’ adding a 17.0 to 21.5% solution of 2.1 to 2.5 Molar Ratio silicate solution to water,âˆ’ then further adding a 17.0 to 21.5% solution of 2.1 to 2.5 Molar Ratio silicate solution together with a 15 to 20% sulfuric acid solution, over a period of over 40 minutes at such flow rates that the pH is maintained in the range from 8.0 to 9.0,âˆ’ then aging the resultant slurry for a period of 0 to 30 minutes at a temperature of 90 to 100Â°C,âˆ’ doing a second addition of a 15 to 20% sulfuric acid solution to bring the pH down to pH 3 to 5, âˆ’ aging the resulting slurry for a period of 0 to 20 minutes at pH 5 at a temperature of between 90 and 100Â°C,âˆ’ adjusting the pH to pH 3.5 to 5, andâˆ’ eventually filtering, washing and drying the final slurryâ€™.The board however notes that the description of the contested patent does not give any details as to how the above process conditions â€˜for preparing amorphous silicas presenting good cleaning characteristics without damaging teeth and which are particularly good at preventing stain formationâ€™ might be modified in order to achieve reliably the parameters of the specific amorphous silicas defined in the claims 1 at issue.[emphasis added in bold italics]164â€ƒOne specific issue which vexed the parties was the absence of any teaching on the appropriate stirring speed to use during the preparation of the silica. The patentee argued that the PSA could determine the appropriate stirring speed by varying it while reworking the two examples in the patent specification. However, the Board held that this did not overcome the lack of teaching for the stirring speed, and other process parameters, in respect of the other amorphous silicas that were not contemplated in the examples but fell within the range of products claimed: 1.8â€ƒ... The board can accept that such a trial and error experimentation might in the present case not be considered as undue burden as far as the silicas illustrated in the examples of the contested patent are concerned. However, this reasoning which can be accepted only for the two examples, does not hold good for the other claimed but non-exemplified amorphous silicas and in the absence of any specific recipe concerning the preparation of such silicas, the problems concerning the stirring speed still remain for silicas claimed over the whole range.1.9â€ƒThe skilled person is thus confronted with the uncontested fact that he has a lot of process variables affecting the claimed parameters, but once he has encountered failure in one parameter value, there is no clear guidance enabling him to adjust the multitude of process steps in order to arrive with certitude at silicas meeting the parameter requirements defined in claim 1 of both requests at issue.Even though a reasonable amount of trial and error is permissible when it comes to assessing sufficiency of disclosure, there must still be adequate instructions in the specification, or on the basis of common general knowledge, leading the skilled person necessarily and directly towards success, through evaluation of initial failures. This is not the case here, since the preparation of the amorphous silicas claimed is made dependent on the adjustment of different process parameters for which no guidance is given in the patent in suit, so that the broad definition of an amorphous silica as presently claimed is no more than an invitation to perform a research program in order to find a suitable way of preparing the amorphous silicas over the whole area claimed.[emphasis added in bold italics and bold italics with underline]165â€ƒAs a result, the Board in Amorphous Silica upheld the revocation of the patent. This reinforces our view at [160] that just providing discrete sets of process parameters in examples without a general or unifying principle to guide the PSA in calibrating these parameters to produce a desired product may not sufficiently enable the invention across its entire breadth. Indeed, in Claim 62, given the complexities described at [155]â€“[156] above, the Example 1 Other Growth Conditions and the modifications in Examples 9 and 14, do not avoid the need for an unduly prolonged research project. 166â€ƒFinally, Saint-Gobain Adfors SAS (a company existing under the laws of France) v 3M Innovative Properties Co (a company existing under the laws of Delaware, United States) [2022] EWHC 1018 (Pat) (â€œSaint-Gobainâ€) underscores the importance of providing guidance on how to vary process parameters to achieve a specific product in the range of products claimed in the patent, in so far as how to calibrate the process parameters is not part of the common general knowledge. The patent contained a product claim for dish-shaped abrasive particles with, among other integers, a sloping sidewall and a specific thickness ratio. The latter was described as follows: â€œa thickness ratio of Tc/Ti for the dish-shaped abrasive particles (20) is between 1.25 and 5.00, wherein Tc is the thickness at a corner (30) of the sidewall (28) and Ti is the smallest thickness of the interior of the first face (24)â€ (at [93]) [emphasis added in italics]. Abrasive products made from abrasive particles are used to abrade, cut, grind, finish or polish a variety of materials (at [13]). The â€œrecessed or concaveâ€ face of the invention was said to allow the claimed products to remove more material, when being applied as an abrasive particle, than a flat abrasive particle (see [59]). Critically, the court held that the patent had to enable the production of particles without undue burden across the whole range of thickness ratios defined in Claim 1, namely 1.25 to 5.00 (at [196]). This also strengthens our construction of the product claims in SG 872 (see [83] above). As to the point on insufficiency, the court held that the patent imposed an undue burden to produce particles across the entire scope of the product claim (at [233]). Part of the patent specification stated that it was possible to produce particles with thickness ratios between 1.55 to 2.32 (at [68] and [211]). But the court was not convinced that the PSA could produce particles at the upper end of the defined range of thickness ratios (that is, approaching 5.00) without an undue burden. The patent provided no indication of how to adjust relevant process parameters to vary the thickness ratio across the range of the claim (at [212] and [233]). For instance, one step in the production process involved drying a wet gel that had been prepared (at [36]). While the patenteeâ€™s expert argued that in order to control the Tc/Ti ratio, the PSA would increase the temperature and hence the â€œdrying rateâ€ of the wet gel, the court held that the PSA would not have thought to do so (at [217]). Claim 62 is likewise deficient for failing to provide adequate guidance on how to produce diamonds across the entire range of each product claim.(C)â€ƒExperimental data is unnecessary 167â€ƒIn the present case, it is also no answer for the respondent to point to the appellant having failed to perform experiments to support its case on insufficiency. In Novartis AG v Johnson & Johnson Medical Ltd [2011] ECC 10, which concerned a patent for extended wear contact lenses, the English Court of Appeal upheld the lower courtâ€™s finding that the patent was insufficient because it did not teach which materials within the specific families and examples described were suitable for the production of ophthalmically compatible extended wear lenses. Neither did the patent enable the PSA to predict whether any lens is likely to be opthalmically compatible over a period of extended wear (at 195). Crucially, the court held that it was â€œirrelevantâ€ that the challenger had not performed any experiments. As observed by Jacob LJ, the more important point was that (at 196): ... the Patent gives no clue as to whether he will be successful. If he happens to have chosen a pair of polymers and proportions which â€˜workâ€™ that will be his luck, not something contributed by the Patent. And even if he is lucky, that luck will tell him nothing about the whole of the remaining vast area claimed. The Patent is manifestly not enabling across the range claimed. [emphasis added in bold italics]168â€ƒIn much the same way, we do not need experimental data to conclude that the patent tells the PSA nothing about how to obtain the appropriate combination of the Other Growth Conditions and nitrogen concentration to grow a single crystal CVD diamond material with characteristics satisfying one or more of the product claims. The PSA attempting to perform Claim 62 may by happenstance stumble on the appropriate combination and grow the low-strain diamond desired, but such a result is not due to the teaching in SG 872. It is clear from the face of SG 872â€™s specification that any success the PSA has in performing Claim 62 will be due to his own luck and efforts. In these circumstances, it would be unfair to allow a patentee to take credit for something the patent does not sufficiently enable and which requires the PSA to expend undue effort to uncover.(D)â€ƒCalibrating the Other Growth Conditions is not common general knowledge169â€ƒWe turn to consider whether the PSA, imputed with common general knowledge, would know how to calibrate all the Other Growth Conditions. In so doing, we will deal with two points that were raised by the respondent and the Judge respectively.170â€ƒThe respondent argues that the PSA â€œwould know to adjust the regular reactor conditions such as temperature and gas flow ratesâ€.
                   141




Foot Note 141

Ã—



 â€ƒRCN at para 49(b).



 Knowledge that the Other Growth Conditions do affect the quality of the diamond grown may have been part of the common general knowledge. But that is quite different from saying that how to calibrate all the Other Growth Conditions so as to produce an SG 872 Diamond of a specific quality was common general knowledge at the filing date. There was simply no evidence at all to support this and all we have said about the lack of sufficiency explains why this is untenable.171â€ƒThe Judge, however, found that Claim 62 is not classically insufficient because the PSA would know how to adjust the Other Growth Conditions (Judgment at [285]). With respect, we find that she erred. According to the Judge, Dr Bergonzoâ€™s evidence was that â€œthe missing details, such as the geometry of the substrate holder, would be within the knowledge of the PSA skilled with working knowledge of the research and development of CVD diamond synthesisâ€ (Judgment at [285]). 172â€ƒThe portion of Dr Bergonzoâ€™s evidence the Judge appears to have relied on is found in Dr Bergonzoâ€™s report dated 26 June 2019 (â€œDr Bergonzoâ€™s Reply Reportâ€), which was written in response to Dr Nebelâ€™s reports.
                   142




Foot Note 142

Ã—



 â€ƒIII(A55) ROA 8, 16, 56â€“58.



 To understand Dr Bergonzoâ€™s evidence in its proper context, we need to summarise the relevant portion of Dr Nebelâ€™s 1st Report,
                   143




Foot Note 143

Ã—



 â€ƒIII(B13) ROA 10; see in particular III(B14) ROA 147â€“149 (paras 1121â€“1128).



 to which Dr Bergonzo was responding.173â€ƒDr Nebel had stated that the PSA would know that the Other Growth Conditions which affect the appropriate concentration of nitrogen include the: â€œGeometry of reaction chamber, Pressure, Temperature, Gas flow rates, Composition of Source Gas, Microwave Power and quality of substrate used.â€
                   144




Foot Note 144

Ã—



 â€ƒNebel-1 at para 1222 (III(B14) ROA 147).



 He noted that Claim 62 â€œfails to provide accurate process conditions at which [300ppb to 5ppm nitrogen] would result in the intended objective of the method.â€
                   145




Foot Note 145

Ã—



 â€ƒNebel-1 at para 1221 (III(B14) ROA 147).



 His views on the Examples bear setting out in full:
                   146




Foot Note 146

Ã—



 â€ƒNebel-1 at para 1227 (III(B14) ROA 149).



 Other than Example 1, only example 9 and 14 provide some variation in conditions of nitrogen in process gas, pressure and methane concentration but no guidance on missing parameters or further clarity of broadly described parameters are provided. Further, the patent also does not provide any correlation or even subjective relationship on how the level of nitrogen in â€˜synthesis atmosphereâ€™ would change if the process conditions vary from what is mentioned in examples, in order to achieve the same quality of diamond as disclosed in the example. In absence of guidance on specific process parameters and their relationship with level of nitrogen in process gas, the range of 300 ppb to 5 ppm is of little use for the PSA. Since the patent itself defines this range to be â€˜process dependentâ€™, claiming this range without specifying the process parameters for which the range would be valid would be of little use.[emphasis added in italics and bold italics]174â€ƒDr Nebel also mentioned that in the absence of a specific value of microwave power, the PSA would not be able to achieve the plasma power density required. He added that the growth of the diamond is â€œstrongly affected by the geometry of the molybdenum substrate holder usedâ€, but SG 872 â€œdoesnâ€™t teach anything about the geometry of the substrate holder or the placement of seeds on the substrate holder.â€
                   147




Foot Note 147

Ã—



 â€ƒNebel-1 at para 1225 (III(B14) ROA 148).



 175â€ƒDr Bergonzoâ€™s response was that the PSA would know how to achieve â€œthe high plasma density requiredâ€ and â€œwhat substrate holder to use with his reactorâ€.
                   148




Foot Note 148

Ã—



 â€ƒBergonzo-2 at paras 196(c) and 200(a) (III(A55) ROA 57).



 It is immediately clear that Dr Bergonzo only addressed two of the Other Growth Conditions and omitted to explain how the PSA would know how to calibrate the remaining variables so as to produce an SG 872 Diamond of a specific quality. Therefore, even taking Dr Bergonzoâ€™s evidence in respect of the geometry of the substrate holder, on which the Judge appeared to focus (Judgement at [285]), at face value, this is no answer to the difficulty the PSA faces in determining all of the remaining Other Growth Conditions.176â€ƒAs for Dr Bergonzoâ€™s evidence on the appropriate plasma power density, he does not claim that the PSA would know how to calibrate this parameter depending on the quality of diamond desired. Dr Bergonzo simply testified that the PSA would combine his knowledge of the typical microwave power with the gas pressure used in Example 1 (263 x 102 Pa) to â€œgive â€¦ the high plasma density requiredâ€:
                   149




Foot Note 149

Ã—



 â€ƒBergonzo-2 at para 196 (III(A55) ROA 56â€“57).



(a) A typical substrate diameter at the time was around 50 mm. Based on the above patent reference this relates to a microwave power around 5 kW.(b) To apply 5 kW effectively to a 50 mm substrate at the high pressures required by the patent (e.g. 263 x 100 Pa) requires a microwave chamber such as that provided in the SEKI/ASTeX cylindrical reactor, which was the most commonly available commercial reactor at the time, and one which had also spawned many â€˜home builtâ€™ replicas.(c) The combination of the pressure and the power then give us the high plasma density required â€“ no variable is missing177â€ƒBut knowing how to achieve a â€œhigh plasma densityâ€ is not the same as knowing how to vary the plasma density to achieve a specific diamond in the range of diamonds covered by SG 872â€™s product claims. 178â€ƒDr Bergonzoâ€™s first report dated 13 May 2019 is also of no assistance to the respondent. There, Dr Bergonzo asserts that the â€œdescription of SG â€˜872 provides ... [a] detailed summary of the substrate conditions used ... includ[ing] sizes, thickness, orientation, surface roughness, plasma etch conditions, duration and temperature, etc. This can be found, for instance, under Example 1 of SG â€˜872. ... I am unable to identify any more points or parameters that needed to be, or should have been, disclosed to a PSAâ€
                   150




Foot Note 150

Ã—



 â€ƒDr Bergonzoâ€™s 1st Report at para 120 (III(A52) ROA 96).



 [emphasis added in bold italics]. However, as we analysed at [152]â€“[168] above, the specification of SG 872 does not provide enabling disclosure across the whole breadth of Claim 62.179â€ƒRead in its proper context, Dr Bergonzoâ€™s evidence does not address the heart of Dr Nebelâ€™s concern: that â€œThe â€˜872 Patent fails to provide any teaching on these other parameters and their relationship with the claimed properties of CVD diamond.â€
                   151




Foot Note 151

Ã—



 â€ƒNebel-1 at para 1266 (III(B14) ROA 161).



 We agree with Dr Nebel. Dr Bergonzo also does not appear to expressly assert that a method to calibrate all the Other Growth Conditions was within the PSAâ€™s common general knowledge at the filing date. In so far as he does, he and the respondent have failed to back this up with evidence to show that this was â€œgenerally known and generally regarded as a good basis for further action by the bulk of those who are engaged in the particular artâ€ (see [74] above) and we reject any such contention.
                   152




Foot Note 152

Ã—



 â€ƒSee also PCS2 at para 1322 (III(G3) ROA 235).



 180â€ƒTherefore, having regard to the language of the claim itself, the relevant context in SG 872 and the expert evidence, we overturn the Judgeâ€™s finding that Claim 62 is not classically insufficient and hold it to be invalid in so far as the respondentâ€™s claim for infringement is concerned. 181â€ƒWe accept that a claim in a patent is not required to specifically describe â€œall possible ways in which the invention can be carried outâ€ (Halsburyâ€™s Singapore IP at para 160.369). The inventor cannot be expected to relieve the PSA from all obligation to take trouble in carrying into effect the description in the specification (First Currency Choice at [67]). Rather, what is lacking in Claim 62, and the specification of SG 872, is a teaching of a general principle that enables the PSA to (a) understand the relationship between the Other Growth Conditions and nitrogen concentration; and (b) determine how to calibrate the Other Growth Conditions to grow a diamond of a specific quality. (E)â€ƒThe other process claims182â€ƒIn light of the foregoing, Claims 63 to 71, process claims which refer back to and narrow the process taught in Claim 62, are likewise classically insufficient. For example, Claim 63 monopolises â€œ[a] method according to claim 62, wherein the synthesis atmosphere contains more than 500 ppb nitrogenâ€ while Claim 67 monopolises â€œ[a] method according to any of claims 62 to 66, wherein the density of defects is such that surface etch features related to defects is below 102/mm2.â€
                   153




Foot Note 153

Ã—



 â€ƒBOM at pp 374â€“375.



 All of these subsequent process claims require an understanding of how to calibrate the Other Growth Conditions in order to grow a diamond of a specific quality, but, like Claim 62, are utterly devoid of such guidance.Whether the Product Claims are also classically insufficient183â€ƒSince all of the process claims in SG 872 (meaning Claims 62 to 71) are classically insufficient, and since it is the respondentâ€™s case that producing an SG 872 Diamond was not possible prior to the discovery of the process in Claim 62 (in particular, the Claim 62 Nitrogen Range) (see [39] above), the sufficiency of these product claims is called into question. 184â€ƒAs a starting point, working a product claim entails making the product (see Regeneron (SC) at [23]). A product claimâ€™s contribution to the art is â€œthe ability of the skilled person to make the product itself ...â€ (Regeneron (SC) at [56(ii)]). The patentee cannot obtain a product monopoly without disclosing how to make the product because if it were otherwise, the public would get nothing of substance in return for the grant of monopoly and the patent bargain described at [57] and [102] would be not be satisfied (see Regeneron (SC) at [23]). And, a claim must enable the invention to be performed over its whole breadth (see [108]â€“[109] and [114] above; Saint-Gobain at [196]). We also explained at [83]â€“[93] that each product claim in SG 872 asserts a monopoly over a class of products. Hence, the question is whether the specification of SG 872 sufficiently enables the PSA to produce diamonds across the entire breadth of each product claim in SG 872.185â€ƒHaving found that all the process claims in SG 872 are classically insufficient, we are satisfied that all the product claims are invalid for the same reason. Claims 62 to 71 assert that the process taught therein enables the PSA to produce an SG 872 Diamond.
                   154




Foot Note 154

Ã—



 â€ƒBOM at p 374.



 Since these process claims are classically insufficient, the PSA is faced with an undue burden to grow diamonds across the entire range of products claimed in each product claim. This is not to say that the sufficiency or, more generally, the validity of a product claim is necessarily tied to that of a related process claim as a matter of law. This happens to be the case on the present facts because SG 872 does not teach an alternative method of producing an SG 872 Diamond besides the one found in Claims 62 to 71 (see also [39] above), and neither is it the respondentâ€™s case that there is a method within the PSAâ€™s common general knowledge to grow SG 872 Diamonds.186â€ƒWe return to our earlier reference to the substantiality threshold in Regeneron (SC) (see [112] above). In our view, even if all that is required is enablement substantially across the breadth of each product claim, that standard is not met. As we observed above at [154], the specification of SG 872 only teaches the production of five variants of an SG 872 Diamond. There are, however, innumerable combinations of values of Other Growth Conditions and nitrogen concentrations to use, and innumerable embodiments of an SG 872 Diamond disclosed in Claim 1 (which we take to be the broadest product claim in SG 872). Enabling five variants of an SG 872 Diamond is not substantial enablement.Revocation187â€ƒAs all claims in SG 872 are invalid for classical insufficiency, we allow the appellantâ€™s counterclaim and revoke SG 872 in its entirety under s 80(1)(c) of the Patents Act (2005 Rev Ed). Although this is sufficient to dispose of the appeal, we briefly consider one further difficulty.Whether any or all of the claims in SG 872 are invalid due to uncertaintyWhether Claim 1 is uncertain188â€ƒTo recap, low birefringence is quantified in Claim 1ii) as a sample with (a) Î´ remaining in the SG 872 First Order; and (b) |sin  Î´| not exceeding 0.9. Low birefringence is quantified in Claim 1iii) as a sample with (a) Î´ remaining in the SG 872 First Order; and (b) Î”n[average] not exceeding 1.5 x 10-4. The specification of SG 872 directs the PSA to use a Deltascan (which has been renamed as the Metripol since 2001) or a â€œsimilar instrument with similar resolutionâ€. The question which arises for our consideration is whether the PSA would know what test he should apply to ascertain whether a particular single crystal CVD diamond satisfies the integer that Î´ is within the SG 872 First Order.189â€ƒThe respondent claims that there are three instruments which are similar to the Metripol â€“ the Polscope, the Millipol and the Rotopol.
                   155




Foot Note 155

Ã—



 â€ƒRC at para 177.



 We reject the respondentâ€™s allegation that the Polscope is a similar instrument. According to Dr Geday, though the Polscope was available in 2002 and was considered a direct competitor to the Metripol, it was less precise and hence inferior to the Metripol.
                   156




Foot Note 156

Ã—



 â€ƒTranscript, 24 July 2019, pp 8:17â€“9:6 (III(D4) ROA 13â€“14).



 The respondent has not shown us any other material which contradicts Dr Gedayâ€™s evidence. In so far as the Millipol and the Rotopol are concerned, it is common ground that both these instruments are similar to the Metripol but were developed only by 2009.
                   157




Foot Note 157

Ã—



 â€ƒPrimer at para 158.



 As such, they could not have formed part of the PSAâ€™s common general knowledge at the relevant time and cannot be relied upon as enabling the PSA to test for the parameters in Claims 1ii) and 1iii). In these circumstances, the following analysis will focus only on the Metripol.190â€ƒIt is common ground between the parties that the Metripol, on its own, does not give the PSA data to determine whether the Î´ value of a single crystal CVD diamond material falls within the SG 872 First Order. This has been referred to as the â€œMetripol Uncertainty Problemâ€. The reason for this is that the Metripol does not calculate Î´. The Metripol generates the value of |sin Î´|, but each |sin Î´| value corresponds to many Î´ values and only one of these Î´ values lies within the SG 872 First Order. A graphical representation of this can be found at [35] above. It is for this reason that the appellant submits that Claims 1ii) and 1iii), and SG 872 as a whole, is invalid for insufficiency by ambiguity, or, as we prefer to term it, uncertainty.
                   158




Foot Note 158

Ã—



 â€ƒACN at para 16.



191â€ƒAgainst this, the respondent claims that Dr Kaminsky had testified that he â€œtotally disagree[d]â€ that the Metripol Ambiguity Problem was â€œinsolubleâ€.
                   159




Foot Note 159

Ã—



 â€ƒRC at para 178.



 This is a mischaracterisation of Dr Kaminskyâ€™s testimony. The cross-examination of Dr Kaminsky had proceeded on the basis that each â€œorderâ€ is a multiple of 2Ï€, and â€œfirst orderâ€ was defined as Î´ not exceeding 2Ï€. This is distinct from the SG 872 First Order which is specifically and more narrowly defined in terms of Î´ not exceeding . However, it was in the former context that Mr Alvin Yeo SC, counsel for the respondent, asked Dr Kaminsky if he thought that it was an â€œinsoluble problemâ€ to determine â€œwhich orderâ€ Î´ was in. Dr Kaminsky replied that he â€œtotally disagree[d]â€ that it was an insoluble problem.
                   160




Foot Note 160

Ã—



 â€ƒTranscript, 24 July 2019, pp 93:21â€“94:12 (III(D4) ROA 98â€“99).



 Thus, when understood in context, Dr Kaminskyâ€™s position, at its highest, is that it is possible to determine whether Î´ is between 0 and 2Ï€. However, this does not necessarily mean that it is possible to determine whether Î´ falls within a more narrow range of values between 0 and   (that is, the SG 872 First Order) (see above at [31]).192â€ƒThe respondent further submits that there are four solutions to the Metripol Uncertainty Problem which the PSA would know of. The first solution is to interpret the data obtained from the Metripol using the PSAâ€™s knowledge of the nature and characteristics of single crystal CVD diamond material, with reference to Dr Glazerâ€™s Gap Theory.
                   161




Foot Note 161

Ã—



 â€ƒRC at paras 179â€“184.



 If the PSA remained in doubt as to whether Î´ is within the SG 872 First Order, he could use a second method known as the Cross-Polariser Method. This involves the use of cross-polar microscopy and the Michel-Levy interference colour chart.
                   162




Foot Note 162

Ã—



 â€ƒRC at paras 185â€“189.



 The third entails the use of a standard compensating plate with white light. The fourth and final solution is to carry out the measurements using the Metripol at two or more wavelengths.
                   163




Foot Note 163

Ã—



 â€ƒRC at paras 190â€“193.



 The last two solutions will be collectively referred to as the â€œGlazer 1996 Solutionsâ€, as they are found in â€œAn Automatic Optical Imaging System for Birefringent Mediaâ€ (1996) 452 Proc R Soc Lond A 2751 (â€œGlazer 1996â€), a scientific paper referred to in SG 872.
                   164




Foot Note 164

Ã—



 â€ƒBOM at p 330.



193â€ƒIn turn, the appellant disagrees that these solutions would enable the PSA to determine if Î´ is within the SG 872 First Order. We note in passing that although the appellantâ€™s argument focuses on whether a particular solution is part of the PSAâ€™s common general knowledge at the priority date of SG 872 (meaning 21 November 2002),
                   165




Foot Note 165

Ã—



 â€ƒSee AC at para 160.



 it is not in dispute that there is no material difference in the common general knowledge of the PSA as at the filing date (20 November 2003) and the priority date (21 November 2002).
                   166




Foot Note 166

Ã—



 â€ƒSee AC at p 70.



194â€ƒIn our judgment, the appellant, by highlighting the Metripol Uncertainty Problem, has adduced sufficient evidence to suggest that the PSA would not have been able to determine if Î´ is within the SG 872 First Order for a particular single crystal CVD diamond. The evidential burden thus shifts to the respondent to show that the PSA would know of a workable solution to overcome this and would be able to ascertain whether Î´ is within the SG 872 First Order in so far as single crystal CVD diamonds are concerned. This means that the respondent must show that any of the four solutions set out at [192] above fulfil two cumulative criteria: (a) it is a workable solution for ascertaining whether Î´ is within the SG 872 First Order where single crystal CVD diamonds are concerned, and (b) it is a solution that would have been known to the PSA either because (i) it is taught in the patent or (ii) it is part of the common general knowledge (Glaxo Group at [180]â€“[181]). The four solutions raised by the respondent do not fulfil either or both of these criteria.(1)â€ƒThe Gap Theory195â€ƒWe begin with the Gap Theory, which was accepted by the Judge as providing a solution to the Metripol Uncertainty Problem (Judgment at [200]â€“[204]).196â€ƒThe respondent, relying on the evidence of Dr Glazer and Dr Newton, submits that the PSA using the Gap Theory would be able to tell from the Metripol measurements whether the sample remained in the SG 872 First Order. According to the respondent and Dr Glazer, the Gap Theory works on the premise that the PSA would know the following (collectively, the â€œPremisesâ€):
                   167




Foot Note 167

Ã—



 â€ƒRC at para 180; RSA at para 55; Transcript, 22 July 2019, pp 123:23â€“127:5, 141:3 (III(D3) ROA 128â€“132, 146); Dr Anthony Michael Glazerâ€™s 2nd Report (â€œGlazer-2â€) at paras 7, 62 and 75 (III(A43) ROA 16, 28 and 31).



(a)â€ƒA theoretically perfect diamond with no strain-causing defects is isotropic and would, if measured, show |sin Î´|=0 and Î´=0 (the â€œFirst Premiseâ€).(b)â€ƒIf the Metripol |sin Î´| Map of the analysed area of a sample shows regions in which |sin Î´| is close to 0 without significant spatial variations associated with defects causing strain, these regions correspond to Î´ being close to 0 (the â€œSecond Premiseâ€).(c)â€ƒStrain in the material varies continuously, and thus, Î´ and the |sin Î´| measurements are continuous with no gaps (the â€œThird Premiseâ€).197â€ƒThe respondent submits that with the knowledge of the Premises, the PSA, in respect of an analysed area without significant spatial variations associated with defects causing strain, would know that the analysed area remains in the SG 872 First Order (Î´â‰¤ ) if the |sin Î´| values extend upwards from close to zero to a maximum value (|sin Î´|max) that is not close to 1 (meaning that there is a gap between |sin Î´|max and 1).
                   168




Foot Note 168

Ã—



 â€ƒRC at paras 180 and 181.



 Dr Glazer explained at the trial that this interpretation is based on the understanding that Î´ varies continuously. He said that it is not possible for there to be a gap between |sin Î´|max and 1, and for there to be Î´ values outside the SG 872 First Order simultaneously. If there are Î´ values outside the SG 872 First Order, there must have been a continuous range of Î´ values which extends from 0 up to those values beyond the SG 872 First Order, in which case, there would be no gap between |sin Î´|max and 1.
                   169




Foot Note 169

Ã—



 â€ƒTranscript, 22 July 2019, pp 123:23â€“127:5, 141:3 (III(D3) ROA 128â€“132, 146).



 The Gap Theory therefore determines whether Î´ remains in the SG 872 First Order by looking at whether there is a gap between |sin Î´|max and 1. If this gap exists, the range of Î´ values must be within the SG 872 First Order; if this gap does not exist, the range of Î´ values must have extended beyond the SG 872 First Order.198â€ƒWhether the Gap Theory is sound is a major point of dispute between the parties both at trial below and on appeal. Much of the dispute on this point turned on whether the Gap Theory has been disproved in the light of a small yellow streak in a cross-polarised image of Sample 2. However, it is unnecessary for us to resolve this factual dispute because even if we assume in the respondentâ€™s favour that the Gap Theory is sound, the respondent has not proven that the Gap Theory would have been known to the PSA at the relevant time.199â€ƒAt the outset, a PSA reading the specification of SG 872 would not know of the Premises or know that he should use the Gap Theory to determine whether Î´ falls within the SG 872 First Order. At trial, Dr Glazer tried to rely on the following passage to claim that it teaches the PSA to use the Gap Theory:
                   170




Foot Note 170

Ã—



 â€ƒTranscript, 22 July 2019, pp 149:11â€“151:5 (III(D3) ROA 154â€“156); BOM at p 302.



â€¦[T]he modulus of the sine of the phase shift, |sin ğ›¿|, as measured by a Deltascan or similar instrumentâ€¦ does not exceed 0.9, and preferably does not exceed 0.6, and more preferably does not exceed 0.4, and more preferably does not exceed 0.3, and more preferably does not exceed 0.2.We disagree with Dr Glazer. This passage does not even tell the PSA to look out for a gap between |sin Î´|max and 1, much less the significance of that gap in determining whether Î´ falls within the SG 872 First Order. Notably, the respondent did not seek to rely on Dr Glazerâ€™s evidence in this regard.200â€ƒThe Gap Theory, including its Premises, must be part of the common general knowledge at the relevant date in order for it to be attributed to the PSA. In this regard, we agree with the appellantâ€™s submission that the respondent has not established that the Gap Theory was part of the PSAâ€™s common general knowledge.
                   171




Foot Note 171

Ã—



 â€ƒAC at paras 160â€“164; ACN at paras 16(f) and 16(j).



 This evidential gap is fatal to the respondentâ€™s case, given that it is the respondent which bears the evidential burden to show that the PSA would know, as part of his common general knowledge, a workable solution to determine if Î´ is within the SG 872 First Order (see above at [194]). 201â€ƒDr Glazer and Dr Newton gave evidence that the PSA would know how to interpret the Metripol data with reference to the Gap Theory, but neither expert cited any publications, released at or before the relevant date, which referred to the Gap Theory. Proof that scientific publications have described the Gap Theory as a solution to the Metripol Uncertainty Problem does not necessarily demonstrate that the Gap Theory was part of the common general knowledge, but it would, at the very least, have been prima facie evidence that it was (see above at [74]). Indeed, while the First Premise can be inferred from what the parties agreed to be the common general knowledge (see above at [24]â€“[27]), the same cannot be said for the Second and Third Premises. Yet, the respondent, Dr Glazer and Dr Newton did not refer us to any publications which would establish these two premises as part of the common general knowledge.202â€ƒTo bolster the Third Premise, the respondent relies on a histogram prepared for each Sample. Each histogram graphically depicts the number of pixels which have a particular |sin Î´| value as measured by the Metripol. These histograms were set out in Dr Newtonâ€™s first report dated 13 May 2019 (â€œDr Newtonâ€™s 1st Reportâ€), wherein he sought to prove that the Samples infringed Claims 1ii) and 1iii).
                   172




Foot Note 172

Ã—



 â€ƒIII(A24) ROA 91 (Sample 2), 114 (Sample 3) and 142 (Sample 4).



 We set out the histogram for Sample 3 for illustration:According to the respondent, these histograms demonstrate that the continuity of strain in single crystal CVD diamonds results in |sin Î´| measurements which are continuous.
                   173




Foot Note 173

Ã—



 â€ƒRC at para 182.



 We find that these histograms do little to advance the respondentâ€™s case. These histograms do not show the more crucial point that Î´ varies continuously with no gaps (see above at [197]).
                   174




Foot Note 174

Ã—



 â€ƒTranscript, 22 July 2019, pp 123:23â€“127:5, 141:3 (III(D3) ROA 128â€“132, 146).



 More importantly, neither Dr Glazer nor Dr Newton relied on such a histogram in their expert reports to show that the PSA knew that |sin Î´| measurements of a single crystal CVD diamond would vary continuously in value because of the continuity of strain in the diamond. After all, these histograms are only prepared in respect of three samples and cannot be representative of a wider trend, or proof that this fact was well accepted by those skilled in the art.203â€ƒThe respondent notes that Dr Kaminsky did not challenge Dr Glazerâ€™s and Dr Newtonâ€™s evidence that the PSA would be aware of the Gap Theory and its Premises.
                   175




Foot Note 175

Ã—



 â€ƒRC at paras 183â€“184.



 In our judgment, however, that alone cannot suffice to establish that the Gap Theory and its Premises were common general knowledge at the relevant time because no supporting material was cited. Dr Glazerâ€™s and Dr Newtonâ€™s evidence, whilst unchallenged, remain bare assertions and do not justify a finding of fact that the Gap Theory and its Premises were common general knowledge.204â€ƒThis difficulty is enhanced when we have regard to a point made by the appellant in seeking to undermine the credibility of Dr Glazerâ€™s and Dr Newtonâ€™s assertion that the PSA would know of the Gap Theory and its Premises. The Gap Theory and its Premises were first raised in Dr Glazerâ€™s and Dr Newtonâ€™s second reports, after Dr Newton had concluded in the infringement analysis of his 1st Report that each Sample had a range of Î´ values within the SG 872 First Order. As pointed out by the appellant,
                   176




Foot Note 176

Ã—



 â€ƒAC at para 163.



 Dr Newton did not use the Gap Theory or any of its Premises in coming to his conclusion on infringement in his 1st Report. For each Sample, Dr Newton observed that â€œthe Metripol images show regions that clearly have a low density of strain-inducing defectsâ€,
                   177




Foot Note 177

Ã—



 â€ƒIII(A24) ROA 91 (Sample 2), 114 (Sample 3) and 142 (Sample 4). 



 and supports this by simply pointing to a Metripol |sinÂ Î´| Map (in greyscale and colour) of the entire Sample which is created by taking overlapping Metripol |sin Î´| Maps and stitching them together using a software programme.
                   178




Foot Note 178

Ã—



 â€ƒIII(A30) 95 (NL 625-03 (Sample 2)); III(A13) ROA 204 (NL 702 (Sample 3)); III(A32) ROA 59â€“60 (NL 719-06 (Sample 4)).



 No further elaboration was given. In respect of each Sample, Dr Newton then proceeded to identify the |sin Î´|max value of the analysed area, and computed one maximum Î´ value (Î´max) from |sinÂ Î´|max. We emphasise the fact that Dr Newton only derived one Î´max value. This is curious, since it is common ground that as a matter of arithmetic, each |sin Î´| value corresponds to many Î´ values (see above at [35]). Dr Newtonâ€™s 1st Report did not explain why he was able to derive only one Î´max value from the |sin Î´|max value. What is even more notable is that the Î´max value Dr Newton arrived at happened to be within the SG 872 First Order. From this, Dr Newton concluded that the range of Î´ values is confined within the SG 872 First Order. At no point in his 1st Report did Dr Newton expressly rely on the Gap Theory, or make any statement which shows that he deduced that the Î´max value must have been within the SG 872 First Order because there is a gap between |sin Î´|max and 1.  If the PSA would have known of and deployed the Gap Theory (because the Gap Theory was part of the common general knowledge at the relevant time), one would have expected Dr Newton to use it in his infringement analysis to prove that the Î´max value of each Sample must have been within the SG 872 First Order. This was not done. Instead, the Gap Theory was only raised in Dr Glazerâ€™s and Dr Newtonâ€™s second expert reports, after the appellant raised the objection that the PSA would not know how to determine when Î´ was within the SG 872 First Order.205â€ƒThe foregoing is further reinforced by the fact that Dr Glazer, the main proponent of the Gap Theory,
                   179




Foot Note 179

Ã—



 â€ƒNewton-2 at para 41 (III(A56) ROA 48).



 simply stated in his first expert report that he agreed with Dr Newtonâ€™s infringement analysis without seeking to plug the gap in Dr Newtonâ€™s infringement analysis by referring the court to the Gap Theory.
                   180




Foot Note 180

Ã—



 â€ƒDr Glazerâ€™s 1st Report (â€œGlazer-1â€) at paras 54â€“55 (III(A21) ROA 24â€“25).



206â€ƒFor these reasons, in our judgment, the respondent cannot rely on the Gap Theory to resolve the Metripol Uncertainty Problem. The Judge therefore erred when she accepted the Gap Theory without first considering whether it was part of the common general knowledge at the relevant time.207â€ƒThere is a further issue with the Gap Theory, even if we were to assume that it was part of the common general knowledge. On the respondentâ€™s own case, the Gap Theory only works on the condition that the sample will show regions in which |sin Î´| is close to zero without significant spatial variations associated with defects causing strain. The appellant points out that not all single crystal CVD diamond samples will have this characteristic.
                   181




Foot Note 181

Ã—



 â€ƒAC at para 157.



 The respondent derides the appellant for not adducing expert evidence to make good the assertion that not all single crystal CVD diamond samples will fulfil that condition,
                   182




Foot Note 182

Ã—



 â€ƒRC at para 182.



 but in our judgment, it is the respondent who has the evidential burden of showing that single crystal CVD diamond samples will generally fulfil that condition. As noted earlier at [194] above, the evidential burden has shifted to the respondent to show that there exists a workable test to determine whether Î´ falls within the SG 872 First Order. The respondent points to the Gap Theory, which works only when the sample shows regions in which |sin Î´| is close to zero without significant spatial variations associated with defects causing strain.
                   183




Foot Note 183

Ã—



 â€ƒSee RC at para 180; RSA at para 55; Glazer-2 at paras 62 and 75 (III(A43) ROA 28 and 31).



 To discharge its evidential burden of showing a workable test, the respondent must at least show that most, if not all, single crystal CVD diamond samples would satisfy the condition upon which the Gap Theory works. In our judgment, the respondent has not done so. Accordingly, the respondent has not proven that the Gap Theory is a workable test such that a PSA, analysing any single crystal CVD diamond sample in his possession, would be able tell if it fulfils the integer relating to the SG 872 First Order.(2)â€ƒCross-Polariser Method208â€ƒThe Cross-Polariser Method, which involves the use of cross-polar microscopy and the Michel-Levy interference colour chart, was common general knowledge at the relevant time. Cross-polar microscopy works by shining a beam of white light on two polarisers, which are placed perpendicular to one another. If a birefringent material is placed between the first polariser and the second polariser, the polarised light passing through the material is slowed down (or retarded). Depending on the extent of retardation, different wavelengths constituting white light (400nm to 700nm) may interfere and display colour when the resulting beam is imaged on a plane. The cross-polarised image of an isotropic crystal (one with no birefringence) will be completely dark, but the cross-polarised image of a highly anisotropic crystal (one with high birefringence) will be colourful. The colours in the image are then compared against the Michel-Levy interference colour chart to ascertain the birefringence of the material.
                   184




Foot Note 184

Ã—



 â€ƒPrimer at paras 43â€“46.



209â€ƒFigure 16 depicts how Î´ values (within the range of 0 to 2Ï€) can be derived upon locating the colours in the cross-polarised image in the Michel-Levy interference colour chart:
                   185




Foot Note 185

Ã—



 â€ƒIV(B) ROA 33.



Where a particular region of the cross-polarised image contains dark magenta, Î´ is close to 2Ï€. If a particular region is completely dark, Î´ is at or extremely close to 0.
                   186




Foot Note 186

Ã—



 â€ƒSee Primer at para 47; III ACB 152 (para 183(5)).



210â€ƒAccording to the respondent, if the cross-polarised image of the diamond sample only shows black, white or grey contrasts, it indicates that Î´ is within the SG 872 First Order.
                   187




Foot Note 187

Ã—



 â€ƒRC at paras 185 and 187; RCN at para 53(b).



211â€ƒWe are unable to accept the Cross-Polariser Method as a workable test which sufficiently helps a PSA determine whether Î´ is within the SG 872 First Order.212â€ƒFirst, the Cross-Polariser Method is an inherently imprecise method as it requires a qualitative judgment of the shade of colour perceived in the cross-polarised image. Dr Nebel accepted that if a particular region shows up as black in the cross-polarised image, a PSA will know that the region is strain-free or near perfect.
                   188




Foot Note 188

Ã—



 â€ƒIII ACB 152 (para 183(5)).



 Accordingly, the PSA will know that Î´ is within the SG 872 First Order for that particular region. However, Dr Nebel pointed out that the presence of any other colour indicates that a particular region has some birefringence, but the interpretation of that colour will be â€œsubjectiveâ€.
                   189




Foot Note 189

Ã—



 â€ƒIII ACB 152 (para 183(3)).



 This is in line with the respondentâ€™s own acknowledgement that the Cross-Polariser Method is only a â€œqualitative assessmentâ€ that gives the PSA an approximation of whether Î´ is within the SG 872 First Order.
                   190




Foot Note 190

Ã—



 â€ƒRC at paras 188 and 201â€“202; RSA at para 56.



213â€ƒSecond, the parties agree that it is common general knowledge that even if the cross-polarised image shows black, white and grey contrasts, and an absence of other colours, this is not a conclusive indication that Î´ is less than or equal to , even though it can indicate that Î´ is less than or equal to 2Ï€.
                   191




Foot Note 191

Ã—



 â€ƒPrimer at para 155.



 In particular, it is common general knowledge that grey contrasts may be a result of Î´ exceeding  .
                   192




Foot Note 192

Ã—



 â€ƒPrimer at para 155.



 This is illustrated in Figure 16 above at [209].214â€ƒThe respondent points out that Dr Newton, in the infringement analysis of his 1st Report, had cross-checked the Metripol data against the Cross-Polariser Method to confirm that the range of Î´ values of the Samples were within the SG 872 First Order.
                   193




Foot Note 193

Ã—



 â€ƒRC at para 187.



 However, a closer examination of Dr Newtonâ€™s analysis suggests that the Cross-Polariser Method had not conclusively indicated that the range of Î´ values of the Samples were in fact within the SG 872 First Order. In his 1st Report, Dr Newton observed that cross-polarised images of the Samples â€œshow only black/white/grey contrastâ€ with no other colour. On this basis, he ruled out Î´ values near Ï€ and concluded that this was â€œfurther evidenceâ€ that the range of Î´ values was within the SG 872 First Order (Î´ does not exceed ) for 100% of the analysed area.
                   194




Foot Note 194

Ã—



 â€ƒIII(A24) ROA 95 (Sample 2), 118 (Sample 3) and 142 (Sample 4).



 With respect, it is unclear how Dr Newton can reach this conclusion given that it is common general knowledge that the presence of grey contrasts may be because Î´ exceeds  ,
                   195




Foot Note 195

Ã—



 â€ƒPrimer at para 155.



 and the ruling out of Î´ values near Ï€ does not indicate that Î´ must be less than  Dr Newton added that the absence of other colour â€œis consistent with Î´ not exceeding â€. This is true, but the absence of other colour is also consistent with Î´ exceeding . As such, the cross-polarised images do not conclusively show that Î´ is less than or equal to .215â€ƒThus, even though the Cross-Polariser Method was part of the common general knowledge at the relevant time, it is generally an imprecise and inconclusive method. Admittedly, the Cross-Polariser Method can conclusively show that Î´ is at or extremely close to 0 if the particular region under analysis only shows the colour black, in which case the region is strain-free or near perfect and Î´ must be within the SG 872 First Order (Î´ does not exceed ). However, the reliability of the Cross-Polariser Method in this narrow situation cannot save it from being a generally unreliable solution.216â€ƒThe respondent is aware of the drawbacks of the Cross-Polariser Method, and has sought to present the Cross-Polariser Method as a â€œconfirmatory stepâ€ which can be used to cross-check the Metripol data.
                   196




Foot Note 196

Ã—



 â€ƒRC at para 187.



 It suggests that the PSA can use the Cross-Polariser Method to ascertain whether Î´ is approximately within the SG 872 First Order, before going on to determine from the quantitative Metripol data whether Î´ is actually within the SG 872 First Order.
                   197




Foot Note 197

Ã—



 â€ƒRC at para 188.



 We do not see how this helps a PSA conclusively determine that Î´ is within the SG 872 First Order. The Metripol data itself does not tell the PSA whether Î´ is within the SG 872 First Order (see above at [190]), and it is a misnomer to term the Cross-Polariser Method as a confirmatory step when any â€œconfirmationâ€ is not conclusive. In so far as the respondent is saying that the Cross-Polariser Method, coupled with an analysis of the Metripol data using the Gap Theory, can enable the PSA to determine whether Î´ is within the SG 872 First Order, this is impermissible since we have held that the Gap Theory has not been shown to be a part of the common general knowledge at the relevant time (see above at [200]â€“[206]).(3)â€ƒGlazer 1996 Solutions217â€ƒThe patent specification of SG 872 directs the PSA to Glazer 1996 for â€œ[a]n explanation of how the Deltascan worksâ€:
                   198




Foot Note 198

Ã—



 â€ƒBOM at p 330; Transcript, 22 July 2019, pp 172:8â€“173:12 (III(D3) ROA 177â€“178).



The Deltascan (Oxford Cryosystems) gives information on how the refractive index at a given wavelength depends on polarization direction in the plane perpendicular to the viewing direction. An explanation of how the Deltascan works is given by A. M. Glazer et al. in Proc. R. Soc. Lond. A (1996) 452, 2751-2765.As mentioned, the Deltascan was later renamed as the Metripol.
                   199




Foot Note 199

Ã—



 â€ƒPrimer at para 146.



 The only paragraph in Glazer 1996 which sets out the Glazer 1996 Solutions reads:
                   200




Foot Note 200

Ã—



 â€ƒV(A22) ROA 68.



Finally, it should be realized that, because it is |sin ğ›¿| that is obtained at any point in the image, it is not possible to know how many periods (known as the order) of the sine function have been passed through, unless other information is supplied. The easiest way to solve this is to use a standard compensating plate with white light. A quick observation of this type will then suffice to determine the order within which the retardation value lies. Carrying out the measurements at two or more wavelengths can also be used to help in determining the order.[emphasis in original]218â€ƒBoth parties did not submit on whether an external document referred to in a patent specification is incorporated into the patent specification and hence relevant to the assessment of sufficiency. However, even if we assume in the respondentâ€™s favour that Glazer 1996 can be treated as a part of the patent specification and that the PSA knows of the Glazer 1996 Solutions as a result, the respondent has not shown that the Glazer 1996 Solutions are in fact workable tests for the purpose of determining whether a particular single crystal CVD diamond material has a Î´ value within the SG 872 First Order.219â€ƒFirst, Glazer 1996 itself does not indicate that the Glazer 1996 Solutions apply to single crystal CVD diamonds.220â€ƒGlazer 1996 did not expressly or implicitly contemplate the applicability of the Glazer 1996 Solutions to single crystal CVD diamonds. By way of background, Glazer 1996 is a scientific paper which sought to introduce the Metripol (which was at that time a new optical microscope-based imaging system) and demonstrate that it is â€œa potentially important research tool for the study of optical anisotropy in many disciplinesâ€ and â€œany situation where birefringence is of interestâ€.
                   201




Foot Note 201

Ã—



 â€ƒIII(A43) ROA 176.



 It set out a general discussion of how the Metripol works, its usefulness as well as its limitations, including its inability to tell how many â€œperiodsâ€ of the sine function have been passed through in the absence of other information supplied. It was in this general context that Glazer 1996 proposed the Glazer 1996 Solutions. Glazer 1996 was not concerned with the specific application of this system to single crystal CVD diamonds, and in fact made no mention of this particular class of diamonds. Although Glazer 1996 briefly considered the application of the Metripol to a synthetic diamond sample for the purpose of illustrating the versatility and use of the Metripol,
                   202




Foot Note 202

Ã—



 â€ƒIII(A43) ROA 171â€“173.



 Dr Glazer, a co-author of Glazer 1996, clarified in his second expert report that the synthetic diamond sample under consideration was a HPHT synthetic diamond.
                   203




Foot Note 203

Ã—



 â€ƒGlazer-2 at para 6(g) (III(A43) ROA 15â€“16).



 He also testified that Glazer 1996 was not published with single crystal CVD diamonds in mind.
                   204




Foot Note 204

Ã—



 â€ƒTranscript, 22 July 2019, pp 130:19â€“24, 135:6â€“11 (III(D3) ROA 135 and 140).



221â€ƒSecond, Glazer 1996 proposed the Glazer 1996 Solutions as methods to ascertain â€œhow many periods (known as the order) of the sine function have been passed throughâ€ [emphasis in original],
                   205




Foot Note 205

Ã—



 â€ƒV(A22) ROA 68.



 but it is unclear whether the word â€œorderâ€ refers to multiples of . The respondentâ€™s own expert, Dr Newton, points out that the word â€œorderâ€ can have different definitions depending on the specific optics field in question.
                   206




Foot Note 206

Ã—



 â€ƒNewton-2 at para 32 (III(A56) ROA 44); Primer at para 48.



 The word â€œorderâ€ may, in the alternative, refer to multiples of 2Ï€ with the â€œfirst orderâ€ covering a range of values where Î´ does not exceed 2Ï€ ,
                   207




Foot Note 207

Ã—



 â€ƒPrimer at para 154.



 in which case the determination of how many â€œordersâ€ of sine function have been passed through using the Glazer 1996 Solutions would not help the PSA conclusively ascertain if Î´ falls within the more limited range covered by the SG 872 First Order (Î´ does not exceed ). 222â€ƒAnd, apart from Glazer 1996,there is no indication from the body of expert evidence that the Glazer 1996 Solutions can determine whether the Î´ value of a single crystal CVD diamond is within the SG 872 First Order. The respondentâ€™s experts did not expressly mention that the Glazer 1996 Solutions can achieve this.
                   208




Foot Note 208

Ã—



 â€ƒTranscript, 22 July 2019, p 140:5â€“18 (III(D3) ROA 145).



 Neither did they apply the Glazer 1996 Solutions when seeking to prove that the Samples infringed Claim 1.
                   209




Foot Note 209

Ã—



 â€ƒNewton-1 at pp 84â€“88, 107â€“111, 133â€“138 (III(A24) ROA 91â€“95, 114â€“118, 140â€“145).



223â€ƒIn particular, notwithstanding that Dr Glazer was a co-author of Glazer 1996, Dr Glazerâ€™s own expert reports did not rely on the Glazer 1996 Solutions to solve the Metripol Uncertainty Problem, even though he was aware, by the time of his second expert report, that the Metripol Uncertainty Problem was the subject of contention between the parties.
                   210




Foot Note 210

Ã—



 â€ƒTranscript, 22 July 2019, pp 133:12â€“134:5, 145:5â€“18 (III(D3) ROA 138â€“139, 150).



 Dr Glazerâ€™s second expert report only contained a vague comment that â€œthe PSA could look to Glazer 1996 for the details of the optical pathâ€.
                   211




Foot Note 211

Ã—



 â€ƒGlazer-2 at para 40 (III(A43) ROA 23).



 When asked during cross-examination why he did not mention that the Glazer 1996 Solutions could solve the Metripol Uncertainty Problem in his expert reports, Dr Glazer did not give a satisfactory response:
                   212




Foot Note 212

Ã—



 â€ƒTranscript, 22 July 2019, pp 132:10â€“133:4 (III(D3) ROA 137â€“138).



Q. If you believed [the Glazer 1996 Solutions] were solutions and ready solutions, at that, how is it you don't say that in any of your reports?A. Because it's nothing to do with this particular case.Q. What do you mean it's nothing to do with this particular case? It's got everything to do with it because -- can you let me finish, please. We are concerned with the orders and there you were suggesting the easiest way to solve it is by doing this or that.Now, if that is a valid solution, then that would have been the easiest thing for you to have said in either your first or second expert report, but you didn't.A. I was asked to look at the patents and I am commenting on the words of the patent and what that means, and if the patent didn't raise these points, there's no reason why I should raise these points.Dr Glazerâ€™s response is at odds with his first expert report, which stated that he was requested to opine on the use of the Metripol as a method of measurement for birefringence as set out in Claims 1ii) and iii) of SG 872.
                   213




Foot Note 213

Ã—



 â€ƒGlazer-1 at para 12 (III(A21) ROA 13).



 The scope of his instructions clearly covered the limitations of the Metripol in ascertaining whether Î´ is within the SG 872 First Order and solutions to overcome them. Dr Glazerâ€™s response also does not sit well with his second expert report, which stated that he was requested to respond to Dr Kaminskyâ€™s first expert report,
                   214




Foot Note 214

Ã—



 â€ƒGlazer-2 at para 2 (III(A43) ROA 13).



 which, amongst other matters, highlighted the Metripol Uncertainty Problem. It is troubling that Dr Glazer did not expressly point to or elaborate on the use of the Glazer 1996 Solutions, notwithstanding that he was a co-author of Glazer 1996 and it was well within the scope of his instructions to raise these solutions.224â€ƒWe further note that Dr Glazer testified in re-examination that the use of a standard compensating plate with white light is a â€œstandard way of doing thingsâ€ which â€œgoes back to the 19th centuryâ€,
                   215




Foot Note 215

Ã—



 â€ƒTranscript, 22 July 2019, pp 173:3â€“174:14 (III(D3) ROA 178â€“179).



 but he does not go so far as to say this is a â€œstandardâ€ means of ascertaining whether Î´ in single crystal CVD diamonds is less than or equal to .225â€ƒIn fact, a comment made by Dr Glazer at trial raises doubts as to the feasibility of using the Glazer 1996 Solutions on single crystal CVD diamonds to ascertain if Î´ is less than or equal to :
                   216




Foot Note 216

Ã—



 â€ƒTranscript, 22 July 2019, p 134:6â€“12 (III(D3) ROA 139).



Q. You would have wondered why Dr Kaminsky raised that as a problem when, according to [Glazer 1996] that was prepared, what, 23-24 years ago, there was a ready solution? A. The ready solutions are varied and to apply some of these solutions to this particular case can be rather difficult, actually. But it depends. â€¦226â€ƒThe appellant, relying on Dr Kaminskyâ€™s evidence, argues that the Glazer 1996 Solutions cannot determine if Î´ is less than or equal to  in highly heterogeneous diamond samples.
                   217




Foot Note 217

Ã—



 â€ƒAC at para 154.



 The respondent in turn submits that this limitation does not apply to single crystal CVD diamonds, which are homogeneous along the light path. In support of this, the respondent points out that the Judge had accepted Dr Glazerâ€™s evidence that birefringence in single crystal CVD diamond mainly results from strain associated with dislocations grown into the material with a line direction that is close to parallel to the growth direction and the strain fields tend to show little variation through the depth of a sample (see Judgment at [207]â€“[210]).
                   218




Foot Note 218

Ã—



 â€ƒRC at paras 191â€“192; RS at para 57; see also Glazer-2 at para 63 (III(A43) ROA 28).



 We see no reason to disagree with the Judgeâ€™s acceptance of Dr Glazerâ€™s evidence in so far as this specific factual point is concerned. However, even if we accept that the Judgeâ€™s findings meant that the limitation identified by Dr Kaminsky is inapplicable, it does not go towards discharging the respondentâ€™s evidential burden of proving that the Glazer 1996 Solutions could be used on single crystal CVD diamonds.
                   219




Foot Note 219

Ã—



 â€ƒDr Werner Kaminskyâ€™s 1st Report (â€œKaminsky-1â€) at para 112 (III(B45) ROA 45).



 The inapplicability of one possible limitation does not necessarily mean that the Glazer 1996 Solutions can be used on single crystal CVD diamonds. Apart from submitting that the appellant has no scientific basis for its assertion that the Glazer 1996 Solutions are inapplicable to single crystal CVD diamonds, the respondent has not drawn our attention to evidence which positively proves that they are in fact applicable.227â€ƒGiven the dearth of evidence establishing that the Glazer 1996 Solutions can be used to determine whether Î´ is within the SG 872 First Order (Î´ does not exceed ) for single crystal CVD diamonds, the respondent cannot rely on the Glazer 1996 Solutions to stave off an insufficiency attack.(4)â€ƒSub-conclusion: Claim 1 is uncertain228â€ƒFor these reasons, we find that the PSA trying to perform the claimed invention would not know which test to apply to ascertain whether the Î´ value of a particular single crystal CVD diamond material remained within the SG 872 First Order. Although this uncertainty only affects one out of two integers in limbs ii) and iii) of Claim 1 respectively, the result is that the PSA would not be able to determine whether a particular single crystal CVD diamond material satisfies either limb ii) or limb iii). This bears some similarity to the facts of Sandvik Intellectual Property AB v Kennametal UK Ltd and another [2011] EWHC 3311 (Pat), where the uncertainty affecting one out of five integers of the claim in that case likewise caused the entire claim to be held insufficient (at [83] and [162]â€“[165]).229â€ƒIt follows from this that the PSA is unable to perform the invention across the full breadth of the monopoly in Claim 1. As we have found at [83] above, the monopoly asserted in Claim 1 covers a range of single crystal CVD diamond materials, each with a different combination of the physical properties defined in the various limbs of Claim 1. This necessarily includes single crystal CVD diamond materials which satisfy either limb ii) or limb iii), or both. Since the PSA would not know if a particular single crystal CVD diamond material has satisfied limb ii) or limb iii), the PSA would not be able to make a portion of the range of single crystal CVD diamond materials that Claim 1 seeks to monopolise. We therefore find that Claim 1 is invalid for insufficiency.230â€ƒFor completeness, we mention two other matters. First, we note that the non-enablement of two out of the eight limbs in Claim 1 does not result in insufficiency of a de minimis nature, such that it can nonetheless be said that substantially all products within the scope of Claim 1 have been enabled.231â€ƒSecond, we recognise that our finding that the PSA could not determine whether limb ii) or limb iii) has been satisfied raises the question as to how the Judge was able to conclude that all the Samples satisfied both limbs and hence infringed Claim 1 of SG 872. In our judgment, the Judge erred in coming to this conclusion.232â€ƒIn respect of Sample 2, the Judge reached her finding of infringement on the basis that the Gap Theory was capable of addressing the Metripol Uncertainty Problem (Judgment at [431]â€“[432] and [202]â€“[204]). With respect, the Judgeâ€™s analysis on infringement overlooks the issue of whether the Gap Theory was in fact used to prove that the Î´ value of Sample 2 was within the SG 872 First Order. Once that is considered, it is apparent from the description of Dr Newtonâ€™s infringement analysis (see above at [204]) that the Gap Theory was not relied upon. In fact, the Gap Theory as described by Dr Newton and Dr Glazer works on the condition that the sample must show regions in which |sin Î´| is close to zero without significant spatial variations associated with defects causing strain, but neither expert expressly stated that Sample 2 fulfilled this condition. Dr Newton stated in his 1st Report that â€œ[t]he Metripol images show regions that clearly have a low density of strain-inducing defectsâ€,
                   220




Foot Note 220

Ã—



 â€ƒIII(A24) ROA 91 (Sample 2), 114 (Sample 3) and 142 (Sample 4).



 but it is unclear if this satisfies the condition for the applicability of the Gap Theory. Further, the Judge did not evaluate the reasoning behind Dr Newtonâ€™s conclusion that the Î´ value of Sample 2 was within the SG 872 First Order. As we have indicated at [204] above, in our judgment, Dr Newton did not give a clear and satisfactory explanation of how he reached this conclusion. We therefore overturn the Judgeâ€™s finding that Sample 2 infringed Claim 1.233â€ƒApart from Sample 2, the Judge also found that Samples 3 and 4 infringed Claim 1 of SG 872 on the basis that they satisfied limbs ii) and iii) of Claim 1 (Judgment at [435]â€“[443]). With respect, the Judge arrived at this conclusion without considering whether the Î´ values of Samples 3 and 4 were within the SG 872 First Order. As with Sample 2, Dr Newtonâ€™s analysis on infringement did not rely on the Gap Theory, nor did it set out a satisfactory chain of reasoning proving that the Î´ value of Samples 3 and 4 were within the SG 872 First Order. Accordingly, we overturn the Judgeâ€™s findings that Samples 3 and 4 infringed Claim 1.Whether the other claims in SG 872 are also uncertain234â€ƒThe appellant, both here and below, argued that if Claim 1 is found to be insufficient due to the Metripol Uncertainty Problem, SG 872 as a whole should be found invalid for insufficiency.
                   221




Foot Note 221

Ã—



 â€ƒIIIG(5) ROA 122 (para 308); AC at paras 143 and 208; ACN at p 16.



235â€ƒWe agree with the appellant. The failure to enable part of the monopoly in Claim 1 resulted in the same in respect of all other claims in SG 872. This is because all other claims, be they product or process claims, have defined the scope of their monopoly by reference to Claim 1. We elaborate.236â€ƒAs we have noted at [87] above, each subsequent product claim in SG 872 relies on Claim 1 to demarcate the scope of its asserted monopoly. Each subsequent product claim covers any diamond within the class of products in Claim 1, which also fulfils the additional parameter embodied in the subsequent claim. This will include diamonds which possess the characteristics listed in limbs ii) and iii) of Claim 1. However, the making of these diamond materials is not enabled because the PSA cannot tell when limbs ii) and iii) of Claim 1 are satisfied. Hence, each subsequent product claim is not enabled across its full scope.237â€ƒIn respect of the process claims in SG 872, Claim 62 defines the claimed process as one which would produce a single crystal CVD diamond material meeting the requirements of any one of the product claims, including Claim 1. In other words, Claim 62 monopolises a process which produces a range of single crystal CVD diamond materials, including those which possess either or both characteristics in limbs ii) and iii) of Claim 1. Part of this monopoly is not enabled given that the PSA cannot tell when limbs ii) and iii) of Claim 1 are satisfied. The same issue arises in respect of each of the other process claims, which defines its monopoly by reference to Claim 62 such that it also covers a process which produces a range of single crystal CVD diamond material satisfying any one of the product claims.238â€ƒFor completeness, we mention in passing that even if all that is required for the sufficiency requirement is for there to be enablement of substantially all the subject matter covered by a claim, this threshold is not met in respect of the subsequent product claims and process claims as the non-enablement in each of these claims is not de minimis.Revocation239â€ƒAs each claim in SG 872 has not been enabled across the full scope of its monopoly due to the uncertainty affecting limbs ii) and iii) of Claim 1, this is another ground for allowing the appellantâ€™s counterclaim and revoking SG 872 in its entirety under s 80(1)(c) of the Patents Act (2005 Rev Ed).240â€ƒBefore concluding, we should add that it is unnecessary for us to rule on the correctness of the observation in Sunseap Group Pte Ltd v Sun Electric Pte Ltd [2019] 1 SLR 645 (â€œSunseapâ€) that a patent should be revoked if â€œall the independent claims in a patent have found to be invalidâ€ because â€œit follows that the dependant claims must also fallâ€ (at [70]). While the appellant appears to rely on this portion of Sunseap,
                   222




Foot Note 222

Ã—



 â€ƒDCS2 at para 283 (ASCB 30), cited in AR at para 76.



 the outcome of this appeal does not turn on its application. We leave further consideration of this observation in Sunseap to an appropriate future case.Conclusion241â€ƒIn light of the foregoing, we allow the appeal and set aside the Judgeâ€™s orders at [45] above. We order the revocation of SG 872. CA 96, which is the appellantâ€™s appeal against the Judgeâ€™s Costs Decision, will, unless we order otherwise, be decided on paper. The parties are to file and exchange written submissions limited to 15 pages in connection with CAÂ 96, within 3 weeks of the date of this judgment, unless they are able to come to an agreement as to its disposal. Similarly, unless the parties come to an agreement, they are to file and exchange written submission limited to 10 pages within 3 weeks of the date of this judgment on the appropriate costs orders we should make in this appeal.Sundaresh MenonChief JusticeJudith PrakashJustice of the Court of AppealSteven ChongJustice of the Court of AppealDavinder Singh SC, Srruthi Ilankathir and Hanspreet Singh (Davinder Singh Chambers LLC) (instructed), Tony Yeo Soo Mong, Meryl Koh Junning, Javier Yeo, Loo Fang Hui, Justin Lai Wen-Jin and Derrick Ng (Drew & Napier LLC) for the appellant;Alvin Yeo SC, Daniel Chan, Daryl Kwok and Yu Zhengyi Victoria (WongPartnership LLP) (instructed), Jason Chan, Melvin Pang and Ong Eu Jin (Amica Law LLC) for the respondent.
